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Abstract	  STRUCTURAL	  DETERMINANTS	  OF	  ABUSE-­‐RELATED	  NEUROCHEMICAL	  AND	  BEHAVIORAL	  EFFECTS	  OF	  PARA-­‐SUBSTITUTED	  METHCATHINONE	  ANALOGS	  IN	  RATS	  	  By	  Julie	  S.	  Bonano	  	  A	  dissertation	  submitted	  in	  partial	  fulfillment	  of	  the	  requirements	  for	  the	  degree	  of	  Doctor	  of	  Philosophy	  at	  Virginia	  Commonwealth	  University	  	   Virginia	  Commonwealth	  University,	  2015	  Advisor:	  S.	  Stevens	  Negus,	  Ph.D.	  	   	  Methcathinone	  (MCAT)	  is	  the	  β-­‐ketone	  analog	  of	  methamphetamine,	  and	  like	  its	  amphetamine	  analog,	  MCAT	  functions	  as	  a	  monoamine	  releaser	   that	  selectively	  promotes	  the	  release	  of	  dopamine	  (DA)	  and	  norepinephrine	  (NE)	  over	  serotonin	  (5-­‐HT).	  MCAT	  produces	  amphetamine-­‐like	  psychostimulant	  effects	  and	  is	  classified	  as	  a	  Schedule	   I	   drug	   of	   abuse	   by	   the	   United	   States	   Drug	   Enforcement	   Administration	  (DEA).	  Recently,	  synthetic	  MCAT	  analogs	  have	  emerged	  as	  designer	  drugs	  of	  abuse	  in	  Europe	  and	  the	  United	  States	  and	  have	  been	  marketed	  under	  deceptively	  benign	  names	   like	   “bath	   salts”	   in	   an	   attempt	   to	   evade	   legal	   restriction.	   These	   dangerous,	  recently	  emergent	  and	  novel	  drugs	  of	  abuse	  display	  varying	  selectivity	  to	  promote	  release	  of	  DA/NE	  vs.	  5-­‐HT,	  and	  selectivity	   for	  DA	  neurotransmission	  is	  believed	  to	  correlate	  with	  abuse	  liability.	  The	  goal	  of	  this	  dissertation	  was	  to	  conduct	  preclinical	  research	   to	   examine	   structural	   determinants	   of	   abuse-­‐related	   behavioral	   and	  neurochemical	  effects	  produced	  by	  a	  series	  of	  synthetic	  MCAT	  analogs.	  Specifically,	  this	   project	   focused	   on	   one	   feature	   of	   the	   methcathinone	   scaffold:	   the	   para	  substituent	  of	  the	  benzene	  ring.	  A	  series	  of	  six	  novel	  MCAT	  analogs	  will	  be	  examined	  
	  	  
to	  evaluate	  how	  physicochemical	  parameters	  (steric,	  Es;	  electronic,	  σp;	  lipophilic,	  πp)	  of	  the	  para	  substituent	  influence	  in	  vitro	  monoamine	  transporter	  selectivity	  as	  well	  as	   in	   vivo	   neurochemical	   and	   behavioral	   effects.	   Results	   from	   this	   body	   of	   work	  implicate	  steric	  factors	  as	  being	  particularly	  important	  in	  determining	  a	  compound’s	  abuse-­‐related	  neurochemical	  and	  behavioral	  effects.	  Thus,	  these	  data	  not	  only	  offer	  an	   improved	   understanding	   of	   the	   mechanism	   of	   abuse-­‐related	   drug	   effects	  produced	  by	  synthetic	  MCAT	  analogs,	  but	  also	  help	   in	   the	  generation	  of	  homology	  models	  of	  the	  human	  DA	  and	  5-­‐HT	  transporters	  (DAT	  and	  SERT,	  respectively).	  	   	  
	  	   1	  
Chapter	  I:	  Introduction	  
I.	  Synthetic	  Cathinone	  Abuse:	  a	  Clinical	  Problem	  Khat	   (Catha	   edulis)	   is	   a	   perennial	   crop	   indigenous	   to	   the	   Eastern	   Horn	   of	  Africa	  and	  the	  Arabian	  Peninsula	  where	  it	  has	  been	  used	  for	  millennia	  for	  its	  central	  stimulant	   effects	   (Alles	   et	   al.,	   1961).	   The	   khat	   plant	   grows	   as	   a	   bush	   or	   tree	   and	  contains	   leaves	   that	   are	   chewed	   or	   brewed	   into	   a	   tea.	   The	   social	   context	  surrounding	   khat	   consumption	   closely	   resembles	   that	   of	   coffee	   consumption	   in	  Western	   society.	   In	   fact,	   khat’s	   cultivation	  and	  use	   in	  Ethiopian	  and	   southwestern	  Arabian	  regions	  predates	  the	  use	  of	  coffee,	  with	  its	  first	  historical	  reference	  dating	  back	  to	  the	  early	  14th	  century	  (Cerulli,	  1936;	  Ukers,	  1955).	  The	  khat	  plant	  itself	  was	  first	  classified	  in	  1762	  by	  botanist	  Forskål	  who	  noted	  its	  cultivation	  and	  reported	  its	  use	  within	  Yemen	  as	  a	  plant	  of	  “medicinal	  virtues”	  (Alles	  et	  al.,	  1961).	  For	  centuries,	  attempts	  were	  made	  at	  elucidating	  the	  chemical	  structure	  of	  the	  active	  compounds	  in	   khat.	   In	   1887,	   Flückiger	   and	  Gerock	   found	   that	   caffeine	  was	  not	   present	   in	   the	  plant	  and	  could	  not	  be	  responsible	  for	  the	  plant’s	  pharmacological	  stimulant	  effects.	  They	   did,	   however,	   discover	   trace	   amounts	   of	   a	   basic	   material	   that	   they	   called	  “katine”	  (Fluckiger	  and	  Gerock,	  1887).	  	  It	  is	  now	  known	  that	  cathinone	  is	  the	  primary	  psychoactive	  component	  of	  the	  khat	   plant.	   Although	   cathinone	   was	   not	   isolated	   from	   khat	   until	   1975	   (U.N.	  Document,	  1975),	   its	  N-­‐methyl	  derivative	  methcathinone	  (MCAT)	  was	  synthesized	  decades	  before	  in	  1928	  as	  a	  precursor	  to	  ephedrine	  (Hyde	  et	  al.,	  1928).	  Structurally,	  cathinone	   and	   MCAT	   are	   the	   β-­‐ketone	   analogs	   of	   amphetamine	   and	  methamphetamine	   (see	   Figure	   I.1),	   and	   they	   function	   similarly	   as	   monoamine	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releasers	   that	   selectivity	   promote	   release	   of	   dopamine	   (DA)	   and	   norepinephrine	  (NE)	  over	  serotonin	  (5-­‐HT)	  (Wagner	  et	  al.,	  1982;	  Nielsen	  and	  Schechter,	  1985;	  Kalix	  and	   Glennon,	   1986;	   Cozzi	   et	   al.,	   1999,	   2013).	   Both	   cathinone	   and	  MCAT	   produce	  amphetamine-­‐like	  stimulant	  effects	  (Glennon	  et	  al.,	  1987;	  Dal	  Cason	  et	  al.,	  1997)	  and	  are	  classified	  as	  Schedule	  I	  drugs	  of	  abuse	  by	  the	  Drug	  Enforcement	  Administration	  (DEA).	  Federal	  scheduling	  of	  cathinone	  and	  MCAT	  in	  the	  early	  1990s	  reduced	  their	  use	  and	  availability,	  but	  it	  also	  stimulated	  a	  wave	  of	  synthesis	  of	  synthetic	  cathinone	  derivatives	  that	  emerged	  as	  designer	  drugs	  in	  the	  U.K.	  in	  2009	  and	  the	  U.S.	  in	  2010.	  These	   novel	   synthetic	   cathinones	   were	  marketed	   as	   legal	   alternatives	   to	   cocaine,	  MDMA	  and	  the	  amphetamines,	  given	  deceptive	  names	  like	  “bath	  salts,”	  and	  labeled	  “not	  for	  human	  consumption”	  to	  evade	  legal	  restriction	  (Spiller	  et	  al.,	  2011).	  Methylenedioxypyrovalerone	  (MDPV),	  mephedrone	  and	  methylone	  are	  three	  cathinone	  derivatives	  that	  were	  amongst	  the	  most	  common	  constituents	  of	  the	  first	  wave	  of	  “bath	  salts.”	   	  Bath	  salts	  are	  generally	  sold	  as	  a	  white	  or	  brown	  powder	  on	  the	  internet	  or	  in	  drug	  paraphernalia	  shops	  and	  produce	  euphoric	  effects,	  as	  well	  as	  increased	   sociability	   and	   sex	   drive	   (NIDA,	   2014).	   In	   addition	   to	   these	   euphoric	  effects,	  bath	  salts	  can	  produce	  dangerous	  side	  effects,	  including	  paranoia,	  agitation,	  and	  hallucinatory	  delirium	  (Hohmann	  et	  al.,	  2014).	  Although	  synthesis	  of	  synthetic	  cathinones	  has	  been	  described	  for	  decades	  (mephedrone	  in	  1929,	  Saem	  de	  Burnaga	  Sanchez,	  1929;	  MDPV	   in	  1967,	  Boehringer	  and	  Sohn,	  1967;	  methylone	   [MDMC]	   in	  1996,	   Jacob	  and	  Shulgin,	  1996;	  Dal	  Cason	  et	   al.,	   1997),	   their	  presence	  was	   largely	  ignored	   until	   their	  marketing	   and	   abuse	   as	   legal	   alternatives	   to	  MDMA	  were	   first	  reported	  on	  Internet	  drug	  websites	  in	  2003	  (Morris,	  2010).	  Following	  an	  increase	  in	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their	   prevalence	   over	   subsequent	   years,	   as	   well	   as	   an	   increase	   in	   associated	  negative	   health	   consequences	   	   (i.e.	   emergency	   department	   visits,	   calls	   to	   poison	  control	   centers)	   (Spiller	   et	   al.,	   2011),	   MDPV,	   mephedrone	   and	   methylone	   were	  emergency	   scheduled	   by	   the	   DEA	   in	   October	   2011.	   After	   preclinical	   testing	  substantiated	   claims	   of	   abuse	   potential,	   these	   three	   bath	   salts	   constituents	   were	  moved	  to	  permanent	  Schedule	  I	  classification	  (DEA,	  2011).	  While	  Schedule	  I	  status	  of	   these	   bath	   salts	   compounds	   has	   reduced	   access	   to	   and	   consumption	   of	   early	  synthetic	  cathinones	  (Stogner	  and	  Miller,	  2013),	  	  it	  has	  also	  triggered	  the	  emergence	  of	  a	  second	  wave	  of	  further	  derivatized	  synthetic	  cathinones	  (Thornton	  et	  al.,	  2012;	  Marinetti	  and	  Antonides,	  2013).	  	  Methedrone	   and	   flephedrone	   are	   two	   additional	   synthetic	   cathinones	   that	  emerged	   in	   the	   second	   wave	   of	   bath	   salts.	   These	   derivatives	   have	   already	   been	  identified	   by	  US	  Drug	   Courts,	   in	   toxicology	   screens,	   and	   in	   the	   international	   drug	  market	  (Prosser	  and	  Nelson,	  2012;	  Leffler	  et	  al.,	  2014),	  and	  both	  were	  added	  to	  the	  growing	   list	   of	   Schedule	   I	   drugs	   of	   abuse	   in	   April	   2014.	   Studies	   on	   the	   effects	   of	  various	  synthetic	  MCAT	  derivatives	  on	  motor	  behavior	  and	  a	  functional	  observation	  battery	   in	   mice	   showed	   that	   methedrone	   and	   flephedrone	   share	   important	  pharmacological	   properties	   with	   other	   Schedule	   I	   synthetic	   cathinones	   (i.e.	  mephedrone,	  MDPV)	   (Marusich	  et	   al.,	   2012),	   supporting	   their	   recent	   classification	  as	  Schedule	  I	  drugs.	  The	  increasing	  prevalence	  of	  para-­‐substituted	  MCAT	  analogs	  in	  the	   drug	   market	   and	   in	   toxicology	   screens	   provides	   significant	   rationale	   for	  investigating	   neurochemical	   and	   behavioral	   effects	   of	   other	   para-­‐substituted	  derivatives	   that	   may	   be	   the	   next	   drugs	   of	   abuse	   to	   emerge,	   such	   as	   4-­‐
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Structural	   comparison	   of	   amphetamine	   and	   cathinone	   analogs.	   Cathinones	   are	  β-­‐
keto	   amphetamines,	   differing	   from	   their	   amphetamine	   analogs	   by	   the	   presence	   of	   a	  
carbonyl	   group	   at	   the	   beta	   position	   relative	   to	   nitrogen.	   Amphetamines	   and	  
cathinones	   exist	   as	   one	   of	   two	   enantiomers,	   designated	   (S)-­‐(+)	   and	   (R)-­‐(-­‐).	  
Enantiomers	   are	   a	   class	   of	   stereoisomers	   in	   which	   each	   drug	   isomer	   is	   a	   non-­‐
superimposable	  mirror	   image	   of	   the	   other,	   differing	   only	   its	   ability	   to	   rotate	   plane-­‐
polarized	   light.	   Racemic	   mixtures,	   containing	   equal	   parts	   of	   each	   enantiomer,	   are	  
investigated	  in	  this	  dissertation.	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Synthetic	  cathinones	  are	  most	  commonly	   ingested	  orally	  (“bombing”)	  or	  by	  insufflation	  in	  doses	  of	  ~100-­‐200mg	  and	  are	  consumed	  in	  binge-­‐like	  patterns	  with	  an	  average	  of	  six	  doses	  across	  a	  nine-­‐hour	  period	  (German	  et	  al.,	  2014).	  Because	  of	  their	  stimulant	  and	  hallucinogenic	  properties,	  synthetic	  cathinones	  are	  often	  used	  as	  alternatives	   to	   MDMA,	   cocaine	   and	   amphetamine.	   As	   with	   many	   drugs	   of	   abuse,	  subjective	   reports	   of	   synthetic	   cathinone	   intoxication	   are	   highly	   variable.	   One	  account	   of	   mephedrone	   intoxication	   from	   the	   Erowid	   Experience	   Vaults	   describes	  the	  high	  as	   a	  positive	  experience:	   “The	  euphoria	  was	  absolutely	   crazy.	   I	   looked	   in	  the	  mirror,	  my	  eyes	  were	  saucers.	  I	  felt	  giddy	  from	  how	  amazing	  I	  felt…	  The	  stuff	  is	  dangerous	   in	   how	  much	   I	   can	   fiend	   it,	   though.”	   Another	   account	   of	   mephedrone	  intoxication,	   however,	   describes	   more	   disconcerting	   drug	   effects:	   “What	   I	  experienced	  was	  rather	  disappointing	  in	  so	  much	  that	  it	  wasn't	  anything	  like	  MDMA,	  though	  my	  pupils	  were	  gigantic,	  my	  heart	  was	  racing,	  my	  teeth	  were	  grinding,	  I	  was	  freezing	  one	  moment	  then	  sweating	  the	  next.	  I	  couldn't	  focus	  my	  eyes	  on	  anything…	  and	  as	  the	  night	  went	  on,	  my	  eyes	  would	  dart	  around	  from	  one	  hallucination	  to	  the	  next	  until	  I	  realized	  those	  things/shadows	  weren't	  really	  there.”	  Moreover,	  various	  case	  reports	  of	  bath	  salts	  intoxication	  have	  demonstrated	  health	  hazards	  associated	  with	  use	  and	  abuse	  of	  synthetic	  cathinones.	  A	  recent	  case	  series	   involving	   five	   patients	   who	   presented	   to	   the	   emergency	   department	   (ED)	  after	  ingesting	  bath	  salts	  describes	  the	  constellation	  of	  symptoms	  as	  similar	  to	  other	  sympathomimetic	   drugs	   with	   “delirium,	   hallucinogenic-­‐delusional	   symptoms,	  extreme	  agitation,	  combativeness,	  and	  rhabdomyolysis”	  (Imam	  et	  al.,	  2013).	  All	  five	  patients	  were	  male,	   and	   their	   ages	   ranged	   from	   28-­‐42	   years	   old.	   Four	   of	   the	   five	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patients	  had	  past	  medical	  histories	  of	  psychiatric	  disease	   (e.g.	  bipolar,	  depression,	  anxiety,	   ADHD),	   and	   all	   presented	   with	   elevated	   heart	   rate	   and	   respiratory	   rate.	  Interestingly,	   despite	   all	   five	   patients	   admitting	   to	   bath	   salts	   ingestion,	   three	  patients	  had	  negative	  urine	  drug	  screens,	  one	  tested	  positive	  for	  cannabinoids,	  and	  one	   tested	   positive	   for	   cocaine.	   These	   negative	   drug	   screens	   for	   bath	   salts	  constituents	   suggest	   that	   hospitals	   either	   lack	   the	   analytical	  methods	   required	   to	  detect	   synthetic	   cathinones	   and	   their	  metabolites	   in	   urine,	   or	   patients	   have	   taken	  drugs	   that	   they	   believed	   to	   be	   bath	   salts	   when,	   in	   fact,	   they	   did	   not.	   In	   either	  scenario,	  the	  discrepancy	  contributes	  to	  skewed	  epidemiology	  and,	  more	  than	  likely,	  an	  overall	  underestimation	  of	  bath	  salts	  use.	  	  
II.	  Anatomy	  and	  Function	  of	  Monoamine	  Systems	  
Monoamines,	  receptor	  location	  and	  binding,	  and	  neuronal	  projections	  	   Synthetic	  cathinones	  produce	  their	  behavioral	  effects	  primarily	  by	  acting	  on	  neural	   circuits	   in	   the	   brain	   that	   use	   the	  monoamine	   neurotransmitters	   dopamine	  (DA),	   serotonin	   (5-­‐HT)	   and	   norepinephrine	   (NE).	   	   Studies	   of	   the	   organization	   of	  monoaminergic	  neuronal	   systems	  and	   their	  projections	   throughout	   the	  brain	  date	  back	  to	  the	  early	  1960s	  when	  the	  two	  primary	  catecholamines	  DA	  and	  NE	  were	  first	  identified	  (Carlsson	  et	  al.,	  1962).	  	  Shortly	  thereafter,	  the	  first	  detailed	  report	  on	  the	  distribution	  of	  DA-­‐,	  NE-­‐	  and	  5-­‐HT-­‐containing	  neurons	  in	  the	  rat	  brain	  was	  published	  (Dahlstroem	   and	   Fuxe,	   1964),	   in	   which	   twelve	   groups	   of	   catecholamine	   cells	  (labeled	  A1-­‐A12)	  were	   identified.	  Then,	  with	   the	  advent	  of	   immunohistochemistry	  for	   the	   catecholamine-­‐synthesizing	   enzymes	   tyrosine	   hydroxylase	   (TH),	   dopa-­‐
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decarboxylase,	   and	  dopamine-­‐β-­‐hydroxlyase	   in	   the	  1970s,	  more	  detailed	  mapping	  of	   the	   catecholaminergic	   systems	   (particularly	   dopaminergic	   projections)	   became	  possible.	   While	   the	   presence	   of	   TH	   at	   detectable	   levels	   remains	   one	   of	   the	   most	  sensitive	  and	  consistent	  markers	  for	  labeling	  DA	  neurons,	  it	  is	  neither	  selective	  nor	  completely	  reliable;	  TH	  is	  also	  present	  in	  noradrenergic	  neurons,	  and	  TH	  expression	  in	  DA	  neurons	  can	  vary	  over	  time	  and	  in	  response	  to	  functional	  demand	  (Björklund	  and	  Dunnett,	  2007).	  	  	  DA,	   synthesized	   from	   the	   non-­‐essential	   amino	   acid	   tyrosine,	   is	   the	  predominant	   catecholamine	   neurotransmitter	   in	   mammals,	   and	   its	   immediate	  precursor	  is	  L-­‐DOPA.	  After	  synthesis,	  DA	  is	  sequestered	  into	  synaptic	  vesicles	  where	  it	  is	  stored	  until	  an	  action	  potential	  is	  fired	  within	  the	  dopaminergic	  neuron,	  which	  causes	   vesicular	   docking	   and	   release	   into	   the	   synaptic	   cleft.	   Once	   DA	   enters	   the	  synapse,	   it	   functions	   as	   a	   neurotransmitter	   by	   binding	   to	   and	   activating	   DA	  receptors.	   DA	   receptors	   are	   seven	   transmembrane	   G-­‐protein	   coupled	   receptors	  (GPCRs),	  and	  at	   least	   five	  DA	  receptor	  subtypes	  (D1-­‐D5)	  exist:	   two	  D1-­‐like	  receptor	  subtypes	   (D1	   and	   D5),	   which	   are	   Gs-­‐coupled	   and	   stimulate	   adenylyl	   cyclase,	   and	  three	  D2-­‐like	  subtypes	  (D2,	  D3,	  D4),	  which	  are	  Gi-­‐coupled	  and	  inhibit	  adenylyl	  cyclase	  (Missale	  et	  al.,	  1998).	  DA	  receptors	  are	  widely	  expressed	  throughout	   the	  CNS,	  and	  they	   are	   involved	   in	   the	   control	   of	   locomotion,	   cognition,	   emotion	   and	   endocrine	  regulation.	  The	  D1	  receptor	  is	  the	  most	  widespread	  and	  most	  highly	  expressed	  of	  the	  DA	  receptors,	  and	  D1	  mRNA	  is	  most	  abundant	   in	  caudate,	  nucleus	  accumbens,	  and	  olfactory	  tubercle	  (Dearry	  et	  al.,	  1990).	  The	  D5	  receptor	  is	   less	  prevalent	  in	  the	  rat	  brain	   compared	   to	   D1,	   and	   D5	   mRNA	   predominates	   in	   cerebral	   cortex,	   lateral	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thalamus	   and	   striatum	   (Choi	   et	   al.,	   1995).	   Furthermore,	   while	   the	   D2	   receptor	   is	  expressed	   in	   all	   major	   brain	   regions	   receiving	   dopaminergic	   projections	   (e.g.	  striatum	   and	   nucleus	   accumbens),	   D3	   receptors	   have	   a	  more	   specific	   distribution	  pattern	  within	   limbic	  areas	   (Bouthenet	  et	  al.,	  1991).	  Lastly,	  D4	   receptors	  are	  most	  highly	   expressed	   in	   frontal	   cortex,	   olfactory	   bulb,	   hypothalamus	   and	   thalamus	  (O’Malley	  et	  al.,	  1992).	  DA	  receptors	  are	  also	  found	  in	  the	  peripheral	  nervous	  system	  (PNS),	  but	  are	  largely	  localized	  to	  the	  kidney,	  vasculature	  and	  pituitary	  where	  they	  function	  primarily	  to	  modulate	  cardiovascular	  and	  renal	  function	  and	  tone.	  	  The	  primary	  sources	  of	  dopaminergic	  neurons	  are	  the	  substantia	  nigra	  (SN;	  A9)	   and	   ventral	   tegmental	   area	   (VTA;	   A10).	   As	   depicted	   below	   in	   Figure	   I.2,	   DA	  neurons	  originating	   in	   the	   SN	  project	  primarily	   to	   the	   caudate-­‐putamen	  along	   the	  nigrostriatal	   pathway,	   while	   those	   originating	   in	   the	   VTA	   project	   mainly	   to	   the	  nucleus	   accumbens	   and	   prefrontal	   cortex	   along	   mesolimbic	   and	   mesocortical	  pathways,	   respectively	   (Oades	   and	   Halliday,	   1987).	   Although	   the	   designation	   of	  these	  three	  historical	  DA	  pathways	  is	  convenient,	  it	  is	  likely	  an	  oversimplification,	  as	  cells	  of	  origin	  in	  the	  SN-­‐VTA	  complex	  are	  intermixed	  such	  that	  SN	  contains	  neurons	  that	   also	   innervate	   cortical	   and	   limbic	   regions,	   and	   VTA	   contains	   DA	   neurons	  projecting	   to	   ventral	   striatum	   and	   parts	   of	   the	   caudate-­‐putamen	   (Björklund	   and	  Dunnett,	  2007).	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Figure	  I.2	  
	  
Distribution	  of	  dopaminergic	  projections	  in	  the	  rat	  brain.	  Dopaminergic	  neuronal	  cell	  
bodies	   in	   the	   SN	   project	   predominantly	   to	   the	   caudate-­‐putamen	   and	   comprise	   the	  
nigrostriatal	  pathway,	  while	  DA	  neurons	   in	   the	  VTA	  project	  primarily	   to	   the	  nucleus	  
accumbens	   and	   neocortex	   along	   the	   mesolimbic	   and	   mesocortical	   pathways,	  
respectively.	   Image	   from	   homepage.psy.utexas.edu/homepage/class/Psy332/Salinas	  
/Neurotransmitters/Slide08.GIF.	  	  Norepinephrine	   (NE)	   is	   the	   other	   primary	   catecholamine	   neurotransmitter	  in	  mammalian	  brains	  and,	   like	  DA,	   is	  synthesized	  from	  tyrosine	  prior	  to	  packaging	  into	  synaptic	  vesicles.	  DA	  is	  the	  direct	  precursor	  to	  NE	  and	  is	  converted	  to	  NE	  by	  the	  enzyme	   dopamine-­‐β-­‐hydroxlyase.	   NE	   functions	   by	   binding	   to	   and	   activating	  adrenergic	   receptors,	  another	  class	  of	  GPCRs	   that	  serve	  as	   targets	  not	  only	   for	  NE	  but	  also	  for	  epinephrine.	  The	  two	  main	  types	  of	  adrenergic	  receptors,	  α	  and	  β,	  are	  further	   divided	   into	   subtypes:	   α1	   (Gq-­‐coupled),	   α2	   (Gi-­‐coupled),	   and	   β1-­‐3	   (all	   Gs-­‐
	  	  10	  
coupled;	  β2	  also	  couples	  to	  Gi)	  (Insel,	  1996).	  Adrenergic	  α1	  receptors	  are	  located	  on	  vascular	  smooth	  muscle,	  gastrointestinal	   (GI)	  and	  urinary	  sphincters,	  and	  arrector	  pili	   muscles	   where	   they	   play	   a	   critical	   role	   in	   the	   ‘fight	   or	   flight’	   sympathetic	  response,	   while	   α2	   receptors	   are	   located	   on	   secretory	   terminals	   of	   noradrenergic	  neurons	  where	  they	  function	  as	  a	  negative	  feedback	  mechanism.	  The	  β1	  adrenergic	  receptor	   is	   predominantly	   expressed	   in	   cardiac	   tissue	   where	   activation	   by	   NE	  increases	   heart	   rate	   and	   cardiac	   muscle	   contractility.	   β2	   receptors	   are	   found	   in	  smooth	  and	  striated	  muscle	  where	  they	  contribute	  to	  sympathetic	  responsiveness,	  and	  the	  β3	  receptor	  is	  located	  mainly	  in	  adipose	  tissue	  where	  it	  plays	  a	  key	  role	  in	  lipolysis	   and	   thermogenesis.	   Synthesis	   of	   NE	   occurs	   primarily	   in	   neuronal	   cell	  bodies	  within	  the	  locus	  ceruleus	  (LC),	  and	  noradrenergic	  neurons	  project	  from	  the	  LC	  to	  the	  lateral	  tegmentum,	  hippocampus,	  amygdala,	  entorhinal	  cortices,	  thalamus	  and	   neocortex	   (Von	   Bohlen	   und	   Halbach	   and	   Dermietzel,	   2006).	   These	  noradrenergic	  projections	  are	  shown	  in	  Figure	  I.3.	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Figure	  I.3	  
	  
Distribution	  of	  noradrenergic	  projections	  in	  the	  rat	  brain.	  The	  LC	  contains	  ~1,500	  NE	  
cells	   that	  project	   to	   the	   ipsilateral	   forebrain,	   and	  axonal	   branching	  permits	  a	   single	  
neuron	  to	  have	  nerve	  terminals	  in	  various	  brain	  regions.	  The	  only	  major	  region	  that	  is	  
not	   innervated	   by	   neurons	   from	   the	   LC	   is	   the	   region	   containing	   the	   basal	   ganglia.	  
Image	  from	  Noradrenergic	  Review	  by	  Sara,	  2009.	  	   Unlike	   DA	   and	   NE,	   which	   are	   catecholamines	   derived	   from	   tyrosine,	  serotonin	  (5-­‐HT)	  is	  a	  monoamine	  neurotransmitter	  that	  belongs	  to	  the	  tryptamine	  class	  and	   is	  biochemically	  derived	   from	  the	  essential	  amino	  acid	   tryptophan.	  5-­‐HT	  and	  its	  receptors	  are	  primarily	  localized	  to	  the	  GI	  tract,	  blood	  platelets	  and,	  notably,	  throughout	   the	   CNS	   (Baumgarten	   and	   Grozdanovic,	   1997).	   5-­‐HT	   receptors	   are	   a	  group	  of	  receptors	  that	  are	  activated	  by	  their	  endogenous	  ligand	  5-­‐HT	  to	  influence	  a	  variety	  of	  biological	  processes,	  including	  anxiety,	  cognition,	  learning,	  memory,	  mood	  and	  sleep,	  amongst	  others.	  Seven	  5-­‐HT	  receptor	  classes	  are	  known	  to	  exist	  (5-­‐HT1-­‐7),	  and	  all	  are	  GPCRs	  with	  the	  exception	  of	  5-­‐HT3,	  which	  is	  a	  ligand-­‐gated	  ion	  channel.	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These	  seven	  receptor	  classes	  include	  a	  total	  of	  14	  5-­‐HT	  receptor	  subtypes:	  5-­‐HT1A,	  1B,	  
1D,	  1E	  and	  1F,	  5-­‐HT2A,	  2B	  and	  2C,	  5-­‐HT3,	  5-­‐HT4,	  5-­‐HT5A	  and	  5B,	  5-­‐HT6	  and	  5-­‐HT7	  (Hoyer	  et	  al.,	  2002).	  5-­‐HT	  receptor	  subtypes	  that	  are	  most	  commonly	  implicated	  in	  addiction	  include	   5-­‐HT1A,	   5-­‐HT1B,	   5-­‐HT2A,	   5-­‐HT2C	   and	   5-­‐HT3.	   5-­‐HT1A	   receptors	   are	   diffusely	  distributed	   throughout	   the	   CNS	   and,	   in	   the	   raphe	   nuclei,	   they	   function	   as	  autoreceptors	   to	   inhibit	   serotonergic	   neuronal	   firing.	   5-­‐HT1B	   receptors	   are	   also	  expressed	   in	   the	  CNS,	  but	   they	  are	  concentrated	   in	   the	  basal	  ganglia,	  striatum	  and	  frontal	   cortex	   (Hoyer	   et	   al.,	   2002).	   5-­‐HT2A	   receptors	   are	   widely	   distributed	   in	  peripheral	   and	   central	   tissues;	   within	   the	   CNS,	   5-­‐HT2A	   receptors	   are	   primarily	  located	  in	  cortex,	  claustrum	  and	  basal	  ganglia.	  5-­‐HT2C	  receptor	  distribution,	  on	  the	  other	  hand,	  is	  confined	  to	  the	  CNS	  and	  choroid	  plexus.	  Lastly,	  5-­‐HT3	  receptors	   	  are	  present	   in	   the	   CA1	   pyramidal	   cell	   layer	   of	   the	   hippocampus,	   the	   dorsal	   motor	  nucleus	  of	  the	  solitary	  tract,	  and	  the	  area	  postrema	  (Laporte	  et	  al.,	  1992).	  The	  raphe	  nuclei	  serve	  as	  the	  primary	  source	  of	  5-­‐HT,	  and	  serotonergic	  neurons	  project	  from	  the	  raphe	  to	  the	  caudate-­‐putamen,	  globus	  pallidus,	  amygdala,	   limbic	   forebrain	  and	  neocortex	   (Steinbusch,	   1981).	   Specifically,	   nine	   groups	   of	   serotonergic	   cell	   bodies	  have	   been	   identified	   and	   designated	   B1-­‐B9	   (Dahlstroem	   and	   Fuxe,	   1964),	   and	  serotonergic	  projections	  from	  these	  nuclei	  are	  depicted	  below	  in	  Figure	  I.4.	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Figure	  I.4	  
	  
Distribution	   of	   serotonergic	   projections	   in	   the	   rat	   brain.	   Image	   from	   Basic	  
Neurochemistry,	  6th	  Edition	  (1999).	  	   	  Although	  monoamine	  systems	  are	  relatively	  distinct	  and	  differentiable,	  both	  functionally	   and	   anatomically,	   there	   is	   also	   a	   great	   degree	   of	   interconnectivity	  between	   them	   (see	   Figure	   I.5).	   Various	   studies	   over	   the	   last	   few	   decades	   have	  demonstrated	   the	   existence	   of	   important	   functional	   interactions	   between	   DA,	   NE	  and	   5-­‐HT	   systems.	   For	   example,	   serotonergic	   systems	   have	   been	   shown	   to	  negatively	   regulate	   NE	   and	   DA	   systems	   through	   5-­‐HT2A	   and	   5-­‐HT2C	   receptor-­‐mediated	  mechanisms,	  respectively	  (Szabo	  and	  Blier,	  2002;	  De	  Deurwaerdère	  et	  al.,	  2004).	   	  Conversely,	  noradrenergic	  systems	  have	  been	  shown	  to	  exert	  positive	  and	  negative	   influences	   on	   5-­‐HT	   systems	   through	   α1-­‐	   and	   α2-­‐adrenergic	   receptors,	  respectively	  (Baraban	  and	  Aghajanian,	  1980).	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Figure	  I.5	  
	  
Interacting	   systems:	   functional	   connectivity	   of	   monoaminergic	   neurons.	   Direct	   and	  
indirect	   connections	   between	   DA,	   NE	   and	   5-­‐HT	   neurons	   are	   mediated	   by	   various	  
receptor	   types,	   and	   monoamine	   systems	   can	   interact	   in	   at	   least	   two	   ways.	   First,	  
neurons	   containing	   one	   neurotransmitter	   type	   can	   be	   directly	   modulated	   by	   inputs	  
from	  neurons	  containing	  a	  different	  neurotransmitter.	  For	  example,	  DA	  neurons	  may	  
express	  5-­‐HT	   receptors	   that	  mediate	   serotonergic	  modulation	  of	  DA	   release.	   Second,	  
neurons	   containing	   different	   monoamines	   can	   provide	   convergent	   input	   on	  
downstream	  neurons.	   For	   example,	   a	   target	   neuron	  may	   express	   both	  DA	   and	   5-­‐HT	  
receptors	  that	  mediate	  convergent	  and	  interacting	  input	  from	  DA	  and	  5-­‐HT	  neurons.	  
Image	  from	  Monoamine	  Neurocircuitry	  Review	  by	  Hamon	  and	  Blier,	  2013.	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Monoamine	  Transporters	  Plasma	   membrane	   and	   vesicular	   monoamine	   transporters	   (see	   Figure	   I.7)	  play	   a	   key	   role	   in	   regulating	   the	   effects	   of	   DA,	   NE	   and	   5-­‐HT.	   Plasmalemmal	  monoamine	  transporters	  belong	  to	  the	  soluble	  carrier	  6	  (SLC6)	  family	  and	  use	  the	  electrochemical	  gradients	  of	  sodium	  (Na+)	  and	  chloride	  (Cl-­‐)	  as	  the	  driving	  force	  to	  mediate	  the	  rapid	  uptake	  of	  substrate	  (i.e.	  monoamine	  neurotransmitter)	  from	  the	  extracellular	   space	   following	   synaptic	   release.	   A	   simplified	   view	   of	   the	   ionic	  stoichiometry	   of	   plasmalemmal	   monoamine	   transporters	   is	   that	   DA	   and	   NE	  transporters	  (DAT	  and	  NET,	  respectively)	  translocate	  one	  neurotransmitter	  with	  2	  Na+	  and	  1	  Cl-­‐,	  while	  the	  5-­‐HT	  transporter	  (SERT)	  transports	  5-­‐HT	  with	  1	  Na+	  and	  1	  Cl-­‐	   (Benarroch,	   2013).	   This	   fixed	   stoichiometry	   is	   based	   largely	   upon	   Michaelis-­‐Menten	   kinetics	   in	   which	   neurotransmitter	   uptake	   is	   plotted	   as	   a	   function	   of	  neurotransmitter	   concentration;	   however,	   these	  M-­‐M	   curves	   are	   generated	   under	  conditions	   of	   constant	   ionic	   (Na+	   and	   Cl-­‐)	   concentrations,	   and	   experiments	   are	  performed	  without	  controlling	  for	  voltage.	  Consequently,	  while	  this	  notion	  of	  fixed	  stoichiometry	   at	   plasmalemmal	   transporters	   is	   easy	   to	   understand	   and	   generally	  accepted	   within	   the	   scientific	   community,	   it	   is	   likely	   a	   vast	   oversimplification	   of	  transporter	  function.	  Alternative	  views	  suggest	  that	  changes	  in	  membrane	  potential	  (i.e.	   voltage)	   and/or	   transporter	   substrate	   concentrations	   contribute	   to	   variable	  “channel	  modes”	  of	  monoamine	  transport	  that	  produce	  coincident	  changes	  in	  ionic	  stoichiometry	   (Pramod	  et	   al.,	   2013).	  An	   “alternating	   access”	  model	   of	  monoamine	  transport	   shown	   in	   Figure	   I.6	   illustrates	   the	   dynamic	   nature	   of	   plasmalemmal	  monoamine	  transporters,	  which	  supports	  the	  concept	  of	  variable	  stoichiometry.	  	  	  
	  	  16	  
Figure	  I.6	  	  
	  
Diagram	  of	  alternating	  access	  and	  channel	  modes	  of	  monoamine	  transport.	  Substrate	  
and	  ions	  have	  access	  to	  the	  binding	  site	  of	  outward	  facing	  transporters	  (i).	  Once	  inside	  
the	   transporter,	   the	   outer	   gate	   closes	   and	   generates	   an	   occluded	   state	   (ii),	   which	  
ultimately	   transitions	   to	  an	   inward	   facing	  state	  (iii)	   that	  releases	  substrate	  and	   ions	  
into	  the	  cytosol.	  The	  transporter	  may	  also	  undergo	  a	  transition	  to	  a	  channel	  state	   in	  
which	  outward	  and	   inward	   facing	  gates	  are	  open	  simultaneously,	  allowing	   for	  a	   less	  
restricted,	   variable	   stoichiometry	   flow	  of	   substrate	  and	   ions.	   Figure	   from	  Pramod	  et	  
al.,	  2013.	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DAT,	  NET	  and	  SERT	  are	  expressed	  in	  the	  plasma	  membrane	  of	  dendrites	  and	  axons	  of	   their	  respective	  monoaminergic	  neurons,	  and	  these	  transporters	  serve	  as	  the	   major	   mechanism	   for	   terminating	   monoaminergic	   signaling.	   Vesicular	  monoamine	   transporters	   (VMATs),	   on	   the	   other	   hand,	   are	  members	   of	   the	   SLC18	  family	  and	  utilize	  the	  vesicular	  pH	  gradient	  as	  the	  driving	  force	  for	  sequestration	  of	  cytoplasmic	   DA,	   NE	   and	   5-­‐HT	   into	   the	   synaptic	   vesicle.	   While	   plasmalemmal	  transporters	   function	   to	   clear	  monoamines	   from	   the	   synapse	   and	   recycle	   them	   to	  maintain	   vesicular	   stores,	   VMATs	   function	   to	   sequester	   monoamines	   within	  synaptic	   vesicles	   at	   presynaptic	   axon	   terminals	   and	   thus	   play	   a	   major	   role	   in	  regulating	  synaptic	  homeostasis	  (Benarroch,	  2013).	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Figure	  I.7	  
	  
Plasma	   membrane	   and	   vesicular	   monoamine	   transporters	   belong	   to	   the	   soluble	  
carrier	  (SLC)	  superfamily	  and	  play	  a	  major	  role	  in	  regulating	  effects	  of	  DA,	  NE	  and	  5-­‐
HT.	  Plasmalemmal	  transporters	  are	  expressed	  in	  the	  dendrites	  and	  axons	  and	  mediate	  
reuptake	   of	   synaptically	   released	   neurotransmitter	   from	   the	   extracellular	   space.	  
VMATs	   are	   expressed	   within	   monoaminergic	   axons	   and	   mediate	   sequestration	   of	  
cytoplasmic	  neurotransmitter	  into	  synaptic	  vesicles.	  Image	  from	  Benarroch,	  2013.	  	  
III.	  Pharmacology	  of	  Monoamine	  Releasers	  and	  Uptake	  Inhibitors	  Monoamine	   releasers,	   like	   the	   amphetamines,	   are	   drugs	   that	   function	   as	  substrates	  at	  monoamine	  transporters	  to	  promote	  release	  of	  DA,	  NE	  and/or	  5-­‐HT	  in	  an	  action	  potential-­‐independent	  manner	  (Rothman	  et	  al.,	  2001).	  Monoamine	  uptake	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inhibitors	   like	   cocaine,	   on	   the	   other	   hand,	   function	   as	   transporter	   blockers	   to	  impede	  removal	  of	  synaptic	  DA,	  NE	  and/or	  5-­‐HT	  after	  their	  release	  in	  response	  to	  an	  action	   potential;	   thus,	   uptake	   inhibitors	   are	   action	   potential-­‐dependent	   under	  normal	   physiological	   conditions	   (O’Brien,	   2006).	   Although	   monoamine	   releasers	  and	   uptake	   inhibitors	   act	   through	   different	  mechanisms,	   they	   yield	   the	   same	   end	  result	   of	   elevating	   brain	   monoamine	   levels.	   Various	   monoamine	   releasers	   and	  uptake	   inhibitors	   (e.g.	   d-­‐amphetamine,	   phentermine,	  methylphenidate,	   fluoxetine)	  are	   available	   for	   clinical	   use	   in	   the	   treatment	   of	   disorders	   like	   ADHD,	   obesity,	  anxiety	  and	  depression,	  but	  accessibility	  to	  many	  of	  these	  drugs	  is	  tightly	  regulated	  due	  to	  their	  potential	  for	  abuse.	  	  At	  the	  level	  of	  the	  synapse,	  monoamine	  releasers	  and	  uptake	  inhibitors	  exert	  opposite	   effects	   at	   plasmalemmal	  monoamine	   transporters,	   yet	   produce	   the	   same	  outcome	   of	   increasing	   extracellular	   monoamine	   levels.	   Monoamine	   uptake	  inhibitors,	   like	   cocaine	   and	   MDPV,	   prevent	   transporter-­‐mediated	   reuptake	   of	  synaptic	  monoamines	  into	  presynaptic	  terminals	  by	  acting	  as	  competitive	  blockers	  that	   bind	   membrane	   transporters	   and	   inhibit	   transport	   of	   endogenous	  neurotransmitters	   (Izenwasser,	   2004;	   Baumann	   et	   al.,	   2013).	   The	   mechanism	   of	  action	   of	   monoamine	   releasers,	   like	   amphetamine	   and	   methcathinone,	   is	   more	  complicated	  and	  controversial.	  First	  and	  less	  debated	  is	  the	  notion	  that	  monoamine	  releasers	   are	   actively	   transported	   into	   the	   presynaptic	   neuron	   by	   acting	   as	  substrates	   at	   plasmalemmal	   transporters	   (Connor	   and	   Kuczenski,	   1986).	   Upon	  gaining	   access	   to	   the	   cytoplasm	   of	   the	   presynaptic	   neuron,	   the	   actions	   of	  monoamine	  releasers	  are	  more	  contentious.	  Perhaps	  the	  most	  commonly	  held	  belief	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is	   that	   monoamine	   releasers	   function	   within	   the	   presynaptic	   neuron	   to	   disrupt	  packaging	  of	  newly	  synthesized	  and/or	  recycled	  neurotransmitters	  from	  the	  cytosol	  into	   vesicles	   by	   VMATs.	   This	   leads	   to	   a	   depletion	   of	   DA	   vesicular	   stores	   and	   an	  increase	   in	   cytosolic	   monoamine	   levels	   that	   promotes	   reverse	   transport	   through	  plasma	  membrane	  monoamine	  transporters	  back	  into	  the	  synapse,	   independent	  of	  vesicular	   fusion	   and	   exocytotic	   efflux	   (Sulzer	   et	   al.,	   1995;	   Kahlig	   et	   al.,	   2005;	  Lüscher,	  2012;	  see	  Figure	   I.8).	  A	  more	  recent,	  alternative	  hypothesis	  suggests	   that	  transport	   of	   monoamine	   releasers	   (i.e.	   amphetamine)	   as	   substrates	   through	  membrane	  transporters	  can	  actually	  produce	  local	  depolarization	  of	  the	  presynaptic	  neuron,	  causing	  vesicular	  docking,	  fusion,	  and	  neurotransmitter	  release	  in	  a	  similar	  fashion	   to	   “normal,”	   exocytotic	  monoamine	   release	   generated	  by	   action	  potentials	  (Ramsson	   et	   al.,	   2011a,	   2011b;	   Avelar	   et	   al.,	   2013).	   Additional	   studies	   have	  supported	   and	   extended	   upon	   this	   alternative	   hypothesis	   by	   showing	   that	  amphetamine	  not	  only	  enhances	  evoked	  DA	  responses	   to	  current	  pulse	   trains,	  but	  also	  increases	  the	  amplitude,	  duration	  and	  frequency	  of	  spontaneous	  DA	  transients	  (i.e.	   naturally	   occurring,	   non-­‐electrically	   evoked,	   phasic	   increases	   in	   extracellular	  DA)	  (Daberkow	  et	  al.,	  2013).	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Figure	  I.8	  
	  
Cocaine,	   a	   classic	   monoamine	   uptake	   inhibitor,	   blocks	   plasmalemmal	   transporter-­‐
mediated	   reuptake	   of	  monoamine	   neurotransmitters	   from	   the	   synapse	   into	   the	   pre-­‐
synaptic	   neuron,	   causing	   an	   increase	   in	   extracellular	   levels	   of	   neurotransmitter.	  
Amphetamine,	  a	  monoamine	  releaser,	  acts	  as	  a	  plasmalemmal	   transporter	   substrate	  
such	   that	   the	   drug	   molecule	   itself	   passes	   through	   the	   transporter,	   thereby	   gaining	  
access	   to	   the	   presynaptic	   neuron	   and	   exerting	   effects	   that	   induce	   release	   of	  
neurotransmitter	   into	   the	   synapse.	   Image	   from	   Basic	   &	   Clinical	   Pharmacology,	   12th	  
Edition,	  McGraw	  Hill.	  	  A	   major	   distinguishing	   feature	   between	   any	   given	   monoamine	   releaser	   or	  uptake	  inhibitor	  is	  its	  differential	  selectivity	  for	  DAT,	  NET	  and	  SERT.	  For	  releasers,	  potency	  at	  DAT	  and	  NET	  are	  generally	  similar;	  however,	  potency	  to	  promote	  release	  via	   DAT/NET	   can	   vary	   widely	   from	   potency	   to	   act	   at	   SERT.	   The	   selectivity	   of	  
	  	  22	  




DAT	  EC50	  (nM)	   NET	  EC50	  (nM)	   SERT	  EC50	  (nM)	  
DAT-­‐vs.-­‐SERT	  
Selectivity	  Amphetamine	   24.8±3.5	   7.2±0.4	   1765±94	   71	  MDMA	   376±16	   77.4±3.4	   56.6±2.1	   0.15	  Fenfluramine	   >10,000	   739±57	   79.3±11.5	   <0.01	  
EC50	   values	   to	   release	   DA,	   NE	   and	   5-­‐HT,	   and	   DAT-­‐vs.-­‐SERT	   selectivities,	   for	  
representative	  monoamine	  releasers	  (Rothman	  et	  al.,	  2001).	  
	  





DAT	  IC50	  (nM)	   NET	  IC50	  (nM)	   SERT	  IC50	  (nM)	  
DAT-­‐vs.-­‐SERT	  
Selectivity	  RTI-­‐113	  a	   3.0	   31	   229	   76	  Nisoxetine*	  b	   505±50	   0.460±0.20	   158±29	   0.31	  Citalopram	  c	   20,485±923	   4,332±295	   2.40±0.09	   0.0001	  Cocaine	  d	   478±25	   779±30	   304±10	   0.64	  
IC50	   values	   to	   inhibit	   uptake	   of	   DA,	  NE	   and	   5-­‐HT,	   and	  DAT-­‐vs.-­‐SERT	   selectivities	   for	  
representative	  monoamine	  uptake	  inhibitors.	  
*IC50	  values	  have	  not	  been	  reported	  for	  the	  selective	  NE	  reuptake	  inhibitor	  nisoxetine.	  
Instead,	  affinities	  (Ki,	  nM±SEM)	  at	  monoamine	  transporters	  are	  included.	  
a	  Kuhar	  et	  al.,	  1999,	  b	  Kula	  et	  al.,	  1999,	  c	  Rothman	  et	  al.,	  2001,	  d	  Matecka	  et	  al.,	  1996	  	  	   In	  order	   to	  characterize	  neurochemical	  effects	  produced	  by	  drugs	  of	  abuse,	  including	   monoamine	   releasers	   like	   amphetamine	   and	   uptake	   inhibitors	   like	  cocaine,	   investigators	   have	   focused	   on	  measuring	   the	   impact	   of	   various	   drugs	   on	  brain	  monoamine	  levels	  in	  the	  nucleus	  accumbens	  (NAc),	  the	  major	  terminal	  of	  the	  mesolimbic	   dopaminergic	   system,	   using	   in	   vivo	   assays	   like	   microdialysis.	  Intracerebral	  microdialysis	   is	  an	  experimental	   technique	  that,	   in	  combination	  with	  high	   performance	   liquid	   chromatography	   and	   electrochemical	   detection	   (HPLC-­‐ECD),	  can	  be	  used	  to	  recover	  and	  measure	  endogenous	  extracellular	  monoamines	  in	  discrete	  brain	  regions	  (Zetterström	  et	  al.,	  1983).	  Early	  studies	  of	  the	  neurochemical	  effects	  of	   various	  drugs	  of	   abuse	  on	  extracellular	   levels	  of	  DA	   in	   the	   striatum	  and	  NAc	   showed	   that	   virtually	   all	   drugs	   abused	   by	   humans	   (e.g.	   opiates,	   ethanol,	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nicotine,	   amphetamine	   and	   cocaine)	   increased	   DA	   levels	   in	   both	   regions,	   but	  particularly	   in	   the	  accumbens	  (Di	  Chiara	  and	   Imperato,	  1988).	  Subsequent	  studies	  confirmed	   that	   various	   classes	   of	   abused	  drugs,	   particularly	  monoamine	   releasers	  and	   uptake	   inhibitors,	   elevate	   accumbal	   DA	   levels	   (Carboni	   et	   al.,	   1989)	   and	  extended	   on	   those	   findings	   by	   demonstrating	   that	   alterations	   in	   other	   accumbal	  monoamine	   levels	   (i.e.	   especially	   5-­‐HT)	   also	   influence	   a	   drug’s	   abuse	  potential.	   In	  fact,	  studies	  have	  suggested	  that	  drug-­‐induced	  increases	  in	  accumbal	  5-­‐HT	  levels	  are	  not	   associated	   with	   abuse	   and	   may	   actually	   inhibit	   DA	   neurotransmission	  (Baumann	  et	  al.,	  2011,	  2012).	  	  With	   regards	   to	   neurochemical	   effects	   of	  monoamine	   releasers	   specifically,	  amphetamine	  has	  been	  repeatedly	  shown	  to	  produce	  selective	  increases	  in	  NAc	  DA	  levels	   without	   significantly	   increasing	   accumbal	   5-­‐HT	   (Ichikawa	   et	   al.,	   1998;	  Kankaanpää	   et	   al.,	   1998).	   Fenfluramine,	   on	   the	   other	   hand,	   selectively	   increases	  accumbal	  5-­‐HT	  without	  impacting	  DA	  levels	  (Benloucif	  and	  Galloway,	  1991;	  Shoaib	  et	  al.,	  1997).	  Mixed-­‐action	  monoamine	  releasers	  like	  MDMA	  (Gough	  et	  al.,	  1991)	  and	  methylone	  (Baumann	  et	  al.,	  2012)	  produce	  increases	  in	  both	  DA	  and	  5-­‐HT	  levels	  in	  nucleus	   accumbens.	   Figure	   I.9	   illustrates	   neurochemical	   effects	   of	   amphetamine,	  MDMA	  and	  fenfluramine	  on	  extracellular	  NAc	  DA	  and	  5-­‐HT	  levels,	  as	  determined	  by	  microdialysis	   in	   preliminary	   experiments	   that	   I	   conducted	   (Bonano	   et	   al.,	   in	  submission).	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Figure	  I.9	  
	  
Effects	   of	   amphetamine	   (AMPH),	   methylenedioxymethamphetamine	   (MDMA),	   and	  
fenfluramine	   (FEN)	   on	  DA	   and	   5-­‐HT	   levels	   in	   the	  NAc	   of	   awake	   rats	   expressed	   as	   a	  
percentage	  of	  baseline	  neurotransmitter	  levels.	  Left	  panels	  indicate	  temporal	  changes	  
in	   %	   baseline	   DA,	   while	   right	   panels	   indicate	   changes	   in	   %	   baseline	   5-­‐HT.	   Arrow	  
indicates	   time	  of	   drug	  administration.	   Filled	   symbols	   indicate	   statistical	   significance	  
(P<0.05)	   compared	   to	   vehicle	   conditions	   within	   a	   given	   time	   point.	   Figure	   from	  
Bonano	  et	  al.,	  in	  submission.	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Substantial	  evidence	  exists	  to	  suggest	  that	  elevations	  in	  synaptic	  5-­‐HT	  levels	  attenuate	  the	  stimulant	  properties	  of	  DA-­‐selective	  monoamine	  releasers	  and	  uptake	  inhibitors.	   For	   one,	   elevations	   in	   synaptic	   5-­‐HT	   have	   been	   shown	   to	   exert	   an	  inhibitory	  influence	  on	  mesolimbic	  DA	  neurons	  (Rothman	  and	  Baumann,	  2006).	  In	  particular,	  as	  depicted	  and	  described	  previously	   in	  Figure	   I.5,	  5-­‐HT	  can	   inhibit	  DA	  neurons	   directly	   or	   by	   producing	   convergent	   effects	   that	   inhibit	   DA	   effects	   on	  downstream,	  postsynaptic	  neurons.	  For	  example,	  a	  study	  investigating	  the	  effects	  of	  a	   null	  mutation	   that	   eliminates	   expression	   of	   5-­‐HT2C	   receptors	   found	   that	  mutant	  mice	  had	   increased	  activity	  of	  substantia	  nigra	  pars	  compacta	  (SNc)	  dopaminergic	  neurons,	   elevated	   baseline	   DA	   levels	   in	   dorsal	   striatum	   (DSt),	   and	   enhanced	  sensitivity	   to	   behavioral	   effects	   of	   d-­‐amphetamine	   (a	   DA-­‐selective	   monoamine	  releaser)	  and	  GBR	  12909	  (a	  DA-­‐selective	  uptake	   inhibitor)	   (Abdallah	  et	  al.,	  2009).	  Another	  group	  investigated	  5-­‐HT1B	  receptor	  knockout	  mice	  to	  assess	  the	  function	  of	  5-­‐HT1B	   receptors	   in	  modulating	   synaptic	   transmission	  of	   the	  dorsal	   raphe,	   ventral	  midbrain	   and	   nucleus	   accumbens,	   and	   they	   concluded	   that	   5-­‐HT1B	   receptors	  function	  as	  auto-­‐	  and	  heteroreceptors	  to	  exert	  presynaptic	  inhibition	  of	  monoamine	  transmitter	  release	  in	  the	  CNS	  (Morikawa	  et	  al.,	  2000).	  Furthermore,	  supplementing	  dietary	   tryptophan	   (5-­‐HT	   precursor)	   in	   rats	   has	   been	   shown	   to	   attenuate	  amphetamine	   self-­‐administration	   (Smith	   et	   al.,	   1986).	   	   Studies	   have	   also	   reported	  that	   increasing	  brain	  5-­‐HT	  activity	   can	  attenuate	   the	   reinforcing	  effects	  of	   cocaine	  (Czoty	  et	  al.,	  2002).	  Additionally,	  cocaine	  analogs	  with	  higher	  SERT	  potency	  support	  lower	   rates	   of	   self-­‐administration	   than	   cocaine	   analogs	  with	   lower	   SERT	   potency	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(Roberts	   et	   al.,	   1999).	   Together,	   these	   findings	   suggest	   that	   serotonergic	   systems	  exert	  an	  inhibitory	  effect	  on	  dopaminergic	  systems.	  An	   implication	   of	   these	   findings	   is	   that	   abuse	   liability	   of	   monoamine	  releasers	   might	   be	   determined	   in	   part	   by	   their	   relative	   selectivity	   to	   promote	  release	  of	  DA/NE	  vs.	  5-­‐HT,	  and	  published	  data	  from	  our	  lab	  support	  a	  relationship	  between	   pharmacological	   selectivity	   for	   DA/NE	   vs.	   5-­‐HT	   release	   and	   behavioral	  efficacy	   to	  produce	  abuse-­‐related	   facilitation	  of	   intracranial	   self-­‐stimulation	   (ICSS)	  (Bauer	  et	  al.,	  2013b;	  Bonano	  et	  al.,	   in	  press).	   ICSS	   is	  an	  experimental	   tool	   that	  has	  been	   used	   to	   study	   abuse	   liability	   of	   stimulants,	   among	   other	   classes	   of	   drugs	  (Kornetsky	  and	  Esposito,	  1979;	  Wise,	  1996;	  Bonano	  et	  al.,	  2014b;	  Negus	  and	  Miller,	  2014).	  The	  idea	  that	  specialized	  neural	  circuits,	  or	  “reward	  pathways,”	  exist	  largely	  originated	  based	  on	  early	  observations	  of	  ICSS;	  that	  is,	  rats	  would	  work	  vigorously	  to	  earn	  electrical	  brain	  stimulation	  delivered	  to	  some	  brain	  targets	  (Olds	  and	  Milner,	  1954).	   Olds	   began	   using	   the	   phrase	   “reward	   neuron”	   in	   the	   late	   1950s	   to	   discuss	  such	   neural	   circuits.	   Now,	   the	   mesolimbic	   DA	   pathway	   (VTA	   to	   NAc)	   is	   widely	  regarded	   as	   the	   central	   “reward	   pathway,”	   implicating	   midbrain	   DA	   neurons	   as	  major	  mediators	  of	  the	  rewarding	  effects	  of	  drugs	  of	  abuse	  (Wise	  and	  Bozarth,	  1987;	  Koob,	  1992;	  Ikemoto	  and	  Bonci,	  2014).	   	  In	  ICSS,	  subjects	  are	  trained	  to	  lever	  press	  for	  pulses	  of	  brain	  stimulation	  delivered	  via	  microelectrodes	  implanted	  in	  reward-­‐related	   brain	   regions	   like	   the	   medial	   forebrain	   bundle	   (see	   Figure	   I.10),	   and	  different	   frequencies	  or	   intensities	  of	  brain	  stimulation	  maintain	  different	   rates	  of	  lever-­‐press	  responding.	  Many	  drugs	  of	  abuse	  increase	  (“facilitate”)	  low	  rates	  of	  ICSS	  maintained	   by	   low	   frequencies	   or	   intensities	   of	   brain	   stimulation;	   thus,	   ICSS	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The	   medial	   forebrain	   bundle	   (MFB),	   a	   fiber	   tract	   that	   passes	   through	   the	   lateral	  
hypothalamus	  (LH),	  is	  a	  common	  target	  for	  electrical	  brain	  stimulation	  in	  ICSS	  studies.	  
A)	  Sagittal	  and	  B)	  coronal	  sections	  of	   the	  rat	  brain	   indicate	  MFB	  location	   in	  orange.	  
Electrical	  stimulation	  of	  MFB	  in	  ICSS	   is	  believed	  to	  activate	  excitatory	  glutamatergic	  
inputs	  from	  LH	  to	  DA	  neuron	  cell	  bodies	  in	  the	  ventral	  tegmental	  area	  (VTA),	  as	  shown	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in	  panel	  C.	  In	  VTA,	  glutamate	  binds	  ionotropic	  glutamate	  receptors	  and	  increases	  the	  
firing	   rate	   of	   DA	   neurons	  whose	   cell	   bodies	   reside	   there.	   Images	   adapted	   from	   ICSS	  
Review	  by	  Negus	  and	  Miller,	  2014.	  	  An	  additional	  benefit	  of	  ICSS	  is	  its	  ability	  to	  discriminate	  both	  abuse-­‐related	  and	   abuse-­‐limiting	   drug	   effects	   in	   a	   single	   procedure.	   Monoamine	   releasers	   and	  reuptake	  inhibitors	  can	  simultaneously	  produce	  DA-­‐mediated,	  abuse-­‐related	  effects	  (facilitation	   of	   low	   ICSS	   rates)	   and	   5-­‐HT-­‐mediated,	   abuse-­‐limiting	   effects	  (depression	   of	   high	   rates	   of	   ICSS).	  For	   example,	   DA-­‐selective	   releasers	   like	  amphetamine	  produce	   exclusive	   facilitation	  of	   ICSS	   across	   a	   broad	   range	  of	   doses	  (Bauer	  et	  al.,	  2013b).	  Conversely,	  the	  5-­‐HT-­‐selective	  releaser	  fenfluramine	  produces	  exclusive	  depression	  of	   ICSS	  (Olds	  and	  Yuwiler,	  1992;	  Bauer	  et	  al.,	  2013b).	  Mixed-­‐action	  DA/5-­‐HT	  releasers	  like	  MDMA	  produce	  simultaneous	  facilitation	  of	  low	  ICSS	  rates	  and	  depression	  of	  high	  ICSS	  rates	  (Bauer	  et	  al.,	  2013b).	  These	  results,	  depicted	  in	  Figure	  I.11,	  support	  the	  assertion	  that	  ICSS	  is	  capable	  of	  discerning	  abuse-­‐related	  and	  abuse-­‐limiting	  drug	  effects,	  and	  that	  a	  drug’s	  selectivity	  to	  promote	  DA	  vs.	  5-­‐HT	  release	  correlates	  with	  its	  profile	  of	  abuse-­‐related	  facilitation	  and/or	  abuse-­‐limiting	  depression	  of	  ICSS.	  Furthermore,	  these	  findings	  lend	  additional,	  behavioral	  support	  to	   the	   assertion	   that	   serotonergic	   systems	   are	   capable	   of	   exerting	   an	   inhibitory	  effect	  on	  dopaminergic	  systems.	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Figure	  I.11	  
	  
Effects	  of	  representative	  doses	  of	  amphetamine	  (1.0	  mg/kg),	  MDMA	  (3.2	  mg/kg),	  and	  
fenfluramine	   (3.2	   mg/kg)	   on	   ICSS	   behavior.	   Amphetamine,	   a	   DA-­‐selective	   releaser,	  
produces	  exclusive	  facilitation	  of	  ICSS,	  whereas	  fenfluramine,	  a	  5-­‐HT-­‐selective	  releaser,	  
produces	   exclusive	   depression	   of	   ICSS.	   MDMA,	   a	   nonselective	   releaser,	   produces	   a	  
mixed	  behavioral	  profile	  of	  rate-­‐increasing	  and	  rate-­‐decreasing	  effects	  on	  ICSS.	  Filled	  
points	  represent	   frequencies	  at	  which	  reinforcement	  rates	  were	  statistically	  different	  
from	  vehicle	  rates	  as	  determined	  by	  two-­‐way	  ANOVA	  followed	  by	  Holm-­‐Sidak	  post	  hoc	  
test,	  P<0.05.	  	  Figure	  adapted	  from	  Bauer	  et	  al.,	  2013b.	  	  
IV.	  Pharmacology	  of	  Synthetic	  Cathinones	  In	   the	   late	   1980s,	   cathinone	   and	   MCAT	   were	   shown	   to	   induce	   release	   of	  radioactivity	  from	  [3H]DA-­‐prelabeled	  tissue	  from	  rat	  caudate	  in	  a	  manner	  similar	  to	  that	   observed	   with	   amphetamine	   and	   methamphetamine	   (Glennon	   et	   al.,	   1987).	  Later	   studies	   found	   that	  MCAT	   is	  potent	  both	  as	   a	  monoamine	   releaser	   and	  as	   an	  uptake	   inhibitor,	   and	   that	   its	   selectivity	   favors	   DA	   and	   NE	   vs.	   5-­‐HT	   (Cozzi	   et	   al.,	  1999,	   2013).	   Despite	   its	   potent	   effects	   as	   an	   uptake	   inhibitor,	   MCAT’s	   relatively	  higher	   potency	   as	   a	   monoamine	   transporter	   substrate	   suggests	   that	   it	   produces	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neurochemical	  and	  behavioral	  effects	  primarily	  as	  a	  result	  of	  its	  capacity	  to	  induce	  monoamine	  release.	  Three	  early	   synthetic	   cathinone	  bath	  salts	   that	  were	  amongst	  the	   first	   to	   be	   investigated	   preclinically	  were	  mephedrone,	  methylone	   and	  MDPV.	  One	  study	  showed	  that	  mephedrone	  and	  methylone	  both	  function	  as	  substrates	  for	  monoamine	   transporters	   (i.e.	   monoamine	   releasers),	   with	   a	   release	   profile	  comparable	  to	  MDMA	  (Baumann	  et	  al.,	  2012).	  Subsequently,	  using	  frog	  oocytes	  that	  had	   been	   transfected	   with	   cRNA	   to	   express	   hDAT,	   mephedrone	   was	   shown	   to	  produce	   inward	   currents	   that	   resembled	   depolarization	   produced	   by	  monoamine	  releasers	   (i.e.	   transporter	   substrates)	   like	  amphetamine,	  whereas	  MDPV	  produced	  outward	  currents	   that	   resembled	  cocaine-­‐induced	  hyperpolarization	  characteristic	  of	  monoamine	  uptake	   inhibitors	  (i.e.	   transporter	  blockers)	  (Cameron	  et	  al.,	  2013a,	  2013b).	  Studies	  by	  Simmler	  et	  al.	  (2013)	  demonstrated	  that	  mephedrone	  was	  nearly	  equipotent	  as	  a	  releaser	  and	  inhibitor	  of	  DA	  and	  5-­‐HT,	  but	  was	  much	  more	  potent	  as	  an	  inhibitor	  of	  NET.	  Conversely,	  MDPV	  was	  a	  potent	  inhibitor	  of	  DAT	  and	  NET	  with	  weak	  inhibition	  at	  SERT,	  and	  MDPV	  had	  no	  detectable	  function	  as	  a	  releaser	  at	  any	  monoamine	   transporter	   (Simmler	   et	   al.,	   2013),	   consistent	   with	   the	   “uptake	  inhibitor-­‐like”	   electrophysiological	   signature	   demonstrated	   by	   Cameron	   et	   al.	  (2013a).	  	  In	  terms	  of	  behavior,	  mephedrone,	  methylone	  and	  MDPV	  have	  been	  shown	  to	  induce	   abuse-­‐related,	   amphetamine-­‐like	   stimulant	   effects	   including	   locomotor	  activation,	   facilitation	  of	   ICSS,	  maintenance	  of	  self-­‐administration,	  and	  substitution	  for	  abused	  drugs	  in	  assays	  of	  drug	  discrimination	  (summary	  provided	  in	  Table	  I.3).	  First,	  mephedrone,	  methylone	  and	  MDPV	  have	  repeatedly	  been	  reported	  to	  induce	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hyperlocomotion	   in	   rodents	   (Baumann	   et	   al.,	   2012;	   López-­‐Arnau	   et	   al.,	   2012;	  Marusich	  et	  al.,	  2012;	  Fantegrossi	  et	  al.,	  2013).	  In	  a	  locomotor	  study	  in	  rats,	  which	  compared	   various	   synthetic	   cathinones	   (mephedrone,	   methylone,	   methedrone,	  MDPV,	   3-­‐fluoromethylmethcathinone,	   4-­‐fluoromethylmethcathinone),	   MDPV	   was	  the	   most	   potent	   and	   mephedrone	   was	   the	   least	   potent	   at	   inducing	   locomotion	  (Marusich	   et	   al.,	   2012).	  Despite	   their	  potency	  differences,	  MDPV	  and	  mephedrone	  displayed	  similar	  efficacies	  to	  increase	  locomotion	  (measured	  by	  total	  beam	  breaks	  in	   open	   field	   activity	   chambers),	   whereas	   methedrone	   produced	   weak	   effects	   on	  locomotor	  stimulation	  (Marusich	  et	  al.,	  2012).	  Another	  locomotor	  study	  performed	  in	   mice	   examined	   MDPV,	   mephedrone,	   methylone,	   4-­‐fluoromethylmethcathinone	  (flephedrone),	  butylone	  and	  naphylone	  and	  found	  that	  MDPV	  and	  mephedrone	  were	  nearly	  equipotent	  at	  producing	  hyperlocomotion,	  but	  MDPV	  produced	  much	  longer	  lasting	  effects	  (Gatch	  et	  al.,	  2013).	  	  In	  ICSS	  studies	  published	  during	  the	  early	  stages	  of	  this	  dissertation	  project,	  synthetic	   cathinones	   were	   reported	   to	   increase	   response	   rates	   and	   reduce	  thresholds	   for	   electrical	   brain	   stimulation.	   	   MDPV	   (0.1-­‐2.0	   mg/kg,	   i.p.)	   produced	  ICSS	   facilitation	   and	   reduced	   current-­‐intensity	   threshold	   in	   a	   discrete	   trial	  procedure	   in	  male	  Sprague-­‐Dawley	   rats	   (Watterson	  et	   al.,	   2012b),	   consistent	  with	  abuse	   potential.	   Mephedrone	   (1-­‐10	   mg/kg,	   i.p.)	   produced	   mixed	   effects	   on	  frequency-­‐rate	   ICSS	   curves	   in	  male	   C57BL/6J	  mice,	  with	   a	   facilitation	   of	   low	   ICSS	  rates	   maintained	   by	   low	   brain-­‐stimulation	   frequencies,	   but	   also	   a	   reduction	   in	  maximal	   rates	   (Robinson	   et	   al.,	   2012).	   	   This	   overall	   profile	   of	   effects	   is	   similar	   to	  results	   shown	   in	   Figure	   I.11	   for	  MDMA.	   	  Methylone	   (0.1-­‐10mg/kg,	   i.p.)	   showed	   a	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dose-­‐dependent	   trend	   to	   decrease	   ICSS	   current-­‐intensity	   thresholds,	   but	   these	  reductions	  were	  not	  statistically	  significant	  (Watterson	  et	  al.,	  2012a).	  	  Synthetic	   cathinones	   have	   also	   been	   reported	   to	   produce	   abuse-­‐related	  behavioral	   effects	   in	   assays	   of	   drug	   self-­‐administration.	   MCAT	   maintained	   self-­‐administration	  in	  baboons	  (Kaminski	  and	  Griffiths,	  1994),	  and	  MDPV	  showed	  potent	  stimulant	  effects	  and	  was	  self-­‐administered	  in	  rats	  (Watterson	  et	  al.,	  2012b;	  Aarde	  et	  al.,	  2013b).	  Likewise,	  mephedrone	  (Hadlock	  et	  al.,	  2011;	  Aarde	  et	  al.,	  2013a)	  and	  methylone	  served	  as	  reinforcers	  and	  produced	  dose-­‐dependent	  acquisition	  of	  self-­‐administration	  in	  rats	  (Watterson	  et	  al.,	  2012a).	  Fewer	   synthetic	   cathinones	   have	   been	   investigated	   in	   drug	   discrimination;	  however,	  results	  are	  largely	  consistent	  in	  showing	  that	  several	  synthetic	  cathinones	  substitute	   for	   other	   psychostimulant	   drugs	   of	   abuse,	   primarily	   amphetamine.	  Cathinone	  and	  MCAT	  substituted	   for	   (+)-­‐amphetamine	   in	   rats	   (Kalix	  and	  Glennon,	  1986;	   Glennon	   et	   al.,	   1987).	   Interestingly,	   methylone	   substituted	   for	   	   (+)-­‐amphetamine	  in	  rats,	  but	  3,4-­‐methylenedioxycathinone	  (the	  N-­‐desmethyl	  analog	  of	  methylone)	   did	   not	   (Dal	   Cason	   et	   al.,	   1997).	   Furthermore,	   in	   rats	   trained	   to	  discriminate	   mephedrone,	   MDMA	   fully	   substituted	   while	   methamphetamine	   and	  cocaine	   produced	   only	   partial	   substitution	   (Varner	   et	   al.,	   2013).	   Results	   from	  behavioral	   studies	   of	   various	   synthetic	   cathinones’	   effects	   published	   before	   or	  during	  my	  dissertation	  studies	  are	  summarized	  in	  Table	  I.3.	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Table	  I.3	  
Drug	   Pharmacology	   Dose/Route	   Sex/	  Strain/	  
Species	  
Behavioral	  Effects	   Reference	  MDPV	   Monoamine	  uptake	  inhibitor,	  DAT>>SERT	  
1-­‐30	  mg/kg,	  i.p.	   Male	  ICR	  mice	  	   é	  locomotion	   Marusich	  et	  al.	  2012	  0.3-­‐30	  mg/kg,	  inj?	   Male	  Swiss-­‐Webster	  mice	   é	  locomotion,	  	  ED50=	  1.26mg/kg	   Gatch	  et	  al.	  2013	  0.1-­‐2mg/kg,	  i.p.	  0.05-­‐0.2	  mg/kg/inf.	   Male	  Sprague-­‐Dawley	  rats	   é	  ICSS,	  Self-­‐administered Watterson	  et	  al.	  2012b	  0.05mg/kg/inf.,	  i.v.	   Male	  Wistar	  rats	   Self-­‐administered,	  avg:	  0.9	  mg/kg/h	   Aarde	  et	  al.	  2013b	  Methylone	  (MDMC)	   Monoamine	  releaser,	  DAT≅SERT	   3-­‐56	  mg/kg	  i.p.	   Male	  ICR	  mice	  	   é	  locomotion	   Marusich	  et	  al.	  2012	  1-­‐30	  mg/kg	   Male	  Swiss-­‐Webster	  mice	   é	  locomotion	  ED50=1.48mg/kg	   Gatch	  et	  al.	  2013	  0.1-­‐10	  mg/kg,	  i.p.	  0.05-­‐0.5	  mg/kg/inf.,	  i.v.	   Male	  Sprague-­‐Dawley	  rats	   é	  ICSS,	  Self-­‐administered	   Watterson	  et	  al.	  2012a	  1-­‐3	  mg/kg,	  i.p.	   Male	  Sprague-­‐Dawley	  rats	   Substituted	  for	  1.0mg/kg	  (+)-­‐Amph	  discrim-­‐stimulus,	  ED50=	  2.36	  mg/kg	  
Dal	  Cason	  et	  al.	  1997	  
Mephedrone	   Monoamine	  releaser,	  DAT≅SERT	   3-­‐56	  mg/kg	  i.p.	   Male	  ICR	  mice	  	   é	  locomotion	   Marusich	  et	  al.	  2012	  0.3-­‐30	  mg/kg	   Male	  Swiss-­‐Webster	  mice	   é	  locomotion	  ED50=1.38mg/kg	   Gatch	  et	  al.	  2013	  1-­‐10	  mg/kg	  i.p.	   Male	  C57BL/6J	  mice	   éê	  ICSS	   Robinson	  et	  al.	  2012	  0.24mg	  per	  10uL	  infusion,	  i.v.	   Male	  Sprague-­‐Dawley	  rats	   Self-­‐administered,	  	  é	  drug	  intake	  1.77	  (d1)	  to	  6.78mg	  (d8)	   Hadlock	  et	  al.	  2011	  1.0mg/kg/	  infusion,	  i.v.	   Male	  Sprague-­‐Dawley	  and	  Wistar	  rats	   Self-­‐administered,	  95%	  (S-­‐D)	  and	  98%	  (Wistar)	  reward-­‐lever	  discrimination	  
Aarde	  et	  al.	  2013a	  
3.2	  mg/kg,	  i.p.	   Male	  Long-­‐Evans	  rats	   3.2mg/kg	  MDMA	  fully	  substituted	  for	  Meph	  discriminative	  stimulus	  
Varner	  et	  al.	  2013	  
Flephedrone	   Monoamine	  releaser,	  DAT>SERT	   10-­‐56	  mg/kg,	  i.p.	   Male	  ICR	  mice	  	   é	  locomotion	   Marusich	  et	  al.	  2012	  0.3-­‐30	  mg/kg	   Male	  Swiss-­‐Webster	  mice	   é	  locomotion	  ED50=2.04mg/kg	   Gatch	  et	  al.	  2013	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   In	   conclusion,	   existing	   data	   suggest	   that	   emerging	   synthetic	   cathinones	  function	  as	  monoamine	  releasers	  and/or	  uptake	  inhibitors	  similarly	  to	  established	  drugs	   of	   abuse,	   like	   amphetamine	   and	   cocaine.	   At	   the	   time	  when	  my	   dissertation	  work	  started,	  relatively	  little	  was	  known	  about	  the	  pharmacology	  of	  these	  emerging	  drugs	   of	   abuse,	   or	   about	   the	   determinants	   of	   their	   abuse-­‐related	   effects.	   In	   the	  subsequent	   section,	   an	   overview	   of	   my	   dissertation	   studies	   is	   provided,	   which	  outlines	   the	   manner	   in	   which	   a	   series	   of	   para-­‐substituted	   MCAT	   analogs	   were	  systematically	  investigated	  not	  only	  to	  determine	  in	  vitro	  and	  in	  vivo	  effects	  of	  these	  compounds	   on	   neurochemistry	   and	   behavior,	   but	   also	   to	   better	   understand	   the	  structural	  determinants	  and	  molecular	  mechanisms	  underlying	  these	  abuse-­‐related	  effects.	  	  	  
V.	  Quantitative	  Structure-­‐Activity	  Relationship	  (QSAR)	  Analysis	  Quantitative	   structure-­‐activity	   relationship	   (QSAR)	   analysis	   served	   as	   an	  organizing	  principle	  for	  the	  analysis	  of	  data	  from	  my	  project.	  	  QSAR	  studies	  are	  used	  to	   correlate	   physicochemical	   parameters	   of	   drug	   molecules	   with	   functional	  outcomes	   of	   drug	   administration,	   both	   in	   vitro	   and	   in	   vivo	   (Glennon	   and	   Young,	  2011).	   For	   the	   studies	   included	   in	   this	   dissertation,	   the	   para	   substituent	   on	   the	  benzene	  ring	  of	  the	  MCAT	  scaffold,	  R,	  was	  manipulated	  to	  include	  substituents	  that	  varied	   systematically	   along	   three	   physicochemical	   dimensions	   [steric	   (Es),	  electronic	  (σp),	  and	  lipophilic	  (πp)]	  (Figure	  I.12).	  Taft’s	  steric	  parameter	  Es	  was	  one	  of	   the	   first	   steric	   parameters	   employed	   in	   QSAR	   analysis	   and	   was	   derived	   by	  measuring	  rates	  of	  hydrolysis	  of	  various	  esters	  (Taft	  1952,	  1953).	  Hydrolysis	  rates	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Figure	  I.12	  
	  
Chemical	  structure	  of	  the	  MCAT	  scaffold	  and	  physicochemical	  parameters	  of	  the	  para	  
substituent,	   R.	   Values	   for	   physicochemical	   parameters	   (Taft’s	   steric	   parameter,	   ES;	  
electron-­‐withdrawing	  capacity,	  σp;	  lipophilicity,	  πp)	  were	  taken	  from	  Wolff	  (1980).	  	  
VI.	  Overview	  of	  Dissertation	  Studies	  	  The	   overall	   goal	   of	   this	   dissertation	   was	   to	   investigate	   expression	   and	  pharmacological	   determinants	   of	   abuse-­‐related	   effects	   produced	   by	   emerging	  synthetic	   cathinone	   drugs	   of	   abuse.	   	   This	   was	   done	   by	   examining	   quantitative	  structure-­‐activity	   relationships	   (QSARs)	   for	  MCAT	   and	   six	  para-­‐substituted	  MCAT	  analogs	   on	   various	   experimental	   endpoints,	   including:	   (1)	   in	   vitro	   potency	   to	  function	   as	   substrates	   for	   DAT	   and	   SERT	   in	   rat	   brain	   synaptosomes,	   (2)	   in	   vivo	  modulation	  of	   ICSS	   in	  male	  Sprague	  Dawley	  rats,	   (3)	  in	  vivo	  potency	  to	  release	  DA	  and	  5-­‐HT	   in	   the	  nucleus	  accumbens	   in	  male	  Sprague-­‐Dawley	   rats,	   and	   (4)	   in	  vitro	  potency	  to	  produce	  DAT-­‐	  and	  SERT-­‐mediated	  currents	   in	  a	   frog-­‐oocyte	  expression	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system.	   QSAR	   studies	   are	   used	   to	   correlate	   physicochemical	   parameters	   of	   drug	  molecules	  with	  functional	  outcomes	  of	  drug	  administration,	  both	  in	  vitro	  and	  in	  vivo	  (Glennon	   and	   Young,	   2011).	   Since	   each	   MCAT	   analog	   was	   designed	   to	   contain	   a	  different	  para	  substituent	  with	  unique	  steric	  (Es),	  electronic	  (σp),	  and	  lipophilic	  (πp)	  features,	   differences	   in	   these	   physicochemical	   parameters	   could	   be	   used	   to	  determine	   correlations	   between	   the	   structure	   of	   each	   compound	   and	   the	  neurochemical	  and	  behavioral	  effects	  it	  produces.	  	  	   Chapter	   II	   of	   this	   dissertation	   describes	   results	   from	   my	   first	   publication	  (Bonano	   et	   al.,	   2014b).	   Because	   of	   the	   recent	   and	   dramatic	   increase	   in	   abuse	   of	  synthetic	   cathinones	   in	   the	   U.S.,	   we	   conducted	   preclinical	   behavioral	   studies	   to	  investigate	   the	   expression	   of	   abuse-­‐related	   effects	   produced	   by	  MCAT	   and	   by	   the	  early	  “bath	  salts”	  constituents	  that	  were	  emergency	  scheduled	  by	  the	  DEA	  in	  2011.	  Specifically,	  this	  study	  examined	  behavioral	  effects	  of	  MCAT,	  MDPV,	  methylone	  and	  mephedrone	  in	  rats	  using	  ICSS.	  	   One	   key	   finding	   from	   this	   early	   study	   on	   ICSS	   modulation	   by	   synthetic	  cathinones	   was	   that	   MCAT	   and	   mephedrone	   produced	   strikingly	   different	  behavioral	  effects	  despite	  having	  similar	  molecular	  structures	  that	  differed	  only	   in	  the	   identity	  of	   the	  para	   substituent	  (-­‐H	  for	  MCAT;	   -­‐CH3	   for	  mephedrone).	  Previous	  studies	  from	  our	  group	  suggested	  that	  differential	  effects	  of	  MCAT	  and	  mephedrone	  might	  be	  related	  to	  their	  differential	  effects	  at	  DA	  vs.	  5-­‐HT	  transporters	  (Bauer	  et	  al.,	  2013b).	   Accordingly,	   the	   remainder	   of	   my	   dissertation	   focused	   on	   use	   of	   QSAR	  analysis	   to	   investigate	   the	   role	   of	   the	   para	   substituent	   of	   the	  MCAT	   scaffold	   as	   a	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determinant	   of	   effects	   produced	   by	   MCAT	   analogs	   on	   behavior	   and	   on	  neurochemical	  and	  electrophysiological	  measures	  of	  DAT	  and	  SERT	  function.	  Chapter	   III	   describes	   results	   from	   a	   subsequent	   publication	   on	   the	   abuse-­‐related	   in	   vitro	   neurochemical	   and	   in	   vivo	   behavioral	   effects	   of	   para-­‐substituted	  MCAT	  analogs	  in	  rats	  (Bonano	  et	  al.,	  2014a).	  This	  study	  examined	  QSARs	  for	  MCAT	  and	   six	   para-­‐substituted	   MCAT	   analogs	   on	   (a)	   in	   vitro	   potency	   to	   promote	  monoamine	   release	   via	   DAT	   and	   SERT,	   and	   (b)	   in	   vivo	   modulation	   of	   ICSS.	  Correlations	   were	   evaluated	   for	   neurochemical	   and	   behavioral	   effects	   relative	   to	  each	  other	   and	   to	   steric	   (Es),	   electronic	   (σp)	   and	   lipophilic	   (πp)	   parameters	   of	   the	  
para	  substituents.	  	  Chapter	   IV	   describes	   the	   in	  vivo	   neurochemical	   effects	   of	   these	   same	  para-­‐substituted	   MCAT	   analogs	   on	   extracellular	   accumbal	   DA	   and	   5-­‐HT	   levels	   using	  microdialysis	   in	   rats.	  As	  a	   follow-­‐up	   to	   the	   studies	  described	   in	  Chapter	   III,	  which	  identified	  steric	  volume	  as	  a	  critical	  determinant	  of	  in	  vitro	  DAT-­‐vs.-­‐SERT	  selectivity,	  correlations	   were	   evaluated	   between	   steric	   volume	   of	   the	   para	   substituents	   of	  tested	  MCAT	  analogs	  and	  the	  efficacy	  of	  those	  analogs	  to	  increase	  DA	  vs.	  5-­‐HT	  levels	  in	  the	  nucleus	  accumbens	  (NAc)	  of	  awake	  rats.	  	  The	   major	   conclusion	   of	   my	   work	   is	   that	   steric	   features	   of	   the	   para	  substituent	   on	   the	   MCAT	   scaffold	   are	   key	   determinants	   of	   the	   abuse-­‐related	  stimulant	  effects	  of	  MCAT	  analogs,	  including	  the	  bath	  salts	  constituent	  mephedrone.	  This	  dissertation	  not	  only	  extends	  the	  body	  of	  literature	  on	  designer	  drugs	  of	  abuse	  by	   investigating	   abuse-­‐related	   behavioral	   effects	   of	   prominent	   bath	   salts	  constituents	  (Chapter	  II),	  but	  it	  also	  provides	  evidence	  to	  support	  physicochemical	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determinants	  of	  both	   in	  vitro	  and	   in	  vivo	  neurochemical	  and	  behavioral	  effects	  of	  a	  novel	  series	  of	  systematically	  derivatized	  MCAT	  analogs	  (Chapters	  III	  &	  IV).	  Overall,	  the	   data	   contained	  within	   the	   body	   of	   this	   dissertation	  will	   provide	   an	   improved	  understanding	   of	   the	   mechanism(s)	   of	   synthetic	   MCAT	   analogs’	   abuse-­‐related	  effects,	  which	  might	  guide	  both	  regulatory	  control	  of	  emerging	  designer	  drugs	  and	  development	   of	   novel	   strategies	   for	   treating	   bath	   salts	   intoxication	   to	   improve	  clinical	  outcomes	  associated	  with	  bath	  salts	  use	  and	  abuse.	  Furthermore,	  these	  data	  will	   aid	   in	   the	   analysis	   of	   docking	   interactions	   between	   MCAT	   analogs	   and	   their	  molecular	   targets	   (DAT	   and	   SERT),	   as	   well	   as	   in	   the	   generation	   of	   hypothetical	  structural	  models	  of	  DAT	  and	  SERT.	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Chapter	  II:	  Abuse-­‐Related	  and	  Abuse-­‐Limiting	  Effects	  of	  Methcathinone	  and	  the	  Synthetic	  “Bath	  Salts”	  Cathinones	  Analogs	  Methylenedioxypyrovalerone	  (MDPV),	  Methylone	  and	  Mephedrone	  on	  Intracranial	  Self-­‐Stimulation	  in	  Rats	  	  
Published:	   Bonano	   JS,	   Glennon	  RA,	  De	   Felice	   LJ,	   Banks	  ML,	   and	  Negus	   SS	   (2014).	  
Psychopharmacology	  231:	  199–207.	   	  
Introduction	  The	  goal	  of	  the	  present	  study	  was	  to	  compare	  the	  potency	  and	  time	  course	  of	  ICSS	  effects	  produced	  by	  methcathinone	  (MCAT)	  and	   the	   three	  recently	  scheduled	  "bath	  salts"	   cathinone	  analogs:	  MDPV,	  methylone	  and	  mephedrone.	  Recent	   studies	  have	   reported	   facilitation	   of	   ICSS	   by	   MDPV	   in	   rats	   (Watterson	   et	   al.	   2012)	   and	  mephedrone	   in	   mice	   (Robinson	   et	   al.	   2012);	   however,	   effects	   of	   MCAT	   and	  methylone	   on	   ICSS	   have	   not	   yet	   been	   described,	   nor	   have	   ICSS	   effects	   of	   these	  structurally,	   pharmacologically	   and	   epidemiologically-­‐related	   drugs	   been	   directly	  compared.	  Based	  on	  the	  in	  vitro	  selectivity	  of	  these	  compounds	  to	  promote	  release	  or	  block	  reuptake	  of	  DA	  vs.	  5-­‐HT,	  we	  predicted	  that	  MCAT	  and	  MDPV	  would	  display	  the	   greatest	   efficacy	   to	   produce	   abuse-­‐related	   facilitation	   of	   ICSS,	   whereas	  methylone	  and	  mephedrone	  would	  produce	  mixed	  effects	   that	  would	   include	  both	  DA-­‐mediated	  facilitation	  of	  low	  ICSS	  rates	  and	  5-­‐HT-­‐mediated	  depression	  of	  higher	  ICSS	  rates.	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Materials	  and	  Methods	  
Subjects	  Eighteen	   adult	   male	   Sprague-­‐Dawley	   rats	   (Harlan,	   Frederick,	   MD,	   USA)	  weighing	  314-­‐387	  g	  at	  the	  time	  of	  surgery	  were	  individually	  housed	  and	  maintained	  on	  a	  12	  h	   light/dark	  cycle	  with	   lights	  on	  from	  6:00	  a.m.	  to	  6:00	  p.m.	  Rats	  had	  free	  access	   to	   food	  and	  water	  except	  during	   testing.	  Animal	  maintenance	  and	   research	  were	  in	  compliance	  with	  the	  National	  Institutes	  of	  Health	  guidelines	  for	  the	  care	  and	  use	   of	   animal	   subjects	   in	   research	   (National	   Academy	   of	   Sciences,	   2011)	   and	  adhered	   to	   guidelines	   of	   the	   Committee	   for	   Research	   (National	   Research	   Council,	  2003).	   All	   animal	   use	   protocols	   were	   approved	   by	   the	   Virginia	   Commonwealth	  University	  Institutional	  Animal	  Care	  and	  Use	  Committee.	  
Intracranial	  self-­‐stimulation	  (ICSS)	  Procedure	  
Surgery.	  Rats	  were	  anesthetized	  with	  isoflurane	  (2.5-­‐3%	  in	  oxygen;	  Webster	  Veterinary,	  Phoenix,	  AZ,	  USA)	  until	  unresponsive	  to	  toe-­‐pinch	  prior	  to	  implantation	  of	  stainless	  steel	  electrodes	  (Plastics	  One,	  Roanoke,	  VA,	  USA).	  The	  cathode	  of	  each	  bipolar	  electrode	  was	  0.25	  mm	  in	  diameter	  and	  covered	  with	  polyamide	  insulation	  except	   at	   the	   flattened	   tip,	   whereas	   the	   anode	   was	   0.125	   mm	   in	   diameter	   and	  uninsulated.	   The	   cathode	   was	   stereotaxically	   implanted	   into	   the	   left	   medial	  forebrain	  bundle	  (MFB)	  at	  the	  level	  of	  the	  lateral	  hypothalamus	  (2.8	  mm	  posterior	  to	   bregma,	   1.7	   mm	   lateral	   to	   midsagittal	   suture,	   8.8	   mm	   ventral	   to	   skull).	   Three	  screws	  were	  placed	  in	  the	  skull,	  and	  the	  anode	  was	  wrapped	  around	  one	  screw	  to	  serve	  as	  the	  ground.	  The	  skull	  screws	  and	  electrode	  were	  secured	  to	  the	  skull	  with	  dental	   acrylic.	   Ketoprofen	   (5	   mg/kg)	   was	   used	   for	   post-­‐operative	   analgesia	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immediately	  and	  24	  h	  after	  surgery.	  Animals	  were	  allowed	  to	  recover	  for	  at	  least	  7	  days	  prior	  to	  commencing	  ICSS	  training.	  	  
	   Apparatus.	   Experiments	   were	   conducted	   in	   sound-­‐attenuating	   boxes	   that	  contained	   modular	   acrylic	   and	   metal	   test	   chambers	   (29.2	   x	   30.5	   x	   24.1	   cm)	  equipped	  with	  a	  response	  lever	  (4.5	  cm	  wide,	  2.0	  cm	  deep,	  3	  cm	  off	  the	  floor),	  three	  stimulation	   lights	   (red,	   yellow,	   and	   green,	   positioned	   7.6	   cm	   directly	   above	   the	  response	   lever),	   a	   2	   W	   house	   light	   and	   an	   ICSS	   stimulator	   (Med	   Associates,	   St.	  Albans,	   VT,	   USA).	   Electrodes	   were	   connected	   to	   the	   stimulator	   via	   a	   swivel	  commutator	   (Model	   SL2C,	   Plastics	   One,	   Roanoke,	   VA,	   USA).	   The	   stimulator	   was	  controlled	   by	   Med-­‐PC	   IV	   computer	   software	   that	   also	   controlled	   programming	  parameters	  and	  data	  collection	  (Med	  Associates).	  
	   Training.	   Following	   initial	   shaping	   of	   lever	   press	   responding,	   rats	   were	  trained	  under	  a	  fixed-­‐ratio	  1	  (FR	  1)	  schedule	  of	  brain	  stimulation	  using	  a	  behavioral	  procedure	   identical	   to	   that	   previously	   described	   (Bauer	   et	   al.	   2013).	   During	  behavioral	   sessions,	   each	   lever	   press	   resulted	   in	   the	   delivery	   of	   a	   0.5	   s	   train	   of	  square	   wave	   cathodal	   pulses	   (0.1	   ms	   pulse	   duration)	   and	   illumination	   of	   the	  stimulus	  lights	  over	  the	  lever.	  Stimulation	  intensity	  and	  frequency	  were	  set	  at	  150	  μA	   and	   126	   Hz,	   respectively,	   during	   initial	   60	   min	   training	   sessions.	   Stimulation	  intensity	   was	   then	   individually	   adjusted	   for	   each	   rat	   to	   the	   lowest	   value	   that	  sustained	  ICSS	  rates	  >	  30	  stimulations/min.	  This	  intensity	  (130-­‐240	  µA	  across	  rats)	  was	  then	  held	  constant	  for	  the	  remainder	  of	  the	  study,	  and	  frequency	  manipulations	  were	   introduced.	   Sessions	   involving	   frequency	   manipulations	   consisted	   of	   three	  sequential	  10	  min	  components.	  During	  each	  component,	  a	  descending	  series	  of	  10	  
	  	  44	  
frequencies	   (158	   to	   56	   Hz	   in	   0.05	   log	   increments)	   was	   presented,	   with	   each	  frequency	  available	  for	  a	  1	  min	  trial.	  Each	  frequency	  trial	  consisted	  of	  a	  10	  s	  time-­‐out,	  during	  which	  five	  non-­‐contingent	  “priming”	  stimulations	  were	  delivered	  at	  the	  frequency	  of	  stimulation	  that	  would	  be	  available	  during	  that	  trial,	  followed	  by	  a	  50	  s	  “response”	  period,	  during	  which	  responding	  produced	  electrical	  stimulation	  under	  a	  FR	  1	  schedule	  as	  described	  above.	  Training	  continued	  until	  rats	  reliably	  responded	  for	  only	  the	  first	  three	  to	  six	  frequency	  trials	  of	  each	  component	  over	  a	  period	  of	  at	  least	  three	  consecutive	  training	  days.	  	  
Testing.	  Studies	  with	  the	  racemates	  of	  MCAT	  (0.1-­‐1.0	  mg/kg),	  MDPV	  (0.1-­‐3.2	  mg/kg),	   methylone	   (0.32-­‐10	   mg/kg)	   and	   mephedrone	   (1.0-­‐10	   mg/kg)	   were	  conducted	  in	  two	  phases.	  In	  the	  first	  phase,	  a	  1.0	  to	  1.5	  log	  unit	  range	  of	  doses	  was	  tested	  for	  each	  drug	  with	  the	  goal	  of	  testing	  a	  dose	  range	  from	  an	  ineffective	  dose	  to	  a	   high	   dose	   that	   maximally	   facilitated	   ICSS.	   Dose	   ranges	   were	   based	   on	   extant	  literature	  (Aarde	  et	  al.	  2013;Baumann	  et	  al.	  2012a;	  Cozzi	  et	  al.	  2013;	  Hadlock	  et	  al.	  2011;	  Shortall	  et	  al.	  2012;	  Watterson	  et	  al.	  2012)	  and	  our	  own	  empirical	  results.	  For	  these	   dose-­‐effect	   studies,	   test	   sessions	   consisted	   of	   three	   sequential	   “baseline”	  components	   followed	   by	   a	   30	   min	   time-­‐out	   period	   and	   then	   by	   three	   sequential	  “test”	   components.	   	   A	   single	   dose	   of	   test	   drug	  was	   administered	   intraperitoneally	  (i.p.)	  at	  the	  beginning	  of	  the	  time-­‐out	  period.	  In	  the	  second	  phase,	  a	  time	  course	  was	  determined	  for	  effects	  produced	  by	  the	  highest	  dose	  of	  each	  compound.	  Time	  course	  test	   sessions	   consisted	   of	   three	   consecutive	   baseline	   components	   followed	   by	  immediate	   drug	   injection,	   and	   then	   by	   pairs	   of	   consecutive	   test	   components	  beginning	  after	  10,	  30,	  100	  and	  300	  min.	   In	  the	  case	  of	  MDPV,	  which	  had	  a	   longer	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duration	   of	   action,	   an	   additional	   pair	   of	   test	   components	  was	   initiated	   24	   h	   after	  drug	   injection.	  Test	  sessions	  were	  completed	  on	  Tuesdays	  and	  Fridays,	  and	   three-­‐component	   training	   sessions	  were	   conducted	  on	  all	   other	  weekdays.	  The	  order	  of	  testing	  with	  vehicle	  and	  drug	  doses	  was	  varied	  across	  subjects	  using	  a	  Latin-­‐square	  design.	  MCAT,	  MDPV	   and	  mephedrone	  were	   tested	   in	   separate	   groups	   of	   six	   rats	  each,	   and	  methylone	  was	   tested	   in	   five	   rats	   from	   the	   group	   that	   initially	   received	  methcathinone	   (the	   sixth	   rat	   lost	   its	   headcap	   and	   could	   no	   longer	   be	   tested).	  Methylone	   testing	   began	   one	   week	   after	   completion	   of	   methcathinone	   testing	   to	  minimize	  potential	  for	  carryover	  effects,	  and	  a	  vehicle	  test	  session	  was	  conducted	  in	  this	  interval	  to	  confirm	  stable	  responding.	  
	   Data	   Analysis.	  The	  primary	  dependent	   variable	  was	   reinforcement	   rate	   in	  stimulations	  per	  minute	  during	  each	   frequency	   trial.	  To	  normalize	   these	  data,	   raw	  reinforcement	  rates	  from	  each	  trial	  in	  each	  rat	  were	  converted	  to	  percent	  maximum	  control	  rate	  (%MCR),	  with	  MCR	  defined	  as	  the	  mean	  of	  the	  maximal	  rates	  observed	  during	  the	  second	  and	  third	  baseline	  components	  of	  any	  given	  session	  in	  any	  given	  rat.	  Thus,	  %MCR	  values	  for	  each	  trial	  were	  calculated	  as	  (reinforcement	  rate	  during	  a	   frequency	   trial)	   /	   (MCR)	  x	  100.	  For	  each	   test	   session,	  data	   from	   the	   second	  and	  third	  baseline	  components	  were	  averaged	  to	  yield	  a	  baseline	  frequency-­‐rate	  curve,	  and	   data	   from	   test	   components	   were	   averaged	   to	   generate	   test	   frequency-­‐rate	  curves.	   Baseline	   and	   test	   curves	   were	   then	   averaged	   across	   rats	   to	   yield	   mean	  baseline	  and	  test	  curves	  for	  each	  manipulation.	  For	  statistical	  analyses,	  results	  were	  compared	  by	  repeated	  measures	  two-­‐way	  ANOVA	  with	  ICSS	  frequency	  as	  one	  factor	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and	  either	  dose	  or	  time	  as	  the	  second	  factor.	  A	  significant	  ANOVA	  was	  followed	  by	  the	  Holm-­‐Sidak	  post	  hoc	  test	  and	  the	  criterion	  for	  significance	  was	  set	  at	  P<0.05.	  	   Two	  other	  analytic	  strategies	  were	  also	  used	  to	  provide	  summary	  measures	  for	  stratification	  of	  drug	  efficacies	  to	  facilitate	  ICSS	  (Altarifi	  and	  Negus	  2011;	  Bauer	  et	  al.	  2013;	  Bauer	  et	  al.	  in	  press).	  The	  first	  approach	  calculated	  the	  total	  number	  of	  stimulations	  delivered	  per	  component	  across	  all	  10	  frequency-­‐trials.	  Test	  data	  were	  normalized	   to	   individual	   baseline	   data	   using	   the	   equation	   %	   baseline	   total	  stimulations	   per	   component	   =	   (mean	   total	   stimulations	   per	   test	   component)	   /	  (mean	  total	  stimulations	  per	  baseline	  component)	  x	  100.	  Data	  were	  then	  averaged	  across	   rats	   in	   each	   experimental	   condition.	   The	   second	   approach	   employed	   rate-­‐dependency	  analysis	   to	  provide	  a	  measure	  of	   the	  degree	  of	   facilitation	  of	   low	  ICSS	  rates	  maintained	  by	  low	  brain	  stimulation	  frequencies.	  Specifically,	  baseline	  and	  test	  frequency-­‐rate	   curves	  were	   used	   to	   generate	   rate-­‐dependency	   plots	  where	   the	   x-­‐axis	  was	   log	  baseline	  rate	  and	   the	  y-­‐axis	  was	   log	   [(test	   rate/baseline	  rate)	  x	  100].	  Each	   rate-­‐dependency	   plot	   consisted	   of	   10	   points	   for	   baseline	   and	   test	   rates	  maintained	  by	  each	  brain	  stimulation	  frequency.	  These	  plots	  were	  then	  subjected	  to	  linear	  regression	  analysis	  to	  determine	  two	  parameters:	  (1)	  the	  slope	  (expressed	  as	  -­‐slope	  such	  that	  increasingly	  steep	  slopes	  were	  increasingly	  positive	  numbers),	  and	  (2)	  Y-­‐intercept	  (expressed	  as	  the	  intercept	  at	  x=1,	  where	  the	  baseline	  rate	  equaled	  10%	   MCR	   and	   log	   baseline	   rate=1).	   Summary	   measures	   across	   conditions	   were	  considered	   to	   be	   significantly	   different	   if	   95%	   confidence	   limits	   did	   not	   overlap	  between	  drugs.	  Note	  that	  ICSS	  thresholds	  were	  not	  used	  to	  compare	  drug	  effects	  for	  reasons	  discussed	  previously	  (Bauer	  et	  al.	  2013).	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Drugs	  	  (±)-­‐Methcathinone	   HCl	   and	   (±)-­‐3,4-­‐methylenedioxymethcathinone	   HCl	  (methylone)	  were	  prepared	  as	  previously	  reported	  (Glennon	  et	  al.	  1987;	  Dal	  Cason	  et	   al.	   1997).	   (±)-­‐3,4-­‐Methylenedioxypyrovalerone	   HCl	   (MDPV)	   and	   (±)-­‐4-­‐methylmethcathinone	  HCl	  (mephedrone)	  were	  available	  from	  a	  recent	  investigation	  (Cameron	   et	   al.	   2013a)	   and	  were	   prepared	   as	   previously	   described	   (Köppe	   et	   al.	  1969;	  de	  Durnaga	   and	  Sanchez	  1929,	   respectively).	   Compounds	  were	  prepared	   in	  sterile	  saline	  and	  delivered	  i.p.	  
	  
Results	  Electrical	   brain	   stimulation	   maintained	   a	   frequency-­‐dependent	   increase	   in	  ICSS	  rates	  under	  baseline	  conditions	  (e.g.	  “vehicle”	  data	  in	  Figure	  II.1).	  Across	  the	  18	  rats	   used	   in	   these	   studies,	   the	   average	   ±	   SEM	   baseline	   MCR	   was	   64.4	   ±	   1.98	  stimulations	   per	   trial,	   and	   the	  mean	   ±	   SEM	  number	   of	   total	   baseline	   stimulations	  was	  330	  ±	  20.7	  stimulations	  per	  component.	  Figure	  II.1	  shows	  dose-­‐effect	  data	  for	  MCAT	   (0.1-­‐1.0	   mg/kg),	   MDPV	   (0.32-­‐3.2	   mg/kg),	   methylone	   (1.0-­‐10	   mg/kg)	   and	  mephedrone	  (1.0-­‐10	  mg/kg).	  Two-­‐way	  ANOVA	  indicated	  significant	  main	  effects	  of	  frequency	  and	  dose	  and	  significant	  frequency	  x	  dose	  interactions	  for	  all	  drugs,	  and	  interaction	   effects	   are	   reported	   below	   for	   each	   drug.	   MCAT	   [F(27,135)=	   6.43,	  P<0.0001]	   and	   MDPV	   [F(27,135)=	   5.11,	   P<0.0001]	   produced	   dose-­‐dependent	  facilitation	  of	   low	  ICSS	  rates	  maintained	  by	  low	  brain	  stimulation	  frequencies	  with	  no	  evidence	  at	  these	  doses	  and	  pretreatment	  times	  of	  depression	  of	  high	  ICSS	  rates	  maintained	   by	   high	   brain	   stimulation	   frequencies.	   Methylone	   [F(36,144)=	   7.94,	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P<0.0001]	  also	  produced	  a	  dose-­‐dependent	  facilitation	  of	  low	  ICSS	  rates	  maintained	  by	  low	  stimulation	  frequencies;	  however,	  the	  highest	  dose	  of	  10	  mg/kg	  methylone	  also	   significantly	  decreased	  high	   ICSS	   rates.	   Lastly,	  mephedrone	   [F(27,135)=	  13.9,	  P<0.0001]	   produced	   weak	   facilitation	   of	   low	   ICSS	   rates	   while	   dose-­‐dependently	  depressing	  high	  ICSS	  rates	  maintained	  by	  high	  brain	  stimulation	  frequencies.	  MCAT	  was	   the	   most	   potent	   compound	   to	   alter	   ICSS	   (significant	   effects	   at	   doses	   ≥0.1	  mg/kg),	   followed	   by	  MDPV	   (≥0.32	  mg/kg),	   and	  methylone	   and	  mephedrone(≥1.0	  mg/kg).	  Lower	  doses	  of	  MDPV	  (0.1	  mg/kg)	  and	  methylone	  (0.32	  mg/kg)	  were	  also	  tested	  but	  had	  no	  effect	  (data	  not	  shown).	  	  Figure	  II.2	  shows	  the	  time	  course	  of	  effects	  produced	  by	  the	  highest	  dose	  of	  each	   compound.	   Two-­‐way	   ANOVA	   indicated	   significant	   main	   effects	   of	   frequency	  and	  time	  and	  significant	  frequency	  x	  time	  interactions	  for	  all	  drugs,	  and	  interaction	  effects	   are	   reported	   below	   for	   each	   drug.	   MCAT	   (1.0	   mg/kg;	   [F(36,180)=	   5.23,	  P<0.001])	  produced	  maximal	  facilitation	  of	  ICSS	  at	  the	  earliest	  time	  point	  (10	  min),	  and	   significant	   ICSS	   facilitation	  was	  no	   longer	   apparent	   after	  300	  min.	  MDPV	   (3.2	  mg/kg;	   [F(45,225)=	   5.52,	   P<0.0001])	   produced	   maximal	   facilitation	   of	   ICSS	  maintained	  by	  low	  stimulation	  frequencies	  after	  10	  min,	  but	  it	  also	  depressed	  ICSS	  at	   the	   two	   highest	   stimulation	   frequencies	   at	   this	   same	   early	   time	   point.	   At	   later	  times,	  MDPV	  produced	  only	  ICSS	  facilitation,	  and	  this	  facilitation	  was	  still	  significant	  after	  300	  min	  (1.85-­‐1.95	  log	  Hz)	  and	  24	  hr	  (1.85	  log	  Hz;	  data	  not	  shown).	  Methylone	  (10	  mg/kg;	  [F(36,144)=	  8.93,	  P<0.0001])	  yielded	  a	  mixed	  profile	  of	  effects	  with	  both	  rate-­‐increasing	   and	   maximal	   rate-­‐decreasing	   effects	   at	   10	   min.	   Rate-­‐decreasing	  effects	  were	  no	  longer	  significant	  after	  30	  min,	  but	  significant	  rate-­‐increasing	  effects	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persisted	  at	  30	  and	  100	  min.	  Mephedrone	  (10	  mg/kg;	  [F(36,180)=	  6.26,	  P<0.0001])	  produced	   only	   rate-­‐decreasing	   effects	   in	   the	   time	   course	   study.	   ICSS	   depression	  peaked	  at	  10	  min	  and	  was	  no	  longer	  significant	  after	  300	  min.	  	  Figure	   II.3	   shows	   dose-­‐dependence	   and	   time	   course	   of	   each	   compound	  expressed	  as	  total	  number	  of	  stimulations	  per	  component,	  a	  summary	  measure	  that	  integrates	  both	   rate-­‐increasing	  and	  rate-­‐decreasing	  drug	  effects	  on	   ICSS.	  All	  drugs	  produced	   dose-­‐dependent	   changes	   in	   this	   metric	   (Figure	   II.3A),	   and	   Table	   II.1	  compares	  peak	  effects	  of	  each	  drug.	  By	   this	  metric,	   the	   rank	  order	  of	  efficacy	  was	  MCAT	  ≥	  MDPV	  ≥	  methylone	  ≥	  mephedrone.	  All	  drugs	  had	  a	  rapid	  onset,	  and	  effects	  at	  10	  min	  provided	  further	  evidence	  for	  efficacy	  differences	  between	  MCAT,	  MDPV	  and	   methylone.	   Durations	   of	   action	   were	   MDPV	   >	   methylone	   >	   MCAT	   =	  mephedrone.	  Figure	   II.4	   shows	   results	   of	   rate-­‐dependency	   analysis	   to	   assess	   efficacy	   of	  ICSS	   facilitation.	  Figure	   II.4A	  shows	  rate-­‐dependency	  plots	   for	  each	  dose	  of	  MCAT.	  	  Figure	   II.4B	   shows	   rate-­‐dependency	   plots	   for	   doses	   of	   other	   drugs	   that	   produced	  peak	   Y-­‐intercepts.	   Figure	   II.4C	   shows	   dose-­‐dependent	   effects	   of	   each	   drug	   on	   Y-­‐intercept,	  and	  Table	  II.1	  compares	  peak	   increases	   in	  Y-­‐intercept	  produced	  by	  each	  drug.	  The	  rank	  order	  of	  efficacy	  was	  MCAT	  ≥	  MDPV	  ≥	  methylone	  >	  mephedrone.	  
	  
Summary	  This	  study	  compared	  effects	  produced	  by	  MCAT	  and	  three	  recently	  scheduled	  bath	   salts	   cathinone	   analogs,	   MDPV,	   methylone	   and	   mephedrone,	   on	   ICSS	   in	  rats.	  There	  were	  three	  main	  findings.	  First,	  all	   four	  analogs	  facilitated	  ICSS	  at	  some	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dose.	  To	  the	  extent	  that	  facilitation	  of	  ICSS	  is	  suggestive	  of	  a	  drug’s	  abuse	  potential,	  these	  findings	  are	  consistent	  with	  abuse	  liability	  for	  all	  four	  compounds.	  Second,	  the	  compounds	  differed	  in	  their	  relative	  efficacy	  to	  facilitate	  ICSS,	  with	  a	  rank	  order	  of	  MCAT	   ≥	   MDPV	   ≥	   methylone	   >	   mephedrone	   based	   on	   the	   maximal	   Y-­‐intercept	   in	  rate-­‐dependency	  analysis.	  Third,	   the	   compounds	  differed	   in	   their	   time	  courses.	  All	  compounds	   displayed	   a	   rapid	   onset	   of	   action,	   but	   the	  methylenedioxy-­‐substituted	  compounds	  MDPV	  and	  methylone	  had	  longer	  durations	  of	  action.	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Table	  II.1	  
	  
Efficacy	   to	   facilitate	   ICSS	   as	   indicated	   by	   maximal	   drug	   effects	   on	   (a)	   %	   Baseline	  
Number	  of	  Stimulations	  per	  Component,	  and	  (b)	  Y-­‐intercept	  of	  rate-­‐dependency	  plots.	  
The	  dose	  producing	  the	  maximum	  effect	  on	  each	  measure	  is	  also	  indicated.	  Doses	  are	  
expressed	  in	  mg/kg,	  and	  data	  for	  %	  Baseline	  Stimulations	  and	  Y-­‐Intercepts	  are	  given	  
as	   mean	   (95%	   CL).	   Values	   were	   considered	   to	   be	   significantly	   different	   if	   95%	  
confidence	  limits	  did	  not	  overlap.	  
*Significantly	   different	   from	   methcathinone	   as	   indicated	   by	   non-­‐overlapping	   95%	  











Maximum	  	  	  	  	  	  	  	  
Y-­‐Intercept	  
	  
Methcathinone	   1.0	   192	  (147-­‐237)	   1.0	   0.86	  (0.80-­‐0.92)	  
MDPV	   3.2	   150	  (105-­‐196)	   3.2	   0.84	  (0.82-­‐0.86)	  
Methylone	   10	   148	  (117-­‐180)	   10	   0.78	  (0.72-­‐0.84)	  
Mephedrone	   3.2	   102*	  (87-­‐118)	   10	   0.36*	  (0.30-­‐0.43)	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Figure	  II.1	  
	  
Effects	   of	   (±)-­‐methcathinone,	   (±)-­‐MDPV,	   (±)-­‐methylone	   and	   (±)-­‐mephedrone	   on	   full	  
ICSS	  frequency-­‐rate	  curves.	  Abscissae:	  frequency	  of	  electrical	  brain	  stimulation	  in	  log	  
Hz.	  Ordinates:	  percent	  maximum	  control	  reinforcement	  rate	  (%MCR).	  Drug	  doses	  are	  
indicated	   in	   legends	   in	   units	   of	  mg/kg.	   Filled	   points	   represent	   frequencies	   at	   which	  
reinforcement	   rates	   were	   statistically	   different	   from	   vehicle	   rates	   as	   determined	   by	  
two-­‐way	  ANOVA	  followed	  by	  Holm-­‐Sidak	  post	  hoc	  test,	  P<0.05.	  All	  data	  show	  mean	  ±	  
SEM	  for	  five	  rats	  (methylone)	  or	  six	  rats	  (all	  other	  drugs).	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Figure	  II.2	  
	  
Time	   courses	   of	   (±)-­‐methcathinone,	   (±)-­‐MDPV,	   (±)-­‐methylone	   and	   (±)-­‐mephedrone	  
effects	  on	  full	  ICSS	  frequency-­‐rate	  curves.	  Drug	  doses	  are	  expressed	  in	  mg/kg	  and	  are	  
indicated	   in	   front	  of	   the	  drug	  name	   in	   the	   title	  of	  each	  panel.	  Filled	  points	  represent	  
frequencies	  at	  which	  reinforcement	  rates	  were	  statistically	  different	  from	  vehicle	  rates	  
as	   determined	  by	   two-­‐way	  ANOVA	   followed	  by	  Holm-­‐Sidak	  post	   hoc	   test,	   P<0.05.	  All	  
data	  show	  mean	  ±	  SEM	  for	  five	  rats	  (methylone)	  or	  six	  rats	  (all	  other	  drugs).	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Figure	  II.3	  
	  
Summary	   of	   effects	   of	   (±)-­‐methcathinone,	   (±)-­‐MDPV,	   (±)-­‐methylone	   and	   (±)-­‐
mephedrone	   on	   ICSS	   expressed	  as	   percent	   pre-­‐drug	  baseline	  number	   of	   stimulations	  
delivered	  across	  all	  frequencies	  of	  brain	  stimulation.	  Left	  panel	  (a)	  compares	  potencies	  
and	   efficacies	   of	   drugs.	   	   Abscissa:	   drug	   dose	   in	   mg/kg.	   Ordinate:	   percent	   pre-­‐drug	  
baseline	  number	  of	  ICSS	  reinforcers.	  	  Right	  panel	  (b)	  compares	  time	  course	  profiles	  of	  
drugs.	   Abscissa:	   pretreatment	   time	   in	   min.	   Ordinate:	   percent	   pre-­‐drug	   baseline	  
number	  of	  ICSS	  reinforcers.	  	  
	   	  
	  	  55	  
Figure	  II.4	  
	  
Rate-­‐dependency	  analysis	  of	  methcathinone	  and	   its	  derivatives	  effects	  on	   ICSS.	   (a,	  b)	  
Abscissae:	  log	  baseline	  ICSS	  rate.	  Ordinates:	  log	  percent	  baseline	  ICSS	  rate.	  	  Horizontal	  
line	  at	  Y=2.0	  indicates	  no	  change	  from	  baseline	  rates.	  	  Vertical	  line	  at	  X=1.0	  indicates	  
the	  position	  of	  the	  Y-­‐intercept	  values	  used	  in	  Panel	  c.	  	  (c)	  Abscissa:	  drug	  dose	  in	  mg/kg.	  
Ordinate:	   Y-­‐intercept	   from	   linear	   regression	   analysis	   of	   rate-­‐dependency	   plots.	   All	  
points	  show	  mean	  data	  for	  5-­‐6	  rats.	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Chapter	  III:	  Quantitative	  Structure-­‐Activity	  Relationship	  (QSAR)	  Analysis	  of	  the	  Pharmacology	  of	  Para-­‐Substituted	  Methcathinone	  Analogues	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Introduction	  The	  goal	  of	  this	  study	  was	  to	  use	  quantitative	  structure-­‐activity	  relationship	  (QSAR)	  analysis	  (Glennon	  and	  Young,	  2011)	  to	  evaluate	  molecular	  determinants	  of	  abuse-­‐related	   neurochemical	   and	   behavioral	   effects	   of	   MCAT	   and	   six	   para-­‐substituted	  MCAT	   analogs.	   Figure	   III.1	   shows	   the	   chemical	   structure	   of	   the	  MCAT	  scaffold,	  which	  served	  as	  the	  base	  molecule	  for	  all	  analogs	  investigated	  in	  this	  study.	  The	  para	  substituent	  on	  the	  benzene	  ring	  of	  the	  MCAT	  scaffold,	  R,	  was	  manipulated	  to	   include	   substituents	   that	   varied	   systematically	   along	   three	   physicochemical	  dimensions	   [steric	   (Es),	   electronic	   (σp),	   and	   lipophilic	   (πp)],	   and	   Table	   III.1	   shows	  quantitative	  measures	   for	  each	  substituent	  on	  each	  parameter.	  The	  effects	  of	  each	  drug	   were	   examined	   on	   two	   experimental	   endpoints:	   (1)	   in	   vitro	   potency	   to	  promote	  monoamine	   release	   through	   DA	   and	   5-­‐HT	   transporters	   (DAT	   and	   SERT,	  respectively)	  in	  rat-­‐brain	  synaptosomes,	  and	  (2)	   in	  vivo	  modulation	  of	  ICSS	  in	  rats.	  These	  two	  endpoints	  were	  selected	   for	  study	   in	  part	  because	  ICSS	   in	  rats	   is	  useful	  for	   predicting	   abuse	   potential	   of	   drugs	   in	   humans	   (Negus	   and	  Miller,	   2014),	   and	  previous	   data	  with	   a	   different	   set	   of	  monoamine	   releasers	   indicated	   a	   correlation	  
	  	  57	  
between	   in	  vitro	  DAT-­‐vs.-­‐SERT	  selectivity	  and	  in	  vivo	  efficacy	  to	  produce	  an	  abuse-­‐related	   facilitation	   of	   ICSS	   in	   rats	   (Bauer	   et	   al.,	   2013b).	   QSAR	   analysis	   was	  accomplished	   by	   correlating	   measures	   for	   each	   physicochemical	   parameter	   with	  data	  from	  neurochemical	  and	  behavioral	  studies.	  We	  predicted	  that	  in	  vitro	  DAT-­‐vs.-­‐SERT	  selectivity	  would	  correlate	  with	  maximal	  ICSS	  facilitation,	  and	  that	  one	  of	  the	  physicochemical	   parameters	   would	   correlate	   with	   both	   DAT-­‐vs.-­‐SERT	   selectivity	  and	   maximal	   ICSS	   facilitation.	   Results	   support	   this	   hypothesis	   and	   suggest	   that	  “steric	  bulk”	  of	  the	  para	  substituent,	  as	  quantified	  by	  Taft’s	  steric	  parameter	  (Es),	  is	  a	   key	  determinant	   of	   abuse-­‐related	  neurochemical	   and	  behavioral	   effects	   of	  para-­‐substituted	  MCAT	  analogs.	  	  
Materials	  and	  Methods	  
Drugs	  This	   study	   examined	   effects	   of	   MCAT	   and	   six	   analogs	   with	   different	  substitutions	  at	   the	  para,	   or	   “4,”	  position	  on	   the	  phenyl	   ring.	   	  For	  MCAT,	   the	  para	  substituent	   is	  hydrogen,	  and	   for	   the	  purposes	  of	   this	   study,	   the	  MCAT	  analogs	  are	  designated	  using	  the	  nomenclature	  “4-­‐R	  MCAT,”	  with	  “R”	  being	  the	  substitution	  for	  hydrogen	   at	   the	   para	   position.	   	   In	   some	   cases,	   these	   compounds	   also	   have	   other	  generic	   names	   or	   other	   chemical	   names	   based	   on	   the	   abbreviation	   “MAP”	   (for	  methylaminopropiophenone,	   the	   chemical	   name	   for	   MCAT),	   and	   all	   compounds	  were	  synthesized	  as	  their	  racemic	  HCl	  salts	  using	  previously	  published	  procedures.	  	  Specifically,	   the	   following	   compounds	   were	   studied,	   and	   alternative	   names	   and	  published	   syntheses	   are	   shown	   in	   parentheses:	   MCAT	   (Findlay	   et	   al.,	   1981),	   4-­‐F	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MCAT	   (flephedrone;	   Archer,	   2009),	   4-­‐OCH3	   (methedrone;	   Lespagnol	   and	   Hallot,	  1954),	  4-­‐Cl	  MCAT	  (Trepanier	  and	  Sprancmanis,	  1964),	  4-­‐Br	  MCAT	  (4-­‐BMAP;	  Foley	  and	   Cozzi,	   2003),	   4-­‐CH3	  MCAT	   (mephedrone;	   McDermott	   et	   al.,	   2011),	   and	   4-­‐CF3	  MCAT	  (4-­‐TFMAP;	  Cozzi	  et	  al.,	  2013).	  All	  compounds	  were	  dissolved	  in	  sterile	  saline	  for	  i.p.	  injection.	  	  	  	  
In	  Vitro	  Release	  Assays	  All	   in	   vitro	   synaptosome	   studies	   were	   conducted	   by	   our	   collaborators	  Michael	   Baumann	   and	   John	   Partilla	   of	   the	   NIDA	   Intramural	   Research	   Program	   in	  Baltimore,	  MD.	  However,	  I	  conducted	  the	  correlational	  analyses	  with	  data	  generated	  from	  these	  studies.	  
Subjects.	   Male	   Sprague-­‐Dawley	   rats	   (Charles	   River,	  Wilmington,	  MA,	   USA)	  weighing	  250-­‐350	  g	  were	  housed	  three	  per	  cage	  with	  free	  access	  to	  food	  and	  water	  and	  maintained	  on	  a	  12	  h	  light/dark	  cycle	  with	  lights	  on	  from	  7:00	  a.m.	  to	  7:00	  p.m.	  Animal	   facilities	   were	   accredited	   by	   the	   Association	   for	   the	   Assessment	   and	  Accreditation	   of	   Laboratory	   Animal	   Care,	   and	   procedures	   were	   carried	   out	   in	  accordance	  with	  the	  Institutional	  Animal	  Care	  and	  Use	  Committee	  and	  the	  National	  Institutes	   of	   Health	   guidelines	   on	   care	   and	   use	   of	   animal	   subjects	   in	   research	  (National	  Research	  Council,	  2011).	  	  
Procedure.	   Rats	   were	   euthanized	   by	   CO2	   narcosis,	   and	   brains	   were	  processed	   to	   yield	   synaptosomes	   as	   previously	   described	   (Rothman	   et	   al.,	   2003).	  For	  release	  assays,	  9	  nM	  [3H]1-­‐methyl-­‐4-­‐phenylpyridinium	  ([3H]MPP+)	  was	  used	  as	  the	  radiolabeled	  substrate	  for	  DAT,	  whereas	  5	  nM	  [3H]5-­‐HT	  was	  used	  as	  a	  substrate	  for	  SERT.	  All	  buffers	  used	  in	  the	  release	  assay	  methods	  contained	  1	  µM	  reserpine	  to	  
	  	  59	  
block	  vesicular	  uptake	  of	  substrates.	  The	  selectivity	  of	  release	  assays	  was	  optimized	  for	   a	   single	   transporter	   by	   including	   unlabeled	   blockers	   to	   prevent	   the	   uptake	   of	  [3H]MPP+	   or	   [3H]5-­‐HT	   by	   competing	   transporters.	   Synaptosomes	  were	   preloaded	  with	   radiolabeled	   substrate	   in	   Krebs-­‐phosphate	   buffer	   for	   1	   h	   (steady	   state).	  Release	  assays	  were	  initiated	  by	  adding	  850	  µl	  of	  preloaded	  synaptosomes	  to	  150	  µl	  of	  test	  drug.	  Release	  was	  terminated	  by	  vacuum	  filtration,	  and	  retained	  radioactivity	  was	  quantified	  by	  liquid	  scintillation	  counting.	  	  Previous	  studies	  have	  used	  these	  procedures	  to	  evaluate	  MCAT,	  4-­‐CH3	  MCAT,	  and	  4-­‐CF3	  MCAT.	  For	  this	  study,	  MCAT	  effects	  were	  redetermined,	  and	  effects	  of	  the	  additional	   analogs	  4-­‐F	  MCAT,	  4-­‐OCH3	  MCAT,	  4-­‐Cl	  MCAT	  and	  4-­‐Br	  MCAT	  were	  also	  determined.	   Correlational	   analysis	   described	   below	   used	   data	   from	   the	   present	  study	  and	  data	  for	  4-­‐CH3	  MCAT	  and	  4-­‐CF3	  MCAT	  from	  previous	  studies	  (Baumann	  et	  
al.,	  2012;	  Cozzi	  et	  al.,	  2013).	  	  
Data	   Analysis.	   Statistical	   analyses	  were	   carried	   out	   using	  GraphPad	  Prism	  (v.	   6.0;	   GraphPad	   Scientific,	   San	   Diego,	   CA,	   USA).	   EC50	   values	   for	   stimulation	   of	  release	   were	   calculated	   based	   on	   non-­‐linear	   regression	   analysis.	   	   DAT-­‐vs.-­‐SERT	  selectivity	   was	   also	   calculated	   as	   SERT	   EC50	   ÷	   DAT	   EC50,	   such	   that	   larger	   ratios	  indicate	  higher	  DAT	  selectivity.	  	  	  	  	  
Reagents.	   [3H]5-­‐HT	  (specific	  activity	  =	  30	  Ci	  mmol-­‐1)	  was	  purchased	   from	  Perkin	  Elmer	  (Shelton,	  CT,	  USA).	   	   [3H]MPP+	  (specific	  activity	  =	  85	  Ci	  mmol-­‐1)	  was	  purchased	   from	   American	   Radiolabeled	   Chemicals	   (St.	   Louis,	   MO,	   USA).	   All	   other	  chemicals	  and	  reagents	  were	  acquired	  from	  Sigma-­‐Aldrich	  (St.	  Louis,	  MO,	  USA).	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Intracranial	  Self-­‐Stimulation	  (ICSS)	  
Subjects.	  Male	  Sprague-­‐Dawley	  rats	   (Harlan,	  Frederick,	  MD,	  USA)	  weighing	  at	  least	  300	  g	  at	  the	  time	  of	  surgery	  were	  individually	  housed	  and	  maintained	  on	  a	  12	  h	  light/dark	  cycle.	  Methods	  for	  surgery,	  training,	  testing	  and	  data	  analysis	  were	  generally	  identical	  to	  those	  described	  in	  the	  ICSS	  Methods	  section	  of	  Chapter	  II.	  Any	  important	  differences	  in	  methods	  for	  this	  study	  are	  described	  below.	  	  
	   Training.	   Rats	   were	   trained	   and	   tested	   under	   a	   FR	   1	   schedule	   of	   brain	  stimulation	  using	  a	  behavioral	  procedure	   identical	   to	   that	  described	   in	  Chapter	   II.	  Stimulation	  intensity	  was	  individually	  adjusted	  for	  each	  rat	  to	  the	  lowest	  value	  that	  sustained	  a	  high	   rate	  of	   reinforcement	   (>	  30	   stimulations/min),	   and	   this	   intensity	  (100-­‐290	  µA	  across	  rats)	  was	  held	  constant	  for	  the	  remainder	  of	  the	  study.	  	  
Testing.	   The	   MCAT	   analogs	   tested	   in	   this	   study	   were	   4-­‐F	   MCAT,	   4-­‐OCH3	  MCAT,	  4-­‐Cl	  MCAT,	  4-­‐Br	  MCAT,	  and	  4-­‐CF3	  MCAT.	  	  Two	  additional	  compounds,	  MCAT	  and	  4-­‐CH3	  MCAT,	  were	  studied	  previously	  (Bonano	  et	  al.,	  2014b;	  see	  Chapter	  II),	  and	  data	   from	   those	   studies	  were	   included	   in	   correlational	   analyses	   described	   below.	  Each	   drug	   was	   studied	   in	   dose-­‐effect	   and	   time-­‐course	   procedures.	   In	   dose-­‐effect	  studies,	  a	  1.0	  to	  1.5	  log	  unit	  range	  of	  doses	  was	  tested	  for	  each	  drug	  with	  the	  goal	  of	  testing	  a	  dose	  range	  from	  a	  low	  dose	  that	  produced	  little	  or	  no	  effect	  to	  a	  high	  dose	  that	  produced	  maximal	  facilitation	  of	  ICSS.	  In	  time-­‐course	  studies,	  the	  highest	  dose	  of	  each	  compound	  was	  tested.	  The	  order	  of	  testing	  with	  vehicle	  and	  drug	  doses	  was	  varied	  across	  subjects	  using	  a	  Latin-­‐square	  design,	  and	  experiments	  with	  any	  single	  compound	   were	   completed	   prior	   to	   beginning	   tests	   with	   another	   compound.	  Furthermore,	  tests	  with	  different	  drugs	  in	  a	  single	  rat	  were	  separated	  by	  at	  least	  1	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week,	  and	  a	  saline	  vehicle	  test	  session	  was	  conducted	  during	  this	  period	  to	  ensure	  that	  injections	  or	  drug	  exposures	  did	  not	  alter	  individual	  ICSS	  baselines.	  	  
	   Data	  Analysis.	   	   ICSS	  data	  were	  analyzed	  as	  described	  previously	  (Bauer	  et	  al.,	   2013b;	   Negus	   and	  Miller,	   2014).	   The	   primary	   dependent	   variable	   in	   this	   ICSS	  procedure	   was	   the	   reinforcement	   rate	   in	   stimulations	   per	   minute	   during	   each	  frequency	  trial.	  To	  normalize	  data,	  raw	  reinforcement	  rates	  from	  each	  trial	  in	  each	  rat	   were	   converted	   to	   %MCR.	   Results	   from	   test	   sessions	   were	   compared	   by	  repeated	  measures	  two-­‐way	  ANOVA,	  with	  ICSS	  frequency	  as	  one	  factor	  and	  dose	  or	  time	  as	  the	  second	  factor.	  A	  significant	  ANOVA	  was	  followed	  by	  Holm-­‐Sidak	  post	  hoc	  test,	   P<0.05.	   As	   a	   summary	  measure	   of	   drug	   effects	   on	   ICSS,	   the	   total	   number	   of	  stimulations	   delivered	   per	   component	   across	   all	   10	   frequency-­‐trials	   was	   also	  calculated	   for	   each	   dose	   and	   time	   point.	   Test	   data	  were	   normalized	   to	   individual	  baseline	  data	  and	  were	  then	  averaged	  across	  rats	  in	  each	  experimental	  condition.	  	  
Correlational	  Analysis	  
	   Correlations	  were	  evaluated	  between	   in	  vitro	   and	   in	  vivo	   drug	  effects	  using	  linear	   regression	   and	   a	   Pearson	   correlation	   test	   as	   described	   previously	   for	   a	  different	   set	   of	   monoamine	   releasers	   (Bauer	   et	   al.,	   2013b).	   	   Specifically,	   in	   vitro	  selectivity	  to	  promote	  DAT-­‐	  vs.	  SERT-­‐mediated	  release	  was	  compared	  to	  maximal	  in	  
vivo	   facilitation	   of	   ICSS	   (defined	   as	   the	   maximum	   increase	   in	   %	   baseline	   total	  stimulations	  per	  component	  produced	  by	  any	  dose	  of	  a	  given	  drug).	   	  Correlational	  analysis	  was	  also	  used	  to	  assess	  quantitative	  structure-­‐activity	  relationships	  (QSAR)	  between	  physicochemical	   features	  and	   the	   in	  vitro	   and	   in	  vivo	   effects	  of	  each	  drug	  (Glennon	   and	   Young,	   2011).	   Specifically,	   steric	   (ES),	   electronic	   (σp)	   and	   lipophilic	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(πp)	   constants	   of	   para	   substituents	   on	   the	   MCAT	   scaffold	   (Wolff,	   1980)	   were	  compared	  to	  in	  vitro	  potency	  for	  DAT-­‐	  and	  SERT-­‐mediated	  release,	  in	  vitro	  DAT-­‐vs.-­‐SERT	   selectivity,	   and	   maximal	   in	   vivo	   facilitation	   of	   ICSS.	   The	   measure	   used	   to	  represent	  steric	  bulk	  of	  para	  substituents	  in	  this	  study	  was	  Taft’s	  steric	  parameter,	  Es,	  which	  was	  developed	  to	  reflect	  the	  steric	  influence	  of	  substituents	  on	  the	  rate	  of	  hydrolysis;	   thus,	   Taft’s	   steric	   constant	   represents	   a	   functional	   measure	   of	   steric	  bulk.	   Correlations	   and	   statistical	   analyses	   were	   carried	   out	   using	   Prism	   6.0	  (GraphPad	   Scientific,	   San	   Diego,	   CA,	   USA),	   and	   correlations	   were	   considered	  statistically	  significant	  if	  P<0.05.	  	  
Results	  
In	  Vitro	  Monoamine	  Release	  Mediated	  by	  DAT	  and	  SERT	   	  All	   seven	   compounds	   considered	   in	   this	   study	   produced	   concentration-­‐dependent	  increases	  in	  DAT-­‐mediated	  [3H]MPP+	  release	  and	  SERT-­‐mediated	  	  [3H]5-­‐HT	   release	   from	   rat	   brain	   synaptosomes.	   	   Data	   for	   4-­‐CH3	  MCAT	   and	   4-­‐CF3	  MCAT	  were	  published	  previously	  (Baumann	  et	  al.,	  2012;	  Cozzi	  et	  al.,	  2013),	  and	  Figure	  III.2	  shows	   data	   for	   the	   other	   five	   compounds.	   Table	   III.1	   shows	   EC50	   values	   for	   each	  compound	  to	  promote	  DAT-­‐	  and	  SERT-­‐mediated	  monoamine	  release.	  	  DAT-­‐vs.-­‐SERT	  selectivity	   is	   also	   reported	   for	   each	   compound.	   DAT-­‐vs.-­‐SERT	   selectivity	   varied	  across	   a	   more	   than	   4000-­‐fold	   range,	   with	   MCAT	   functioning	   as	   the	   most	   DAT-­‐selective	   compound	   and	   4-­‐CF3	   MCAT	   functioning	   as	   the	   most	   SERT-­‐selective	  compound.	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Intracranial	  Self-­‐Stimulation	  Electrical	   brain	   stimulation	   maintained	   a	   frequency-­‐dependent	   increase	   in	  ICSS	  rates	  under	  baseline	  conditions.	  Across	   the	  33	  rats	  used	   in	   these	  studies,	   the	  average	  ±	  SEM	  baseline	  MCR	  was	  61	  ±	  2	  stimulations	  per	  trial,	  and	  the	  mean	  ±	  SEM	  number	   of	   total	   baseline	   stimulations	   across	   all	   frequencies	   was	   291	   ±	   14	  stimulations	  per	  component.	  	  All	   seven	   compounds	   considered	   in	   this	   study	   produced	   dose-­‐dependent	  changes	  in	  ICSS.	  	  Data	  for	  MCAT	  and	  4-­‐CH3	  MCAT	  were	  reported	  previously	  (Bonano	  et	  al.,	  2014b)	  and	  were	  described	  above	  in	  Chapter	  II.	  Figure	  III.3	  shows	  dose-­‐effect	  data	   for	   the	   other	   five	   compounds.	   Two-­‐way	   ANOVA	   indicated	   significant	   main	  effects	   of	   frequency	   and	  dose	   and	   significant	   frequency	   x	   dose	   interactions	   for	   all	  drugs,	  and	  only	  the	  interaction	  effects	  are	  reported	  below	  for	  each	  drug.	  4-­‐F	  MCAT	  [F(36,144)=	   10.54,	   P<0.0002]	   produced	   dose-­‐dependent	   facilitation	   of	   low	   ICSS	  rates	  maintained	   by	   low	   brain	   stimulation	   frequencies	  with	   no	   evidence	   at	   these	  doses	  and	  pretreatment	  times	  of	  depression	  of	  high	  ICSS	  rates	  maintained	  by	  high	  brain	   stimulation	   frequencies.	   4-­‐OCH3	   MCAT	   [F(36,180)=	   5.55,	   P<0.0001]	   ,	   4-­‐Cl	  MCAT	   [F(36,180)=	   7.31,	   P<0.0001],	   and	   4-­‐Br	   MCAT	   [F(36,180)=	   5.30,	   P<0.0001]	  also	   produced	   facilitation	   of	   low	   ICSS	   rates	   maintained	   by	   low	   stimulation	  frequencies;	  however,	  higher	  doses	  of	  these	  compounds	  also	  significantly	  decreased	  high	  ICSS	  rates.	  Lastly,	  4-­‐CF3	  MCAT	  [F(27,135)=	  1.69,	  P=0.027]	  produced	  exclusive	  depression	  of	  high	  ICSS	  rates	  maintained	  by	  high	  brain	  stimulation	  frequencies.	  	  Figure	  III.4	  shows	  the	  time	  course	  of	  effects	  produced	  by	  the	  highest	  tested	  dose	   of	   each	   compound.	   Two-­‐way	   ANOVA	   indicated	   significant	   main	   effects	   of	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frequency	  and	  time	  and	  significant	  frequency	  x	  time	  interactions	  for	  all	  drugs,	  and	  only	  the	  interaction	  effects	  are	  reported	  below	  for	  each	  drug.	  4-­‐F	  MCAT	  (3.2	  mg	  kg-­‐1;	   [F(36,144)=	   5.28,	   P<0.0001])	   produced	   facilitation	   of	   ICSS	  within	   10	  min	   after	  administration,	  and	  significant	  ICSS	  rate-­‐increasing	  effects	  were	  no	  longer	  apparent	  by	  300	  min.	  4-­‐OCH3	  MCAT	  (32	  mg	  kg-­‐1;	  [F(36,144)=	  8.34,	  P<0.0001])	  produced	  only	  depression	  of	  ICSS	  after	  10	  min,	  but	  both	  rate-­‐increasing	  effects	  and	  rate-­‐decreasing	  effects	   were	   apparent	   after	   30	   and	   100	   min.	   4-­‐Cl	   MCAT	   (10	   mg	   kg-­‐1;	  [F(36,180)=7.10,	   P<0.0001])	   and	   4-­‐Br	   MCAT	   (10	   mg	   kg-­‐1;	   [F(45,225)=4.25,	  P<0.0001])	  produced	  rate-­‐decreasing	  effects	  that	  peaked	  after	  10	  min	  and	  were	  still	  significant	  after	  300	  min.	  	  Rate-­‐increasing	  effects	  were	  apparent	  only	  300	  min	  after	  administration	  of	  this	  high	  dose	  of	  4-­‐Cl	  MCAT	  and	  at	  no	  time	  after	  4-­‐Br	  MCAT.	  	  4-­‐CF3	  MCAT	   (10	  mg	   kg-­‐1;	   [F(36,180)=1.96,	   P=0.002])	   produced	   exclusive	   depression	   of	  ICSS	  from	  10	  to	  100	  min,	  and	  these	  effects	  were	  no	  longer	  apparent	  after	  300	  min.	  
Correlational	  Analysis	  Figure	  III.5	  shows	  that	  in	  vitro	  selectivity	  for	  DAT-­‐	  vs.	  SERT-­‐mediated	  release	  correlated	  with	   in	  vivo	  efficacy	  to	  facilitate	  ICSS	   	  (Fig.	  III.5A).	   	  Figure	  III.5,	  together	  with	  Table	  III.2,	  also	  shows	  results	  of	  QSAR	  analysis.	   	  Significant	  correlations	  were	  found	   between	   steric	   bulk	   (Es)	   and	   both	   in	   vitro	   DAT-­‐vs.-­‐SERT	   selectivity	   (Fig.	  III.5B)	   and	   in	   vivo	   efficacy	   to	   facilitate	   ICSS	   (Fig.	   III.5C).	   For	   both	   of	   these	   QSAR	  correlations,	   the	   largest	  outlier	  was	  4-­‐OCH3	  MCAT,	  which	  had	   lower	  DAT-­‐vs.-­‐SERT	  selectivity	   and	  produced	  weaker	   ICSS	   facilitation	   than	  would	  have	  been	  predicted	  based	  on	  the	  correlation	  with	  Es.	  There	  was	  no	  significant	  correlation	  between	  steric	  bulk	  and	   in	  vitro	  potency	  at	  either	  DAT	  or	  SERT	  individually,	  and	  lipophilicity	  (πp)	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and	  electronic	  (σp)	  parameters	  did	  not	  correlate	  significantly	  with	  any	  in	  vitro	  or	  in	  
vivo	  endpoint	  (Table	  III.2).	  	  
Summary	  This	   study	   compared	   in	   vitro	   neurochemical	   and	   in	   vivo	   behavioral	   effects	  produced	   by	   MCAT	   and	   six	   para-­‐substituted	   analogs.	   	   There	   were	   three	   main	  findings.	  	  First,	  all	  seven	  compounds	  functioned	  as	  substrates	  at	  both	  DAT	  and	  SERT,	  and	   DAT-­‐vs.-­‐SERT	   selectivity	   varied	   >4000-­‐fold	   across	   compounds.	   Second,	   all	  drugs	   dose-­‐dependently	   altered	   ICSS,	   and	   efficacy	   to	   produce	   an	   abuse-­‐related	  facilitation	   of	   ICSS	   also	   varied	   across	   compounds.	   In	   agreement	   with	   a	   previous	  study	  using	  a	  different	  set	  of	  compounds	  (Bauer	  et	  al.,	  2013b),	  in	  vitro	  DAT-­‐vs.-­‐SERT	  selectivity	   correlated	   with	   in	   vivo	   efficacy	   to	   facilitate	   ICSS	   (R=0.92,	   P=0.003).	  Finally,	   QSAR	   analysis	   identified	   a	   significant	   correlation	   between	   the	   steric	  parameter	   (ES)	  of	   the	  para	   substituents	  and	  both	   in	  vitro	  DAT-­‐vs.-­‐SERT-­‐selectivity	  (R=0.78,	   P=0.04)	   and	   in	   vivo	   facilitation	   of	   ICSS	   (R=	   0.81,	   P=0.03).	   	   These	   results	  suggest	   that	   steric	   bulk	   of	   the	   para	   substituent	   of	   the	   MCAT	   scaffold	   is	   a	   key	  determinant	   of	   both	   in	   vitro	   DAT-­‐vs.-­‐SERT	   selectivity	   and	   in	   vivo	   expression	   of	  abuse-­‐related	  behavioral	  effects	  in	  an	  ICSS	  procedure.	  	   Steric	  bulk	  can	  be	  further	  broken	  down	  into	  definitive	  parameters	  of	  volume,	  width,	  and	   length	   to	  more	  closely	   investigate	  how	  structural	   characteristics	  of	   the	  
para	  substituent	  influence	  in	  vitro	  and	  in	  vivo	  activity	  of	  MCAT	  analogs.	  As	  a	  follow-­‐up	  to	  the	  initial	  QSAR	  investigation	  described	  here	  in	  Chapter	  III,	  which	  identified	  ES	  as	   a	   critical	   determinant	   of	   DAT	   selectivity	   and	   abuse-­‐related	   facilitation	   of	   ICSS,	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collaborators	  conducted	  additional	  correlations	  between	  volume,	  maximum	  width,	  minimum	   width	   and	   length	   and	   the	   experimental	   endpoints	   described	   above	  (Sakloth	  et	  al.,	  2014).	  Results	  from	  these	  correlations	  concluded	  that	  steric	  volume	  correlates	  most	  strongly	  with	   in	  vitro	  and	   in	  vivo	  abuse-­‐related	  effects,	  even	  better	  than	   ES	   (Figure	   III.6).	   This	   finding	   suggests	   that	   steric	   volume	   is	   a	   particularly	  important	  component	  of	  steric	  contributions	  to	  abuse-­‐related	  drug	  effects	  produced	  by	  para-­‐substituted	  MCAT	  analogs.	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Table	  III.1	  
	  
Physicochemical	   parameters,	   in	   vitro	   release	   activities,	   and	   in	   vivo	   behavioral	   ICSS	  
effects	  of	  MCAT	  and	  its	  para-­‐substituted	  analogs.	  
a	  Physicochemical	  parameters	  of	  para	  substituent	  (functional	  steric	  bulk,	  Es;	  electron-­‐
withdrawing	  capacity,	  σp;	  lipophilicity,	  πp)	  as	  reported	  in	  Wolff,	  1980.	  
b	   EC50	   values	   derived	   from	   concentration-­‐effect	   curves	   in	   Figure	   III.2,	   or	   published	  
previously	  for	  4-­‐CH3	  MCAT	  (Baumann	  et	  al.,	  2012),	  4-­‐CF3	  MCAT	  (Cozzi	  et	  al.,	  2013).	  
c	  DAT	  selectivity	  calculated	  as	  SERT	  EC50	  ÷	  DAT	  EC50.	  
d	  Maximal	  ICSS	  facilitation	  expressed	  as	  maximum	  increase	  in	  %	  Baseline	  Stimulations	  
per	  Component	   from	  Figure	   III.3,	  or	  published	  previously	   for	  MCAT	  and	  4-­‐CH3	  MCAT	  
(Bonano	  et	  al.,	  2014b).	  	  




In	  Vitro	  Release	  EC50	  b	   Maximal	  
ICSS	  
Facilitation	  d	  Es	   σp	   πp	   DAT	  (nM)	   SERT	  (nM)	  
DAT	  
Selectivity	  c	  
MCAT	  	   1.24	   0.00	   0.00	   12.5	  ±	  1.1	   3,860	  ±	  520	   309	   191.9	  
4-­‐F	  MCAT	  	  	   0.78	   0.06	   0.14	   83.4	  ±	  6.0	   1,290	  ±	  220	   15.4	   156.3	  
4-­‐OCH3	  MCAT	  	   0.69	   -­‐0.27	   -­‐0.02	   506	  ±	  62	   120	  ±	  18	   0.24	   110.9	  
4-­‐Cl	  MCAT	  	   0.27	   0.23	   0.71	   42.2	  ±	  5.2	   144	  ±	  22	   3.40	   114.9	  
4-­‐Br	  MCAT	  	   0.08	   0.23	   0.86	   59.4	  ±	  5.1	  	   60.2	  ±	  6.7	   1.01	   118.0	  
4-­‐CH3	  MCAT	  	   0.00	   -­‐0.17	   0.56	   49.1	  ±	  8.3	   118	  ±	  26	   2.41	   102.5	  
4-­‐CF3	  MCAT	  	  	   -­‐1.16	   0.54	   0.88	   2,700	  ±	  300	   190	  ±	  30	   0.07	   90.9	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Table	  III.2	  
	  
Results	   of	   correlational	   analysis	   between	   physicochemical	   parameters,	   in	   vitro	  
potencies	  at	  DAT	  and	  SERT,	  and	  maximal	  ICSS	  facilitation	  
*Significant	  correlation	  
a	  Functional	  steric	  bulk,	  Es;	  electron-­‐withdrawing	  capacity,	  σp;	  lipophilicity,	  πp	  












R=	  -­‐0.71	  P=	  0.07	   R=	  0.58	  P=	  0.17	   R=	  0.78*	  P=	  0.04	   R=	  0.81*	  P=	  0.03	  
σp	   R=	  0.37	  P=	  0.42	   R=	  -­‐0.10	  P=	  0.84	   R=	  -­‐0.29	  P=	  0.53	   R=	  -­‐0.24	  P=	  0.61	  
πp	   R=	  0.26	  P=	  0.57	   R=	  -­‐0.64	  P=	  0.12	   R=	  -­‐0.52	  P=	  0.23	   R=	  -­‐0.66	  P=	  0.11	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Figure	  III.1	  
	  
Chemical	   structure	   of	   MCAT	   scaffold.	   R=site	   of	   para	   substituent,	   which	   was	  
systematically	  varied	  to	  generate	  MCAT	  analogs.	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Figure	  III.2	  
	  
Effects	   of	   test	   drugs	   on	   DAT-­‐	   and	   SERT-­‐mediated	   monoamine	   release	   in	   rat	   brain	  
synaptosomes.	   Abscissae:	   log	   concentration	   of	   drug	   (molar).	   Ordinates:	   percent	  
maximum	   release.	   All	   points	   show	   mean	   ±	   SD	   for	   N=3	   separate	   experiments.	   EC50	  
values	  shown	  in	  Table	  III.1	  were	  derived	  from	  these	  concentration-­‐effect	  curves.	  Data	  
collected	  by	  M.	  Baumann	  and	  J.	  Partilla	  of	  the	  NIDA	  Intramural	  Research	  Program.	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Figure	  III.3	  
	  
Effects	   of	   test	   drugs	   on	   ICSS	   in	   rats.	   Left	   panels	   show	   drug	   effects	   on	   full	   ICSS	  
frequency-­‐rate	   curves.	   Abscissae:	   frequency	   of	   electrical	   brain	   stimulation	   in	   log	  Hz.	  
Ordinates:	   percent	   maximum	   control	   reinforcement	   rate	   (%	   MCR).	   Drug	   doses	   are	  
4-F MCAT
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indicated	   in	   boxed	   legends	   in	   units	   of	  mg/kg.	   Filled	   points	   represent	   frequencies	   at	  
which	  reinforcement	  rates	  were	  statistically	  different	  from	  vehicle	  rates	  as	  determined	  
by	  two-­‐way	  ANOVA	  followed	  by	  Holm-­‐Sidak	  post	  hoc	  test,	  P<0.05.	  Right	  panels	  show	  
summary	   ICSS	   data	   for	   drug	   effects	   across	   all	   frequencies.	   Abscissae:	   drug	   dose	   in	  
mg/kg.	  Ordinates:	  percent	  baseline	  number	  of	   stimulations	  per	   component	  delivered	  
across	   all	   brain	   stimulation	   frequencies.	   Upward/downward	   arrows	   indicate	  
significant	  drug-­‐induced	  increases/decreases	  in	  ICSS	  relative	  to	  vehicle	  for	  at	  least	  one	  
brain	  stimulation	  frequency	  as	  determined	  by	  analysis	  of	  full	  frequency-­‐rate	  curves.	  All	  
data	  show	  mean	  ±	  SEM	  for	  five	  (4-­‐F	  MCAT)	  or	  six	  rats	  (all	  other	  drugs).	  Maximal	  ICSS	  
facilitation	  values	  shown	  in	  Table	  III.1	  were	  taken	  from	  the	  right	  panels	  for	  each	  drug.	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Figure	  III.4	  
	  
Time	  courses	  of	  drug	  effects	  on	  ICSS	  in	  rats.	  	  The	  title	  of	  each	  panel	  shows	  the	  drug	  and	  
test	   dose	   in	   units	   of	  mg/kg.	   Left	   panels	   show	   full	   ICSS	   frequency-­‐rate	   curves.	   	   Time	  
points	   are	   indicated	   in	   the	   boxed	   legend	   in	   units	   of	  minutes.	   Filled	   points	   represent	  
3.2 4-F MCAT
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frequencies	   at	   which	   reinforcement	   rates	   were	   statistically	   different	   from	   baseline	  
rates	  as	  determined	  by	  two-­‐way	  ANOVA	  followed	  by	  Holm-­‐Sidak	  post	  hoc	  test,	  P<0.05.	  	  
Right	   panels	   show	   summary	   ICSS	   data	   for	   drug	   effects	   across	   all	   frequencies.	  
Abscissae:	   time	  after	   treatment	   in	  min.	   	   All	   data	   show	  mean	  ±	   SEM	   for	   five	   rats	   (4-­‐
OCH3	  MCAT	  and	  4-­‐F	  MCAT)	  or	  six	  rats	  (all	  other	  drugs).	  Other	  details	  as	  in	  Figure	  III.3.	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Figure	  III.5	  
	  
Correlational	  analysis	  across	  experimental	  endpoints	  and	  structural	  parameters	  from	  
Table	   III.1.	   Panel	   A	   shows	   the	   correlation	   between	   in	   vitro	   selectivity	   for	   DAT-­‐	   vs.	  
SERT-­‐mediated	  monoamine	  release	  (abscissa)	  and	  maximum	  in	  vivo	  ICSS	  facilitation	  
(ordinate).	   Panel	   B	   shows	   the	   correlation	   between	   steric	   bulk	   (Es,	   abscissa)	   and	   in	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vitro	   selectivity	   for	   DAT-­‐	   vs.	   SERT-­‐mediated	  monoamine	   release	   (ordinate).	   Panel	   C	  
shows	   the	   correlation	   between	   steric	   bulk	   (Es,	   abscissa)	   and	  maximum	   in	   vivo	   ICSS	  
facilitation	  (ordinate).	  All	  points	  show	  mean	  data	  for	  5-­‐6	  rats.	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Figure	  III.6	  
	  
Relationship	  between	   the	   volume	  of	   the	  para	   substituent	   and:	   in	   vitro	   selectivity	   for	  
DAT-­‐vs.-­‐SERT-­‐mediated	  monoamine	  release	  (left	  panel),	  in	  vivo	  ICSS	  facilitation	  (right	  
panel).	  Figure	  adapted	  from	  Sakloth	  et	  al.,	  2014.	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Chapter	  IV:	  Abuse-­‐Related	  Neurochemical	  Effects	  of	  Para-­‐Substituted	  Methcathinone	  Analogs	  in	  Rats:	  Microdialysis	  Studies	  of	  Nucleus	  Accumbens	  Dopamine	  and	  Serotonin	  	  Bonano	   JS,	   Glennon	  RA,	   Lazenka	  MF,	  Negus	   SS,	   and	  Banks	  ML.	   In	   preparation	   for	  submission	  to	  Neuropharmacology.	  	  
Introduction	  The	  goal	  of	  this	  study	  was	  to	  examine	  abuse-­‐related	  neurochemical	  effects	  of	  MCAT	  and	  five	  para-­‐substituted	  MCAT	  analogs on	  dopamine	  (DA)	  and	  serotonin	  (5-­‐HT)	   levels	   in	   the	   nucleus	   accumbens	   (NAc)	   of	   live,	   wake	   rats.	   Abuse-­‐related	  neurochemical	  drug	  effects	  were	  investigated	  using	  microdialysis	  in	  male	  Sprague-­‐Dawley	   rats	   implanted	   with	   guide	   cannula	   targeting	   the	   NAc.	   Microdialysis	   is	   an	  experimental	   technique	   that	   can	   be	   used	   to	   recover	   and	   measure	   endogenous	  extracellular	  monoamines	   in	  discrete	  brain	   regions	   (Zetterström	  et	  al.,	   1983),	   and	  early	  studies	  on	  the	  neurochemical	  effects	  of	  various	  drugs	  of	  abuse	  on	  extracellular	  DA	   levels	   in	   the	   striatum	   and	   NAc	   showed	   that	   virtually	   all	   abused	   drugs	   (e.g.	  opiates,	  ethanol,	  nicotine,	  amphetamine,	  cocaine)	  increase	  DA	  levels	  in	  both	  regions,	  but	   particularly	   in	   the	   accumbens	   (Di	   Chiara	   and	   Imperato,	   1988).	   Subsequent	  studies	   confirmed	   that	   various	   classes	   of	   abused	   drugs,	   especially	   monoamine	  releasers	   and	  uptake	   inhibitors,	   elevate	   accumbal	  DA	   levels	   (Carboni	   et	   al.,	   1989)	  and	  extended	  on	  those	  findings	  by	  demonstrating	  that	  alterations	  in	  other	  accumbal	  monoamine	   levels	   (i.e.	   5-­‐HT)	   also	   influence	   a	   drug’s	   abuse	   potential.	   We	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hypothesized	   that	  MCAT	   and	   each	   of	   its	   para-­‐substituted	   analogs	  would	   increase	  extracellular	  levels	  of	  DA	  and/or	  5-­‐HT	  in	  the	  NAc	  of	  live,	  wake	  rats,	  and	  that	  these	  in	  
vivo	  neurochemical	  measures	  of	  abuse	  potential	  (i.e.	  selectivity	  to	  induce	  release	  of	  DA	   vs.	   5-­‐HT	   in	   NAc)	   would	   correlate	   with:	   a)	   in	   vitro	   selectivity	   for	   monoamine	  release	  via	  DAT-­‐vs.-­‐SERT;	  b)	  in	  vivo	  facilitation	  of	  ICSS;	  and,	  based	  on	  the	  results	  of	  QSAR	  analysis	  described	  in	  Chapter	  III,	  c)	  steric	  volume	  of	  the	  para	  substituent	  on	  the	  MCAT	  scaffold.  	  
Materials	  &	  Methods	  
Subjects	  	   Adult	  male	   Sprague-­‐Dawley	   rats	   (Harlan,	   Frederick,	   MD,	   USA)	   weighing	   at	  least	  300	  g	  at	  the	  time	  of	  surgery	  were	  individually	  housed	  and	  maintained	  on	  a	  12	  h	   light/dark	   cycle	  with	   lights	   on	   from	   6:00	   a.m.	   to	   6:00	   p.m.	   Rats	   had	   ad	   libitum	  access	  to	  food	  and	  water	  except	  during	  microdialysis	  experiments.	  Animal	  facilities	  were	   accredited	   by	   the	   Association	   for	   the	   Assessment	   and	   Accreditation	   of	  Laboratory	   Animal	   Care,	   and	   experimental	   procedures	   were	   approved	   by	   the	  Institutional	   Animal	   Care	   and	   Use	   Committee	   in	   accordance	   with	   guidelines	   (8th	  edition)	   for	   the	   care	   and	   use	   of	   animal	   subjects	   in	   research	   (National	   Research	  Council,	  2011).	  
Drugs	  	   This	   study	   determined	   neurochemical	   effects	   of	   MCAT	   and	   five	   para-­‐substituted	   MCAT	   analogs.	   All	   MCAT	   analogs	   studied	   in	   Chapter	   III,	   with	   the	  exception	  of	  4-­‐CF3	  MCAT,	  were	  also	  examined	  in	  microdialysis	  studies.	  In	  addition,	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prior	   to	   initiation	  of	  experiments	  with	  MCAT	  analogs,	  D-­‐amphetamine	  hemisulfate	  (Sigma	  Aldrich,	  St.	  Louis,	  MO)	  and	  (±)-­‐fenfluramine	  HCl	  (Sigma	  Aldrich)	  effects	  were	  determined	  as	  control	  compounds	  for	  DA-­‐selective	  and	  5-­‐HT-­‐selective	  monoamine	  release,	   respectively.	   All	   compounds	   were	   dissolved	   in	   sterile	   saline	   for	  intraperitoneal	   (i.p.)	   injection,	   and	  all	  doses	  are	  expressed	  as	   the	   salt	   forms	   listed	  above.	  
Microdialysis	  	  
Surgery.	  Rats	  (N=61)	  were	  anesthetized	  with	  3.0%	  isoflurane	  in	  oxygen	  until	  unresponsive	   to	   toe-­‐pinch	   and	   secured	   in	   a	   stereotaxic	   apparatus	   (Kopf	  Instruments,	  Tujunga,	  CA,	  USA).	  Guide	  cannula	  (8mm	  long,	  0.5mm	  outer	  diameter;	  CXG-­‐8,	  Eicom,	  San	  Diego,	  CA,	  USA)	  were	  implanted	  bilaterally	  and	  terminated	  1mm	  above	   the	   nucleus	   accumbens	   (NAc)	   (coordinates:	   1.5mm	   anterior	   to	   bregma,	  1.8mm	   lateral	   to	   midsagittal	   suture,	   6.0mm	   ventral	   to	   dura).	   The	   guide	   cannulas	  were	   secured	   to	   the	   skull	   using	   screws	   (Plastics	  One,	   Inc.,	  Roanoke,	  VA,	  USA)	   and	  orthodontic	   resin	   (Butler	   Schein,	   Dublin,	   OH,	   USA).	   A	   dummy	   cannula	   (CXD-­‐8,	  Eicom)	  was	  inserted	  into	  each	  guide	  cannula	  to	  maintain	  cannula	  patency.	  Animals	  were	  allowed	  at	  least	  7	  recovery	  days	  prior	  to	  initiating	  microdialysis	  testing.	  
Procedure.	  On	  test	  days,	  rats	  were	  briefly	  anesthetized	  with	  3.0%	  isoflurane	  in	   oxygen,	   one	   of	   the	   dummy	   cannulas	   was	   removed,	   and	   a	   microdialysis	   probe	  (10mm	   long,	   CX-­‐I-­‐8-­‐2,	   Eicom)	   with	   a	   2mm	   artificial	   cellulose	   “cuprophan”	  membrane	   (50kDa	   molecular	   weight	   cut-­‐off)	   at	   its	   tip	   was	   inserted	   into	   a	   8mm	  guide	  cannula	  such	  that	  it	  extended	  2mm	  beyond	  the	  end	  of	  the	  guide	  cannula	  and	  into	   the	   NAc.	   The	   probe	  was	   connected	   to	   a	   two-­‐channel	   liquid	   swivel	   (TCS2-­‐23,	  
	  	  81	  
Eicom),	   and	   the	   rat	   was	   placed	   into	   an	   acrylic	   experimental	   cage	   (30	   cm3).	  Microdialysis	   probes	   were	   perfused	   with	   artificial	   cerebrospinal	   fluid	   (aCSF)	  (147mM	  NaCl,	  2.8mM	  KCl,	  1.2mM	  CaCl2,	  1.2mM	  MgCl2)	  at	  a	  rate	  of	  1µL/min.	  Mobile	  phase	   consisted	   of	   2%	   methanol	   (EMD,	   Gibbstown,	   NJ,	   USA),	   100mM	   phosphate	  buffer	  (Sigma	  Chemicals,	  St.	  Louis,	  MO,	  USA),	  500mg/L	  1-­‐decane	  sodium	  sulfonate	  (TCI	   America,	   Montgomeryville,	   PA,	   USA),	   and	   50mg/L	   EDTA-­‐2Na+	   (Dojindo	  Laboratories,	   Kumamoto,	   Japan).	   Dialysate	   samples	   were	   collected	   into	   a	   50µL	  injector	  loop	  at	  10min	  intervals	  using	  an	  online	  auto-­‐injector	  (EAS-­‐20s,	  Eicom)	  and	  immediately	   analyzed	   for	   DA	   and	   5-­‐HT	   concentrations	   by	   high-­‐pressure	   liquid	  chromatography	   (HPLC)	   coupled	   to	   electrochemical	   detection	   (HTEC-­‐500,	   Eicom).	  DA	  and	  5-­‐HT	  were	  separated	  using	  a	  C18-­‐reverse	  phase	  column	  (PP-­‐ODS	  II,	  Eicom)	  and	  were	  detected	  using	  a	  graphite	  working	  electrode	  and	  an	  Ag	  vs.	  AgCl	  reference	  electrode	  with	  an	  applied	  potential	  of	  +450mV.	  Preliminary	  experiments	  conducted	  by	  probe	  immersion	  into	  a	  known	  standard	  concentration	  of	  DA	  indicated	  a	  lag	  time	  of	  ~20min	  for	  dialysate	  to	  traverse	  the	  tubing	  from	  the	  probe	  to	  the	  electrochemical	  detector	   at	   the	   1µL/min	   flow	   rate.	   DA	   and	   5-­‐HT	   were	   identified	   according	   to	  characteristic	   retention	   times	   of	   the	   standard	   solution	   and	   concentrations	   were	  quantified	   by	   comparison	   with	   peak	   heights	   of	   the	   standard	   concentration	   curve	  (0.01-­‐100pg	  per	  10µL)	  generated	  prior	  to	  drug	  administration	  in	  each	  microdialysis	  experiment.	  The	  lower	  limit	  of	  neurotransmitter	  detection	  was	  0.1pg.	  DA	  and	  5-­‐HT	  levels	   were	   determined	   to	   be	   stable	   after	   6	   consecutive	   baseline	   samples	   were	  obtained	   with	   <25%	   variability	   around	   the	   running	   mean	   of	   both	  neurotransmitters.	   Testing	   was	   conducted	   using	   drug	   doses	   based	   on	   previous	  
	  	  82	  
behavioral	   studies	   from	  our	   laboratory	   (Bauer	  et	   al.,	   2013b;	  Bonano	  et	   al.,	   2014a,	  2014b).	   Specifically,	   amphetamine	   (0.1-­‐1.0mg/kg),	   fenfluramine	   (1.0-­‐3.2mg/kg),	  MCAT	  (0.32-­‐3.2mg/kg),	  and	  5	  para-­‐substituted	  MCAT	  analogs	  (4-­‐F,	  4-­‐Cl,	  4-­‐CH3,	  and	  4-­‐Br	  MCAT,	   1-­‐10mg/kg;	   4-­‐OCH3	  MCAT,	   3.2-­‐32mg/kg)	  were	   administered	   i.p.,	   and	  dialysate	   samples	  were	   collected	   for	  180min	  after	  drug	  administration.	  Rats	  were	  tested	  no	  more	  than	  four	  times	  (twice	  per	  cannula;	  at	  least	  two	  weeks	  between	  re-­‐assessment	   of	   a	   given	   site).	   Specifically,	   rats	   were	   administered	   a	   drug	   dose	   and	  tested	  in	  microdialysis	  no	  more	  than	  once	  per	  week,	  and	  accessing	  a	  guide	  cannula	  site	  occurred	  every	  two	  weeks	  at	  most.	  Rats’	  drug	  exposures	  varied,	  such	  that	  any	  given	   rat	   may	   have	   been	   tested	   with	   multiple	   doses	   of	   the	   same	   drug	   or	   with	  different	   drugs.	   However,	   data	   for	   any	   one	   dose	   of	   any	   one	   drug	   were	   always	  collected	  in	  different	  rats	  (N=5-­‐6	  for	  each	  dose	  of	  each	  drug).	  Furthermore,	  a	  single	  set	   of	   vehicle	   (saline,	   i.p.)	   tests	  were	   conducted,	   and	   these	   data	  were	   used	   for	   all	  drug	   and	   dose	   comparisons.	   At	   the	   completion	   of	   all	   experiments,	   rats	   were	  euthanized	  with	  CO2,	  and	  brains	  were	  removed	  and	  stored	  in	  10%	  formalin.	  Probe	  placement	  was	  verified	  by	  gross	  visual	  inspection	  of	  unstained	  brain	  sections.	  Only	  rats	  with	  correct	  probe	  placements	  were	  included	  in	  data	  analyses.	  	  
Data	  Analysis.	  The	  primary	  dependent	  variables	  were	  extracellular	  DA	  and	  5-­‐HT	  concentrations	  in	  each	  dialysate	  fraction	  expressed	  as	  a	  percent	  of	  the	  average	  of	   the	   6	   mean	   baseline	   concentrations	   before	   drug	   or	   vehicle	   administration	   for	  each	   experiment.	   These	   individual	   normalized	   DA	   and	   5-­‐HT	   concentrations	   were	  then	   averaged	   across	   rats	   to	   yield	   group	  mean	   results	   for	   graphical	   presentation.	  Results	  were	  analyzed	  by	  two-­‐way	  repeated	  measures	  ANOVA,	  with	  drug	  dose	  and	  
	  	  83	  
time	  as	  the	  two	  main	  factors.	  A	  significant	  drug	  dose	  ×	  time	  interaction	  was	  followed	  by	  Holm-­‐Sidak	  post	  hoc	  test,	  and	  the	  criterion	  for	  significant	  was	  set	  at	  P<0.05.	  
In	   addition	   to	   the	   analysis	   above,	   peak	   increases	   in	   DA	   and	   5-­‐HT	  concentrations	   produced	   by	   each	   dose	   of	   each	   drug	  were	   used	   to	   generate	   dose-­‐effect	   graphs	   (maximum	   %	   baseline	   neurotransmitter	   vs.	   drug	   dose).	   Linear	  regression	  analysis	  of	   the	  ascending	   limb	  of	   the	  dose-­‐effect	  curve	   for	  a	  given	  drug	  was	  used	  to	  extrapolate	  the	  dose	  (mg/kg)	  of	  that	  drug	  required	  to	  elevate	  DA	  and	  5-­‐HT	  levels	  to	  250%	  of	  baseline	  (DA	  ED250	  and	  5-­‐HT	  ED250,	  respectively).	  In	  vivo	  DA/5-­‐HT	  selectivity	  for	  each	  drug	  was	  defined	  by	  the	  ratio	  DA	  ED250	  ÷	  5-­‐HT	  ED250.	  	  
Correlational	  Analysis	  
	   Correlations	   were	   evaluated	   between	   in	   vivo	   neurochemical	   selectivity	   to	  increase	   accumbal	   DA	   vs.	   5-­‐HT	   and	   each	   of	   the	   following	   measures:	   1)	   in	   vitro	  selectivity	  to	  promote	  DAT-­‐	  vs.	  SERT-­‐mediated	  release	  (Fig.	  IV.5A),	  2)	  abuse-­‐related	  facilitation	  of	  ICSS	  (Fig.	  IV.5B),	  and	  3)	  steric	  volume	  (Fig.	  IV.5C).	  Correlations	  were	  determined	  using	  linear	  regression	  and	  a	  Pearson	  correlation	  test.	  Correlations	  and	  statistical	   analyses	  were	  carried	  out	  using	  Prism	  6.0	   for	  Mac	   (GraphPad	  Scientific,	  San	   Diego,	   CA,	   USA),	   and	   correlations	   were	   considered	   statistically	   significant	   if	  P<0.05.	  
	  
Results	  Across	  microdialysis	  experiments,	  baseline	  (mean	  ±	  S.E.M.)	  NAc	  extracellular	  DA	   and	   5-­‐HT	   levels	  were	   0.83	   ±	   0.04pg	   and	   0.85	   ±	   0.05pg	   per	   9μL,	   respectively.	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Figure	  IV.6	  shows	  placements	  of	  microdialysis	  guide	  cannula	  for	  all	  rats	  included	  in	  data	  analyses.	  	  
Effects	  of	  Amphetamine	  and	  Fenfluramine	  on	  NAc	  DA	  and	  5-­‐HT	  levels	  	   Both	  amphetamine	  and	  fenfluramine	  produced	  time-­‐dependent	  increases	  in	  extracellular	  NAc	  DA	  and/or	  5-­‐HT	  levels,	  and	  these	  data	  are	  summarized	  in	  Figure	  IV.1.	   Two-­‐way	   ANOVA	   indicated	   significant	   main	   effects	   of	   dose	   and	   time	   and	   a	  significant	  dose	  x	  time	  interaction	  for	  amphetamine	  to	  increase	  DA	  levels,	  whereas	  two-­‐way	   ANOVA	   indicated	   a	   significant	   main	   effect	   of	   time,	   but	   not	   dose,	   and	   a	  significant	  dose	  x	  time	  interaction	  for	  fenfluramine	  to	  increase	  5-­‐HT	  levels.	  Only	  the	  interaction	   effects	   are	   reported	   below	   for	   each	   drug	   to	   selectively	   elevate	   its	  relevant	  neurotransmitter	  (i.e.	  DA	  for	  amphetamine,	  5-­‐HT	  for	  fenfluramine).	  Under	  vehicle	  conditions	  (i.p.	  saline),	  no	  significant	  changes	  in	  NAc	  DA	  or	  5-­‐HT	  levels	  were	  observed	  over	  the	  180-­‐min	  observation	  period.	  Amphetamine	  (0.1-­‐1.0mg/kg),	  a	  DA-­‐selective	  monoamine	  releaser	  with	  ~70-­‐fold	  selectivity	  for	  releasing	  DA	  vs.	  5-­‐HT	  in	  
vitro	   (Rothman	   et	   al.,	   2001),	   increased	   NAc	   DA	   concentrations	   to	   a	   maximum	   of	  621%	   from	   baseline	   [F(51,204)=	   4.577,	   P<0.0001],	   compared	   to	   a	  maximal	   5-­‐HT	  increase	   of	   161%	   from	   baseline	   [F(51,204)=	   1.535,	   P=0.02].	   Conversely,	  fenfluramine	   (1.0-­‐3.2mg/kg),	   a	   5-­‐HT-­‐selective	   releaser	   with	   <0.01-­‐fold	   selectivity	  for	   DA	   vs.	   5-­‐HT	   (Rothman	   et	   al.,	   2001),	   increased	   NAc	   5-­‐HT	   concentrations	   to	  maximum	   of	   597%	   from	   baseline	   [F(34,136)=	   2.546,	   P<0.0001],	   compared	   to	   a	  maximal	  DA	  increase	  of	  152%	  from	  baseline	  [no	  significant	  interaction].	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Effects	  of	  MCAT	  and	  its	  para-­‐substituted	  analogs	  on	  NAc	  DA	  and	  5-­‐HT	  levels	  	   MCAT	   and	   all	   five	   para-­‐substituted	   MCAT	   analogs	   produced	   significant	  increases	   in	  NAc	  DA	  and/or	  5-­‐HT	   levels.	   Figure	   IV.2	   illustrates	   the	  neurochemical	  effects	  of	  MCAT,	  4-­‐F	  MCAT	  (flephedrone)	  and	  4-­‐Cl	  MCAT	  on	  accumbal	  DA	  and	  5-­‐HT	  levels.	   Two-­‐way	   ANOVA	   indicated	   significant	   main	   effects	   of	   dose	   and	   time	   and	  significant	  dose	  x	  time	  interactions	   for	  all	  drugs.	  Only	  the	   interaction	  statistics	  are	  reported	  below	  for	  each	  drug.	  MCAT	  (0.32-­‐3.2mg/kg)	  produced	  selective	  dose-­‐	  and	  time-­‐dependent	   increases	   in	   extracellular	   DA	   concentrations	   to	   518%	   of	   baseline	  levels	  [F(34,136)=	  5.749,	  P<0.0001],	  compared	  to	  no	  statistically	  significant	  effects	  on	   5-­‐HT	   concentrations	   at	   any	   dose	   tested.	   4-­‐F	   MCAT	   (1.0-­‐10mg/kg)	   produced	  dose-­‐	  and	  time-­‐dependent	  increases	  in	  DA	  levels	  [F(51,204)=	  5.291,	  P<0.0001]	  to	  a	  maximum	  of	  745%	  of	  baseline,	  and	  in	  5-­‐HT	  levels	  [F(51,204)=	  11.11,	  P<0.0001]	  to	  a	  maximum	   of	   1,567%	   of	   baseline.	   Similarly,	   4-­‐Cl	   MCAT	   (1.0-­‐10mg/kg)	   produced	  dose-­‐	  and	  time-­‐dependent	  increases	  in	  DA	  [F(51,204)=	  5.694,	  P<0.0001]	  to	  1,261%	  of	   baseline,	   and	   in	   5-­‐HT	   [F(51,204)=	   9.710,	   P<0.0001]	   to	   1,834%	   of	   baseline	  concentrations.	  Interestingly,	  for	  these	  two	  halogenated	  MCAT	  analogs,	  increases	  in	  accumbal	  5-­‐HT	   levels	  exhibited	  a	   rapid	  onset	  and	  offset,	  with	  5-­‐HT	   levels	  peaking	  within	   20min	   (controlling	   for	   ~20min	   lag	   time)	   and	   then	   precipitously	   declining.	  Increases	   in	   accumbal	  DA	   levels,	   on	   the	   other	   hand,	   exhibited	   a	   slower	   onset	   and	  sustained	   elevation,	   reaching	   peak	   levels	   towards	   the	   end	   of	   the	   180-­‐min	  experimental	  sessions.	  
 Figure	  IV.3	  shows	  the	  effects	  of	  4-­‐CH3	  MCAT	  (mephedrone),	  4-­‐Br	  MCAT,	  and	  4-­‐OCH3	   MCAT	   (methedrone)	   on	   extracellular	   NAc	   DA	   and	   5-­‐HT	   concentrations.	  
	  	  86	  
Two-­‐way	   ANOVA	   indicated	   significant	   main	   effects	   of	   dose	   and	   time	   and	   a	  significant	  dose	  x	  time	  interaction	  for	  mephedrone	  at	  each	  neurotransmitter.	  Two-­‐way	  ANOVA	  indicated	  a	  significant	  main	  effect	  of	  time	  and	  a	  significant	  dose	  x	  time	  interaction	  for	  4-­‐Br	  MCAT	  at	  both	  neurotransmitters,	  but	  only	  indicated	  a	  significant	  main	  effect	  of	  dose	  for	  4-­‐Br	  MCAT	  at	  DA	  (i.e.	  no	  main	  effect	  of	  dose	  for	  4-­‐Br	  MCAT	  at	  5-­‐HT).	   Lastly,	   two-­‐way	  ANOVA	   indicated	   significant	  main	   effects	  of	  dose	   and	   time	  for	  4-­‐OCH3	  MCAT	  at	  each	  neurotransmitter,	  but	  a	  significant	  dose	  x	  time	  interaction	  only	   existed	   at	   5-­‐HT	   (i.e.	   no	   significant	   interaction	   for	   4-­‐OCH3	   MCAT	   at	   DA).	  Significant	  interaction	  effects	  are	  reported	  below	  for	  each	  drug	  at	  each	  monoamine	  when	  applicable.	  4-­‐CH3	  MCAT	  (1.0-­‐10mg/kg)	  increased	  NAc	  concentrations	  of	  both	  DA	   [F(34,136)=	   2.896,	   P<0.0001]	   and	   5-­‐HT	   [F(34,136)=	   15.61,	   P<0.0001]	   to	   a	  maximum	  of	  523%	  and	  1061%	  of	  baseline,	  respectively.	  4-­‐Br	  MCAT	  (1.0-­‐10mg/kg)	  increased	  extracellular	  concentrations	  of	  both	  DA	  [F(34,136)=	  14.58,	  P<0.0001]	  and	  5-­‐HT	  [F(34,136)=	  4.503,	  P<0.0001]	  in	  Nac.	  DA	  levels	  reached	  a	  maximum	  of	  559%	  of	   baseline,	   and	   5-­‐HT	   levels	   increased	   to	   1,026%	   of	   baseline.	   As	   with	   the	   other	  halogenated	   MCAT	   analogs	   shown	   in	   Figure	   IV.2,	   4-­‐Br	   MCAT-­‐induced	   5-­‐HT	  increases	  exhibited	  a	  rapid	  onset	  and	  offset,	  while	  increases	  in	  DA	  levels	  exhibited	  a	  slower	   onset	   and	   were	   sustained	   for	   a	   longer	   duration.	   4-­‐OCH3	   MCAT	   (3.2-­‐32mg/kg)	   increased	  DA	  concentrations	  maximally	  to	  384%	  of	  baseline,	  and	   it	  was	  the	   least	   potent	   para-­‐substituted	   MCAT	   analog.	   However,	   4-­‐OCH3	   MCAT	   was	   the	  most	  efficacious	  compound	  for	  elevating	  accumbal	  5-­‐HT	  and	  increased	  extracellular	  5-­‐HT	  levels	  to	  2,428%	  of	  baseline	  [F(51,204)=	  6.280,	  P<0.0001].	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Correlational	  Analyses	  	   ED250	  values	  to	  increase	  DA	  and	  5-­‐HT	  levels,	  and	  in	  vivo	  DA/5-­‐HT	  selectivity	  values,	  are	  summarized	  for	  each	  drug	  in	  Table	  IV.1.	  Correlational	  analysis	  indicated	  significant	   correlations	   between	   in	   vivo	  DA/5-­‐HT	   selectivity	   and	   both	   (1)	   in	   vitro	  DA/5-­‐HT	  selectivity	  determined	  from	  rat	  brain	  synaptosome	  preparations	  (R=0.95,	  P<0.01;	   Fig.	   IV.5A),	   and	   (2)	   maximal	   facilitation	   of	   ICSS	   in	   behavioral	   studies	  (R=0.89,	   P=0.02;	   Fig.	   IV.5B).	   Additionally,	   linear	   regression	   analysis	   revealed	   a	  significant	  negative	  correlation	  between	  steric	  volume	  of	  the	  para	  substituent	  and	  in	  
vivo	   neurochemical	   selectivity	   to	  produce	   increases	   in	  NAc	  DA	  vs.	  5-­‐HT	   (R=	   -­‐0.85,	  P=0.03;	   Fig.	   IV.5C),	   such	   that	  para	   substituents	   of	   lower	   volume	   (i.e.	   smaller;	   less	  steric	   bulk)	   are	   more	   selective	   for	   increasing	   NAc	   DA	   relative	   to	   5-­‐HT,	   and	  neurochemical	  selectivity	  to	  increase	  accumbal	  DA	  vs.	  5-­‐HT	  decreases	  as	  volume	  of	  the	  para	  substituent	  increases.	  	  
Summary	  MCAT	  and	  all	  five	  para-­‐substituted	  analogs	  increased	  accumbal	  DA	  and/or	  5-­‐HT	  levels.	  With	  regard	  to	  efficacy,	  4-­‐Cl	  MCAT	  produced	  the	  greatest	  increase	  in	  NAc	  DA	  levels	  (4-­‐Cl	  >	  4-­‐F	  >	  MCAT	  =	  4-­‐Br	  =	  4-­‐CH3	  >	  4-­‐OCH3)	  and	  4-­‐OCH3	  MCAT	  produced	  the	   greatest	   increase	   in	   NAc	   5-­‐HT	   levels	   (4-­‐OCH3	   >	   4-­‐Cl	   >	   4-­‐F	   >	   4-­‐CH3	   =	   4-­‐Br	  >MCAT).	  In	  vivo	  selectivity	  to	  elevate	  DA	  vs.	  5-­‐HT	  levels	  to	  250%	  of	  baseline	  varied	  across	   compounds,	   such	   that	  MCAT	  was	   the	  most	  DA	   selective	   and	  4-­‐OCH3	  MCAT	  was	  the	  most	  5-­‐HT	  selective	  (DA/5-­‐HT	  selectivity:	  MCAT>	  4-­‐F	  >	  4-­‐Cl	  >	  4-­‐Br	  >	  4-­‐CH3	  >	  4-­‐OCH3).	  Furthermore,	  in	  vivo	  DA	  vs.	  5-­‐HT	  selectivity	  correlated	  with	  both	  in	  vitro	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DAT-­‐vs.-­‐SERT	   selectivity	   in	   rat-­‐brain	   synaptosomes	   (R=0.95,	   P<0.01)	   and	   in	   vivo	  facilitation	   of	   intracranial	   self-­‐stimulation	   in	   rats	   (R=0.89,	   P=0.02).	   Overall,	   these	  results	  suggest	   that	   in	  vivo	   selectivity	  of	  para-­‐substituted	  MCAT	  analogs	  to	  elevate	  NAc	   extracellular	   DA	   vs.	   5-­‐HT	   levels	  may	   be	   a	   key	   neurochemical	   determinant	   of	  abuse-­‐related	  behavioral	  effects.	  
	   	  








DA/5-­‐HT	  Selectivity	  MCAT	   0.37	   4.65	   12.56	  4-­‐F	  MCAT	   0.86	   1.07	   1.24	  4-­‐Cl	  MCAT	   0.93	   1.15	   1.23	  4-­‐CH3	  MCAT	   1.82	   1.12	   0.62	  4-­‐Br	  MCAT	   1.46	   1.30	   0.89	  4-­‐OCH3	  MCAT	   11.12	   3.61	   0.32	  
In	   vivo	   selectivity	   of	  MCAT	   and	   its	   para-­‐substituted	   analogs	   to	   produce	   increases	   in	  
nucleus	  accumbens	  DA	  vs.	  5-­‐HT	  of	  wakeful	  rats.	  Drug	  doses	  (mg/kg)	  to	  produce	  250%	  
increases	  in	  baseline	  neurotransmitter	  levels	  (ED250	  values)	  were	  calculated	  by	  linear	  
regression	  analysis	  of	  plots	  of	  maximum	  %	  baseline	  neurotransmitter	  vs.	  drug	  dose.	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Figure	  IV.1	  
	  
Effects	  of	  d-­‐amphetamine	  (AMPH;	  0.1-­‐1.0	  mg/kg,	  i.p.)	  and	  (±)-­‐fenfluramine	  (FEN;	  1.0-­‐
3.2	  mg/kg,	  i.p.)	  on	  DA	  and	  5-­‐HT	  levels	  in	  the	  nucleus	  accumbens	  of	  wakeful	  rats	  (N=8,	  
AMPH;	  N=7,	  FEN)	  expressed	  as	  a	  percentage	  of	  baseline	  neurotransmitter	  levels	  (0.975	  
±	   0.044pg	   DA;	   0.533	   ±	   0.028pg	   5-­‐HT).	   Left	   panels	   indicate	   temporal	   changes	   in	   %	  
baseline	  DA,	  while	  right	  panels	  indicate	  changes	  in	  %	  baseline	  5-­‐HT.	  Arrow	  indicates	  
time	   of	   drug	   administration.	   Filled	   symbols	   indicate	   statistical	   significance	   (P<0.05)	  
compared	  to	  vehicle	  conditions	  within	  a	  given	  time	  point.	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Figure	  IV.2	  
	  
Effects	  of	  MCAT,	  4-­‐F	  MCAT	  (flephedrone)	  and	  4-­‐Cl	  MCAT	  on	  NAc	  DA	  and	  5-­‐HT	  levels	  in	  
wakeful	   rats	   (N=12,	   MCAT;	   N=10,	   4-­‐F	   MCAT;	   N=8,	   4-­‐Cl	   MCAT)	   expressed	   as	   a	  
percentage	  of	  baseline	  neurotransmitter	  levels	  (0.686	  ±	  0.011pg	  DA;	  0.618	  ±	  0.041pg	  
5H-­‐T).	   Filled	   symbols	   indicate	   statistical	   significance	   (P<0.05)	   compared	   to	   vehicle	  
conditions	  within	  a	  given	  time	  point.	  








































































	  	  92	  
Figure	  IV.3	  
	  
Effects	  of	  4-­‐CH3	  MCAT	  (mephedrone),	  4-­‐Br	  MCAT,	  and	  4-­‐OCH3	  MCAT	  (methedrone)	  on	  
NAc	  DA	  and	  5-­‐HT	  levels	  in	  wakeful	  rats	  (N=7,	  4-­‐CH3	  MCAT;	  N=11,	  4-­‐Br	  MCAT;	  N=12,	  4-­‐
OCH3	  MCAT)	   expressed	  as	   a	  percentage	  of	   baseline	  neurotransmitter	   levels	   (0.987	  ±	  
0.061pg	  DA;	  1.216	  ±	  0.056pg	  5-­‐HT).	  Otherwise,	  details	  same	  as	  Figure	  IV.1.	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Figure	  IV.4	  
	  
Group	  mean	  peak	  effects	  on	  %	  baseline	  neurotransmitter	  produced	  by	  a	  1.5-­‐log	  range	  
of	  doses	  of	  MCAT	  and	  each	  para-­‐substituted	  MCAT	  analog.	  Error	  bars	  are	  omitted	  for	  
clarity.	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Figure	  IV.5	  
	  
Correlational	  analysis	  across	  experimental	  endpoints	  and	  steric	  volume.	  Panel	  A	  shows	  
the	  correlation	  between	   in	  vivo	  selectivity	  (abscissa)	  and	   in	  vitro	  selectivity	   for	  DAT-­‐
vs.-­‐SERT-­‐mediated	   monoamine	   release	   (ordinate).	   Panel	   B	   shows	   the	   correlation	  
between	   in	  vivo	  selectivity	  (abscissa)	  and	   in	  vivo	  ICSS	   facilitation	  (ordinate).	  Panel	  C	  
shows	   the	   correlation	   between	   volume	   (abscissa)	   and	   in	   vivo	   selectivity	   to	   increase	  
accumbal	  DA	  vs.	  5-­‐HT	  levels	  (ordinate).	  	  
	   	  
















































































Guide	  cannula	  placements	  for	  the	  61	  rats	  used	  in	  microdialysis	  experiments.	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Chapter	  V:	  Discussion	  
Summary	  Overall,	  the	  studies	  described	  in	  this	  dissertation	  investigated	  neurochemical	  and	   behavioral	   effects	   produced	   by	  MCAT	   and	   a	   series	   of	  para-­‐substituted	  MCAT	  analogs.	  The	  main	  findings	  are	  reiterated	  here.	  First,	  as	  described	  in	  Chapter	  II,	  an	  ICSS	  procedure	  was	  used	  to	  evaluate	  abuse-­‐related	  behavioral	  effects	  produced	  by	  MCAT	  and	  three	  recently	  scheduled	  cathinone	  derivatives	  (mephedrone,	  methylone	  and	   MDPV)	   in	   rats.	   Although	   all	   compounds	   produced	   abuse-­‐related	   ICSS	   effects	  consistent	  with	  their	  emergence	  as	  drugs	  of	  abuse,	  the	  profile	  of	  effects	  produced	  by	  MCAT	   differed	   from	   that	   produced	   by	   mephedrone	   despite	   differing	   only	   by	  substitution	  of	  a	  methyl	  group	  (-­‐CH3)	  at	  the	  para	  position	  on	  the	  phenyl	  ring	  of	  the	  MCAT	  scaffold.	  Accordingly,	  the	  remainder	  of	  my	  dissertation	  focused	  on	  the	  use	  of	  QSAR	   analysis	   to	   investigate	   molecular	   determinants	   of	   abuse-­‐related	  neurochemical	   and	   behavioral	   effects	   of	   a	   novel	   series	   of	   systematically	  manipulated,	  para-­‐substituted	  MCAT	  analogs.	  	  All	   MCAT	   analogs	   functioned	   as	   substrates	   at	   both	   DAT	   and	   SERT,	   and	   in	  
vitro	   DAT-­‐vs.-­‐SERT	   selectivity	   varied	   >4000-­‐fold	   across	   compounds.	   Furthermore,	  all	   para-­‐substituted	  MCAT	   analogs	   dose-­‐dependently	   altered	   ICSS,	   and	   efficacy	   to	  produce	  abuse-­‐related	  facilitation	  of	  ICSS	  also	  varied	  across	  compounds.	  Notably,	  in	  
vitro	   DAT-­‐vs.-­‐SERT	   selectivity	   correlated	   with	   in	   vivo	   efficacy	   to	   facilitate	   ICSS	  (R=0.92,	   P=0.003),	   lending	   support	   to	   the	   hypothesis	   that	   ICSS	   is	   a	   sensitive	  behavioral	   tool	   for	   discerning	   DA-­‐mediated	   abuse-­‐related	   effects	   from	   5-­‐HT-­‐mediated	  abuse-­‐limiting	  effects.	  Third,	  all	  para-­‐substituted	  MCAT	  analogs	  produced	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increases	  in	  accumbal	  DA	  and/or	  5-­‐HT	  levels,	  and	  in	  vivo	  selectivity	  to	  elevate	  DA	  vs.	  5-­‐HT	   levels	   to	   250%	   of	   baseline	   varied	   across	   compounds.	   In	  vivo	   neurochemical	  selectivity	   to	   increase	   NAc	   DA	   vs.	   5-­‐HT	   correlated	   with	   in	   vitro	   DAT-­‐vs.-­‐SERT	  selectivity	  (R=0.95,	  P<0.01)	  and	  in	  vivo	   facilitation	  of	  ICSS	  (R=0.89,	  P=0.02).	  Lastly,	  QSAR	  analysis	  identified	  a	  significant	  correlation	  between	  steric	  volume	  of	  the	  para	  substituents	   and	   in	   vitro	   DAT-­‐vs.-­‐SERT-­‐selectivity	   (R=	   -­‐0.97,	   P<0.01),	   in	   vivo	  facilitation	  of	  ICSS	  (R=	  -­‐0.92,	  P<0.01),	  and	  in	  vivo	  selectivity	  to	  elevate	  accumbal	  DA	  vs.	   5-­‐HT	   (R=-­‐0.85,	   P=0.03).	   The	   correlations	   between	   steric	   volume	   and	   each	  experimental	   endpoint	   are	   outlined	   in	   Figure	   V.1	   below.	   Together,	   these	   results	  suggest	   that	   steric	   volume	   of	   the	   para	   substituent	   of	   the	   MCAT	   scaffold	   is	   a	   key	  determinant	  of	  in	  vitro	  selectivity	  to	  produce	  monoamine	  release	  via	  DAT-­‐vs.-­‐SERT,	  
in	   vivo	   selectivity	   to	   increase	   extracellular	   DA	   vs.	   5-­‐HT	   levels	   in	   NAc,	   and	   in	   vivo	  expression	  of	  abuse-­‐related	  behavioral	  effects	  in	  ICSS.	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Figure	  V.1	  
	  
Results	  of	  QSAR	  and	  correlational	  analyses	   indicate	  significant,	  negative	  correlations	  
between	   steric	   volume	   of	   the	   para	   substituent	   and	   each	   experimental	   endpoint	  
investigated	  (i.e.	  in	  vitro	  selectivity	  for	  monoamine	  release	  mediated	  by	  DAT	  vs.	  SERT,	  
in	  vivo	  selectivity	  to	  increase	  extracellular	  DA	  vs.	  5-­‐HT	  concentrations	  in	  NAc,	  maximal	  
facilitation	   of	   ICSS),	   as	   well	   as	   significant,	   positive	   correlations	   between	   each	  
experimental	   endpoint.	   These	   data	   suggest	   that	   MCAT	   analogs	   containing	   para	  
substituents	  of	  lower	  steric	  volume	  exhibit	  higher	  DAT	  selectivity,	  both	  in	  vitro	  and	  in	  
vivo,	   and	   this	   selectivity	   for	  DAT	   vs.	   SERT	   is	   a	   critical	   determinant	   of	   abuse-­‐related	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Implications	  of	  Chapter	  II:	  MCAT	  vs.	  4-­‐CH3	  MCAT	  The	   study	   described	   in	   Chapter	   II	   was	   the	   first	   to	   report	  MCAT	   effects	   on	  ICSS,	   and	   the	  potency,	   efficacy	   and	   time	   course	  of	  MCAT	   to	   facilitate	   ICSS	  directly	  parallel	   effects	   of	   its	   amphetamine	   counterpart,	   methamphetamine	   (Bauer	   et	   al.	  2013).	   Previous	   studies	   demonstrated	   that	   MCAT	   functions	   as	   a	   monoamine	  releaser	  with	  approximately	  200-­‐fold	  selectivity	  for	  promoting	  in	  vitro	  release	  of	  DA	  versus	   5-­‐HT	   (Cozzi	   et	   al.	   1999,	   2013).	   Accordingly,	   the	   results	   in	   Chapter	   II	   are	  consistent	   with	   previous	   evidence	   to	   suggest	   that	   the	   maximal	   degree	   of	   ICSS	  facilitation	   produced	   by	   monoamine	   releasers	   correlates	   with	   pharmacological	  selectivity	  to	  release	  DA	  vs.	  5-­‐HT	  (Bauer	  et	  al.	  2013).	  Additionally,	  the	  ICSS	  effects	  of	  MCAT	  presented	  in	  Chapter	  II	  agree	  with	  other	  measures	  of	  psychostimulant	  effects	  and	  abuse	  liability.	  For	  example,	  MCAT	  substituted	  for	  amphetamine	  in	  rats	  trained	  to	   discriminate	   amphetamine	   from	   saline	   (Glennon	   et	   al.	   1986),	   and	   reciprocally,	  rats	   trained	   to	   discriminate	   MCAT	   exhibited	   stimulus	   generalization	   to	  amphetamine,	   methamphetamine	   and	   cocaine	   (Young	   and	   Glennon	   1998).	   MCAT	  also	   produced	   a	   dose-­‐related	   increase	   in	   spontaneous	   locomotor	   activity	   in	   rats	  (Glennon	   et	   al.	   1986)	   and	   maintained	   dose-­‐dependent	   self-­‐administration	   in	  baboons	   with	   rates	   comparable	   to	   those	   maintained	   by	   cocaine	   (Kaminski	   and	  Griffiths	   1994).	   Taken	   together,	   results	   from	   Chapter	   II	   support	   previous	   data	   in	  suggesting	   that	  MCAT	   is	   a	  DA-­‐selective	   psychostimulant	  with	   significant	   potential	  for	  abuse,	  consistent	  with	  its	  Schedule	  I	  classification	  by	  the	  DEA.	  	  In	   contrast	   to	   MCAT,	   methylone	   and	   mephedrone	   function	   as	   monoamine	  releasers	  with	  little	  selectivity	  between	  their	  in	  vitro	  potencies	  to	  release	  DA	  and	  5-­‐
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HT	   (Cozzi	   et	   al.,	   1999,	   2013;	   Baumann	   et	   al.,	   2012;	   Rosenauer	   et	   al.,	   2013).	   We	  showed	  previously	  that	  selectivity	  of	  monoamine	  releasers	  to	  promote	  DA	  vs.	  5-­‐HT	  release	   correlated	   with	   efficacy	   to	   facilitate	   ICSS	   (Bauer	   et	   al.,	   2013b),	   and	   in	  agreement	  with	  this	  relationship,	  both	  methylone	  and	  mephedrone	  produced	  mixed	  effects	  that	   included	  abuse-­‐related	  facilitation	  of	   low	  ICSS	  rates	  and	  abuse-­‐limiting	  depression	  of	  high	  ICSS	  rates.	  This	  is	  the	  first	  study	  to	  evaluate	  methylone	  effects	  on	  ICSS;	  however,	  methylone	  is	  the	  β-­‐ketone	  analog	  of	  MDMA,	  and	  methylone	  effects	  in	  the	  present	  study	  were	  similar	  to	  effects	  reported	  previously	  in	  this	  assay	  for	  MDMA	  (Bauer	   et	   al.,	   2013b).	   The	   present	   results	   with	   mephedrone	   in	   rats	   agree	   with	   a	  previous	   study	   that	   reported	   facilitation	   of	   low	   ICSS	   rates	   and	  depression	   of	   high	  ICSS	   rates	   by	   mephedrone	   in	   mice	   (Robinson	   et	   al.,	   2012).	   Results	   outlined	   in	  Chapter	  II	  also	  complement	  previous	  data	  on	  stimulant	  effects	  and	  abuse	  liability	  of	  methylone	   and	   mephedrone.	   For	   example,	   both	   drugs	   produce	   significant	  ambulatory	   hyperactivity	   in	   rodents	   (López-­‐Arnau	   et	   al.,	   2012;	   Marusich	   et	   al.,	  2012;	   Shortall	   et	   al.,	   2012),	   and	   mephedrone	   has	   been	   shown	   to	   support	  intravenous	   self-­‐administration	   in	   rats	   (Hadlock	   et	   al.,	   2011;	   Aarde	   et	   al.,	   2013a;	  Motbey	  et	  al.,	  2013).	  The	  data	   included	  in	  Chapter	  II	  added	  to	  the	  growing	  “bath	  salts”	   literature	  by	  suggesting	  that	  mephedrone	  has	  relatively	  low	  efficacy	  to	  facilitate	  ICSS.	  To	  the	  degree	   that	   methylone	   and	   mephedrone	   display	   similar	   in	   vitro	   selectivities	   to	  release	  DA	  vs.	  5-­‐HT,	  the	  greater	  ICSS	  depressant	  effects	  of	  mephedrone	  suggest	  that	  factors	   other	   than	   5-­‐HT	   release	   may	   also	   contribute	   to	   abuse-­‐limiting	   ICSS	  depressant	  effects.	  As	  one	  possibility,	  methylone	  and	  mephedrone	  also	  block	  DA	  and	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5-­‐HT	   reuptake,	   and	   one	   previous	   study	   suggests	   that	   mephedrone	   has	   lower	  selectivity	  than	  methylone	  to	  block	  reuptake	  of	  DA	  vs.	  5-­‐HT	  (Rosenauer	  et	  al.,	  2013).	  A	  second	  possibility	  is	  that	  mephedrone	  may	  act	  directly	  on	  5-­‐HT	  receptors	  (López-­‐Arnau	  et	  al.,	  2012;	  Simmler	  et	  al.,	  2013).	  Regardless	  of	  mechanism,	  Chapter	  II	  results	  are	  consistent	  with	  the	  conclusion	  that	  mephedrone	  has	   lower	  abuse	   liability	  than	  MCAT	  or	  the	  other	  recently	  scheduled	  bath	  salts.	  One	   implication	  of	   this	   finding	   is	  that	  mephedrone	  abuse	  might	  be	  expected	  to	  decline	  over	  time	  not	  only	  because	  of	  recently	   enacted	   legal	   constraints	   but	   also	   because	   of	   its	   pharmacological	   profile.	  Interestingly,	  data	  from	  the	  DEA	  National	  Forensic	  Laboratory	  Information	  System	  (NFLIS)	   support	   this	   conclusion	   and	   indicate	   that,	   as	   a	  percentage	  of	   all	   synthetic	  cathinones	   reported	   to	   NFLIS	   from	   2010	   to	   2012,	   reports	   of	   mephedrone	  experienced	   a	   steady	   decline	   over	   the	   years,	   falling	   from	   approximately	   40%	   in	  2010	  to	  <5%	  in	  2012	  (see	  Figure	  V.2).	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Figure	  V.2	  
	  
Synthetic	   cathinone	   prevalence	   data	   supplied	   by	   the	   National	   Forensic	   Laboratory	  
Information	   System	   (NFLIS)	   of	   the	  DEA	   Surveillance	  Network.	   Following	   emergency	  
scheduling	   of	   mephedrone,	   methylone	   and	   MDPV	   in	   October	   2011,	   mephedrone	  
reports,	   as	   a	   percentage	   of	   all	   synthetic	   cathinones,	   dropped	   off	   more	   quickly	   than	  
reports	  of	  MDPV.	  	   MDPV,	  the	  primary	  constituent	  of	  “bath	  salts”	  in	  the	  United	  States	  prior	  to	  its	  emergency	   scheduling	   in	   October	   2011	   (Kyle	   et	   al.,	   2011;	   Spiller	   et	   al.,	   2011),	   is	  distinct	  among	  the	  synthetic	  cathinones	  because	  it	  functions	  as	  a	  monoamine	  uptake	  inhibitor	   rather	   than	   as	   a	   releaser	   (Baumann	  et	   al.,	   2013;	  Cameron	   et	   al.,	   2013b).	  Nonetheless,	   it	   displays	   high	   in	   vitro	   selectivity	   to	   block	   DA	   vs.	   5-­‐HT	   uptake	  (Baumann	   et	   al.,	   2013)	   and,	   like	   cocaine	   and	   other	   more	   DA-­‐selective	   uptake	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inhibitors,	   such	   as	   RTI-­‐113	   (Esposito	   et	   al.,	   1978;	   Rosenberg	   et	   al.,	   2013),	   MDPV	  produced	   robust	   facilitation	  of	   ICSS	  with	   an	  efficacy	   similar	   to	   that	  of	  MCAT.	  This	  agrees	  with	  an	  earlier	  report	  that	  MDPV	  facilitated	  ICSS	  in	  rats	  responding	  under	  a	  discrete-­‐trial	  current-­‐threshold	  ICSS	  procedure	  (Watterson	  et	  al.,	  2012b).	  Moreover,	  this	  evidence	  from	  our	  ICSS	  studies	  agrees	  with	  other	  evidence	  of	  psychostimulant	  and	  abuse-­‐related	  effects	  of	  MDPV.	  For	  example,	  MDPV	  maintained	  intravenous	  self-­‐administration	   in	   rats	   (Watterson	  et	   al.,	   2012b)	   and	  produced	  both	   stimulant-­‐like	  discriminative	   stimulus	   effects	   and	   locomotor-­‐activating	   effects	   in	  mice	   (Marusich	  et	   al.,	   2012;	   Fantegrossi	   et	   al.,	   2013).	   Taken	   together,	   these	   data	   converge	   in	  suggesting	  that	  MDPV	  has	  high,	  stimulant-­‐like	  abuse	  liability.	  	  	  A	  distinguishing	  feature	  of	  the	  behavioral	  effects	  of	  MDPV	  in	  this	  study	  was	  its	  long	  duration	  of	  action.	  MDPV	  maintained	  significant	  facilitation	  of	  ICSS	  beyond	  300	  min	  (see	  Figure	  II.2),	  with	  facilitation	  still	  apparent	  as	   long	  as	  24	  h	  after	  drug	  administration.	  While	  the	  present	  study	  provides	  the	  first	   in	  vivo	  data	  to	  suggest	  a	  long	  duration	  of	  action	  for	  MDPV,	  previous	  in	  vitro	  studies	  also	  support	  an	  extended	  time	   course	   profile	   for	   MDPV.	   For	   example,	   electrophysiological	   data	   show	   that	  MDPV	   blocked	   DAT	   longer	   and	   was	   more	   resistant	   to	   washout	   than	   cocaine	  (Cameron	   et	   al.,	   2013b).	   Consequently,	   the	   long	   duration	   of	   ICSS	   effects	   observed	  with	  MDPV	  may	  be	  explained	  by	  its	  high	  potency	  at	  and	  slow	  dissociation	  from	  DAT.	  One	   major	   goal	   of	   the	   study	   described	   in	   Chapter	   II	   was	   to	   stratify	   the	  relative	   efficacies	   of	   MCAT,	   MDPV,	   methylone	   and	   mephedrone	   to	   facilitate	   ICSS.	  This	   was	   accomplished	   using	   two	   approaches	   that	   have	   been	   described	   and	  validated	   previously	   with	   amphetamine	   and	   a	   series	   of	   10	   other	   monoamine	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releasers:	  calculation	  of	  %	  baseline	  total	  stimulations	  and	  rate-­‐dependency	  analysis	  (Bauer	   et	   al.,	   2013a,	   2013b).	   In	   those	   previous	   studies,	   both	   approaches	   yielded	  metrics	  of	  efficacy	  that	  correlated	  with	  both	  (a)	  in	  vitro	  selectivity	  of	  compounds	  to	  release	   DA	   vs.	   5-­‐HT	   and	   (b)	   in	   vivo	   efficacy	   to	   maintain	   self-­‐administration	   in	  nonhuman	  primates	  responding	  under	  a	  progressive-­‐ratio	  procedure.	  Moreover,	  in	  the	   present	   study,	   both	   approaches	   yielded	   similar	   rank-­‐ordering	   of	   efficacies	   to	  facilitate	  ICSS.	  These	  approaches	  differ	  from	  more	  conventional	  approaches	  to	  ICSS	  data	  analysis,	  which	  often	  focus	  on	  calculating	  “threshold”	  intensities	  or	  frequencies	  of	  brain	  stimulation	  to	  maintain	  ICSS	  (Miliaressis	  et	  al.	  1986;	  Carlezon	  and	  Chartoff	  2007).	   As	   discussed	   previously	   (Bauer	   et	   al.,	   2013b),	   threshold	   measures	   have	  proven	   useful	   for	   dissociating	   hedonic	   from	   motor	   effects	   of	   experimental	  manipulations	   on	   brain	   reward	   substrates.	   However,	   the	   abuse	   liability	   of	   drugs	  likely	  reflects	  an	  integration	  of	  hedonic	  and	  motor	  effects,	  and	  the	  approaches	  used	  here	  provide	  analytical	  strategies	  for	  quantifying	  that	  integration.	  	   Despite	   the	   general	   agreement	   in	   results	   from	   ICSS	   and	   drug	   self-­‐administration	  approaches	   to	  abuse	   liability	  assessment,	   results	  with	  mephedrone	  suggest	   a	   potential	   disconnect.	   Mephedrone	   produces	   a	   mixed	   profile	   of	   ICSS	  facilitation	   and	   depression	   in	   both	   rats	   and	  mice	   (present	   study;	   Robinson	   et	   al.,	  2012)	   that	   is	   generally	   associated	   with	   significant	   but	   relatively	   weak	   self-­‐administration	  (Bauer	  et	  al.,	  2013b).	  However,	  recent	  studies	  in	  rats	  have	  reported	  robust	  mephedrone	   self-­‐administration	   (Hadlock	   et	   al.,	   2011;	   Aarde	   et	   al.,	   2013a;	  Motbey	  et	  al.,	  2013).	  Determinants	  of	  this	  apparent	  discrepancy	  and	  implications	  for	  human	  abuse	  liability	  will	  require	  further	  research.	  
	  	  105	  
In	  addition	  to	  being	  one	  of	  the	  first	  studies	  to	  compare	  preclinical,	  behavioral	  effects	   of	   MCAT	   and	   the	   three	   primary	   bath	   salts	   constituents	   mephedrone,	  methylone	   and	   MDPV	   using	   ICSS,	   the	   results	   of	   Chapter	   II	   were	   critical	   to	   this	  dissertation	  by	  setting	  the	  stage	  to	  conduct	  QSAR	  analysis	  of	  para-­‐substituted	  MCAT	  analogs.	  By	  elucidating	  major	  differences	  in	  the	  behavioral	  pharmacological	  profiles	  of	   MCAT	   and	   mephedrone	   (4-­‐CH3	   MCAT),	   which	   differ	   structurally	   only	   by	   the	  substitution	   of	   –H	   with	   –CH3	   at	   the	   para	   position	   on	   the	   benzene	   ring,	   these	  preliminary	  studies	  suggested	  the	  importance	  of	  the	  para	  substituent	  of	  the	  MCAT	  scaffold	  to	  the	  pharmacology	  of	  synthetic	  cathinones	  and	  drove	  the	  remainder	  of	  the	  studies	  described	  in	  Chapters	  III	  and	  IV.	  	  	  
Implications	  of	  Chapter	  III:	  In	  vitro	  Selectivity	  of	  and	  ICSS	  Facilitation	  by	  para-­‐
substituted	  MCAT	  analogs	  Results	  from	  Chapter	  III	  confirm	  and	  extend	  previous	  research	  showing	  that	  MCAT	  and	  its	  para-­‐substituted	  analogs	  act	  as	  substrates	  at	  DAT	  and	  SERT	  but	  differ	  in	  their	  DAT-­‐vs.-­‐SERT	  selectivity.	  Thus,	  results	  with	  MCAT	  in	  this	  study	  were	  similar	  to	   results	   reported	   previously	   using	   the	   same	   in	   vitro	   procedures	   with	   rat	   brain	  homogenates	  (DAT	  EC50	  =	  20±3	  nM;	  SERT	  EC50=4±1	  µM;	  DAT-­‐vs.-­‐SERT	  selectivity	  =	  400;	  Cozzi	  et	  al.,	  2013).	  Results	  here	  are	  also	  consistent	  with	  a	  previous	  study	  using	  HEK	   cells	   expressing	   human	   transporters,	   which	   found	   higher	   DAT-­‐vs.-­‐SERT	  selectivity	   for	  MCAT	   than	   for	  4-­‐F	  MCAT	   (Eshleman	  et	  al.,	   2013).	  4-­‐CH3	  MCAT	  was	  slightly	   more	   DAT-­‐vs.-­‐SERT	   selective	   than	   4-­‐F	   MCAT	   in	   the	   study	   with	   human	  transporters	   expressed	   in	  HEK	  cells	   (Eshleman	  et	  al.,	   2013),	  which	   contrasts	  with	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results	  in	  rat	  brain	  homogenates	  (Baumann	  et	  al.,	  2012;	  present	  study)	  and	  suggests	  some	   potential	   for	   species	   differences	   in	   4-­‐CH3	   MCAT	   effects	   at	   human	   vs.	   rat	  transporters.	  Finally,	  the	  SERT-­‐selectivity	  of	  4-­‐CF3	  MCAT	  agrees	  with	  the	  SERT-­‐vs.-­‐DAT	   selectivity	   of	   fenfluramine	   (Rothman	   et	   al.,	   2001),	   which	   has	   a	   3-­‐trifluoromethyl	  substituent	  on	  the	  phenyl	  ring	  of	  a	  phenethylamine	  scaffold	  closely	  related	  to	  the	  MCAT	  scaffold	  used	  here.	  	  	  	  	  	  	  The	   study	   described	   in	   Chapter	   III	   also	   extends	   these	   previous	   results	   by	  including	   4-­‐OCH3	  MCAT	   and	   two	   halogenated	  MCAT	   analogs,	   4-­‐Cl	  MCAT	   and	   4-­‐Br	  MCAT.	  	  Like	  4-­‐CH3	  MCAT,	  all	  three	  compounds	  had	  similar	  potencies	  for	  promoting	  monoamine	   release	   through	   DAT	   and	   SERT,	   and	   all	   three	   compounds	   had	   lower	  DAT-­‐.vs.-­‐SERT	  selectivity	  than	  4-­‐F	  MCAT.	   	  Consistent	  with	  the	  present	  results	  with	  halogenated	   MCAT	   analogs,	   previous	   studies	   with	   halogenated	   amphetamine	  analogs	   also	   showed	   that	   para-­‐fluoroamphetamine	   had	   greater	   DAT-­‐vs.-­‐SERT	  selectivity	   and	   more	   robust	   amphetamine-­‐like	   behavioral	   effects	   than	   para-­‐choroamphetamine	  (Marona-­‐Lewicka	  et	  al.,	  1995;	  Baumann	  et	  al.,	  2011).	  	  ICSS	   results	  described	   in	  Chapter	   III	   confirm	  and	  extend	  previous	   research	  showing	  that	  MCAT	  and	  many	  of	  its	  analogs	  modulate	  ICSS	  but	  differ	  in	  the	  degree	  to	   which	   they	   facilitate	   low	   rates	   of	   ICSS	   and/or	   depress	   high	   rates	   of	   ICSS.	   We	  showed	  previously	   that	  MCAT,	  which	  has	  high	  DAT-­‐vs.-­‐SERT	  selectivity,	  produced	  exclusive	  facilitation	  of	  ICSS	  across	  a	  broad	  range	  of	  doses	  (Bonano	  et	  al.,	  2014b;	  see	  Chapter	   II),	   and	   the	  present	   study	   found	   that	  4-­‐F	  MCAT,	  which	  also	  has	  moderate	  DAT-­‐vs.-­‐SERT	  selectivity,	  produced	  a	  similar	  profile	  of	  effects.	  MCAT	  and	  4-­‐F	  MCAT	  also	   produced	   similar	   locomotor	   activating	   effects	   in	  mice	   (Marusich	   et	  al.,	   2012)	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and	   fully	   substituted	   for	   the	   discriminative	   stimulus	   effects	   of	   stimulant	   drugs	   of	  abuse,	   such	   as	   cocaine	   and	   methamphetamine,	   in	   rats	   (Gatch	   et	   al.,	  2013).	  	   Conversely,	   4-­‐CF3	   MCAT,	   a	   SERT-­‐vs.-­‐DAT	   selective	   compound,	   produced	  exclusive	   depression	   of	   ICSS,	   a	   profile	   of	   effects	   which	   parallels	   the	   effects	  previously	  reported	  for	  fenfluramine,	  another	  5-­‐HT-­‐selective	  releaser	  (Bauer	  et	  al.,	  2013b).	  Lastly,	  4-­‐CH3	  MCAT,	  which	  is	  a	  relatively	  nonselective	  monoamine	  releaser,	  has	  been	  reported	  to	  produce	  mixed	  effects	  on	  ICSS	  consisting	  of	  both	  facilitation	  of	  low	  ICSS	  rates	  and	  depression	  of	  high	  ICSS	  rates	  (Robinson	  et	  al.,	  2012;	  Bonano	  et	  al.,	   2014b).	   	   In	   the	   present	   study,	   similar	   profiles	   of	  mixed	   ICSS	   effects	  were	   also	  produced	   by	   the	   other	   MCAT	   analogs	   4-­‐OCH3	  MCAT,	   4-­‐Cl	   MCAT	   and	   4-­‐Br	   MCAT,	  which	  also	  have	  low	  DAT-­‐vs.-­‐SERT	  selectivity.	  	  These	  effects	  on	  ICSS	  are	  consistent	  with	  the	  relatively	  weak	  magnitude	  of	  locomotor	  stimulation	  reported	  in	  rodents	  for	  4-­‐OCH3	  MCAT	  (Marusich	  et	  al.,	  2012)	  and	  4-­‐Br	  MCAT	  (Foley	  and	  Cozzi,	  2003).	  	  	  	  	  Correlational	  analysis	  confirmed	  a	  significant	  positive	  correlation	  between	  in	  
vitro	   DAT-­‐vs.-­‐SERT	   selectivity	   and	   ICSS	   facilitation	   (R=0.92,	   P=0.003).	   Insofar	   as	  magnitude	   of	   ICSS	   facilitation	   is	   predictive	   of	   abuse	   potential	   (Negus	   and	   Miller,	  2014),	   these	   results	   suggest	   that	  DAT-­‐vs.-­‐SERT	   selectivity	   is	   a	   key	  determinant	  of	  abuse	  potential	   for	  a	  wide	  range	  of	  monoamine	  releasers.	  Furthermore,	   to	  explore	  molecular	  mechanisms	  that	  contribute	  to	  monoamine	  releaser	  abuse	  potential,	  this	  study	  employed	  QSAR	  analysis	  to	  evaluate	  structural	  determinants	  of	  DAT-­‐vs.-­‐SERT	  selectivity	   and	   abuse-­‐related	   ICSS	   effects.	   Of	   the	   physicochemical	   parameters	  evaluated	  (steric	  bulk,	  Es;	  electron-­‐withdrawing	  capacity,	  σp;	   lipophilicity,	  πp),	  only	  Es	   correlated	   with	   both	   DAT-­‐vs.-­‐SERT	   selectivity	   and	   ICSS	   facilitation,	   suggesting	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that	   steric	   attributes	   of	   the	   para	   substituent	   play	   a	   key	   role	   in	   determining	  selectivity	   of	   releasers	   for	   DAT	   vs.	   SERT.	   Large	   Es	   values	   indicate	   low	   functional	  steric	   bulk	   of	   the	   substituent,	   and	   increasingly	   negative	   Es	   values	   indicate	  progressively	   greater	  magnitudes	   of	   steric	   hindrance.	   Thus,	   these	   results	   suggest	  that	  small	  para	  substituents	  that	  produce	  little	  steric	  hindrance	  promote	  selectivity	  for	  DAT,	  whereas	  larger	  substituents	  that	  produce	  greater	  steric	  hindrance	  promote	  selectivity	  for	  SERT	  (see	  Figure	  V.3).	  	  
	   	  





Effects	  of	  steric	  volume	  on	  monoamine	  transporter	  selectivity,	  DA	  vs.	  5-­‐HT	  release,	  and	  
ICSS.	   Small	   para	   substituents	  with	   low	   volume	  promote	   selectivity	   for	  DAT,	   produce	  
greater	  increases	  in	  DA	  release,	  and	  facilitate	  ICSS.	  Para	  substituents	  of	  intermediate	  
volume	  are	  non-­‐selective	  for	  DAT	  vs.	  SERT,	  produce	  increases	  in	  release	  of	  both	  DA	  and	  
5-­‐HT,	  and	  yield	  mixed	  ICSS	  effects.	  Large	  para	  substituents	  with	  high	  volume	  promote	  
selectivity	  for	  SERT,	  produce	  greater	  increases	  in	  5-­‐HT	  release,	  and	  depress	  ICSS.	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In	   contrast	   to	   the	   significant	   correlations	   obtained	   for	   Es	   values,	  neither	  lipophilic	  (πp)	  nor	  electronic	  (σp)	  parameters	  of	  the	  para	  substituent	  correlated	  with	  
in	  vitro	  or	   in	  vivo	  drug	  effects.	  The	  nonsignificant	  correlations	  of	   these	  values	  with	  DAT-­‐vs.-­‐SERT	   selectivity	   or	   with	   ICSS	   facilitation	   suggest	   that,	   within	   the	   ranges	  studied	   here,	   these	   parameters	   are	   less	   important	   than	   steric	   hindrance	   as	  determinants	   of	   abuse-­‐related	   neurochemical	   and	   behavioral	   effects	   of	   MCAT	  analogs.	  However,	  more	   extreme	   lipophilic	   and/or	   electronic	   values	  beyond	   these	  ranges	   might	   influence	   neurochemical	   and	   behavioral	   effects,	   and	   lipophilic	   and	  electronic	  parameters	  might	  also	   influence	  other	  aspects	  of	  pharmacology,	  such	  as	  pharmacokinetics.	  	  	  	  	  	  As	  a	   follow-­‐up	  to	  preliminary	  QSAR	  analyses,	  which	   indicated	  an	   important	  role	   for	  steric	  bulk	  (Es),	  additional	  aspects	  of	  steric	  hindrance	  underlying	  DAT-­‐vs.-­‐SERT	   selectivity	   and	   ICSS	   behavioral	   effects	   were	   considered	   in	   a	   companion	  manuscript	   (Sakloth	   et	   al.,	   2014).	   In	   these	   supplemental	   studies,	   steric	   bulk	   was	  broken	  down	  further	  to	  determine	  which	  specific	  aspects	  of	  bulk	  were	  playing	  a	  role	  in	   DAT-­‐vs.-­‐SERT	   selectivity.	   Steric	   volume,	   length,	  maximum	  width	   and	  minimum	  width	  of	  the	  para	  substituents	  of	  MCAT	  analogs	  were	  correlated	  with	  in	  vitro	  DAT-­‐vs.-­‐SERT	  selectivity	  and	  in	  vivo	  modulation	  of	  ICSS.	  These	  additional	  studies	  not	  only	  identified	  volume	  as	  the	  primary	  component	  of	  steric	  bulk	  influencing	  monoamine	  transporter	  binding	  (R=-­‐0.97,	  P<0.01)	  and	  facilitation	  of	  ICSS	  (R=-­‐0.92,	  P<0.01),	  but	  also	   contributed	   to	   the	   generation	   of	   molecular	   models,	   which	   help	   explore	  structural	  interactions	  that	  may	  account	  for	  interactions	  between	  MCAT	  analogs	  and	  both	  DAT	  and	  SERT.	  Homology	  models	  of	  DAT	  and	  SERT	  were	  generated	  using	  the	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3.0	  Å	  X-­‐ray	  crystal	  structure	  of	  Drosophila	  melanogaster	  DAT	  (dDAT)	  as	  a	  template.	  Using	   sequence	   alignment	   software	   (ClustalX	   2.1)	   along	   with	   modeling	   software	  (MODELLER	  9.10),	  the	  amino	  acid	  sequences	  of	  hDAT	  and	  hSERT	  (shown	  below	  in	  Figure	  V.4)	  were	  aligned	  with	  dDAT,	  and	  a	  population	  of	  100	  models	  was	  generated	  for	  both	  hDAT	  and	  hSERT.	  The	  molecular	  structures	  of	  compounds	  to	  be	  docked	  (i.e.	  
para-­‐substituted	   MCAT	   analogs)	   were	   sketched	   in	   SYBYL-­‐X	   2.1	   and	   energy-­‐minimized	  using	   the	  Tripos	  Force	  Field	  prior	   to	  docking	   (using	  GOLDSuite	  5.2)	  of	  the	   S-­‐isomer	   of	   each	   substrate	   into	   each	   of	   the	   100	   hDAT	   and	   hSERT	   models.	  Docking	   stimulations	   were	   then	   run	   without	   constraints,	   and	   common	   and	  energetically	   favorable	   transporter-­‐substrate	   complexes	   were	   identified	   for	   all	  substrates	   at	   both	   hDAT	   and	   hSERT.	   The	   molecular	   models	   generated	   using	   this	  procedure	  are	  depicted	   in	  Figure	  V.5.	  A	  major	  conclusion	  of	   this	  analysis	  was	   that	  different	   residues	   located	   at	   homologous	   sites	   in	   transmembrane	   domain	   III	   of	  hDAT	  and	  hSERT	   (S149	   in	  hDAT,	  A169	   in	  hSERT)	  may	   contribute	   to	   the	  different	  preferences	  of	  these	  transporters	  for	  small	  (hDAT)	  vs.	  bulky	  (hSERT)	  substituents	  at	  the	  para	  position	  of	  the	  MCAT	  scaffold	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Figure	  V.4	  
	  
Amino	  acid	  alignment	  for	  complete	  sequences	  of	  hDAT,	  hNET	  and	  hSERT.	  Amino	  acid	  
residues	  of	  interest	  (hDAT	  S149	  and	  hSERT	  A169)	  are	  noted	  in	  both	  (a)	  the	  full	  amino	  
acid	  sequences	  and	  (b)	  the	  schematic	  of	  transmembrane	  domain	  III	  where	  these	  amino	  
acid	   residues	   are	   located	   within	   the	   12	   transmembrane	   monoamine	   transporter	  
proteins.	  Image	  adapted	  from	  Torres	  et	  al.,	  2003.	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Figure	  V.5	  
	  
Superimposed	  positions	  of	  MCAT	  analogs	  in	  the	  putative	  binding	  site	  of	  hDAT	  (A),	  and	  
hSERT	  (B).	  Unfavorable	  interactions	  of	  hDAT	  S149	  with	  para	  substituents	  (shown	  for	  
4-­‐OCH3	  MCAT;	  C)	  are	  not	  seen	  in	  hSERT	  due	  to	  the	  smaller	  side	  chain	  of	  A169	  (again,	  
shown	  for	  4-­‐OCH3	  MCAT;	  D).	  The	  Connolly	  surface	  (grey	  density	  in	  C	  and	  D)	  represents	  
the	  channels	  in	  both	  transporters.	  Image	  from	  Sakloth	  et	  al.,	  2014.	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Implications	  of	  Chapter	  IV:	  In	  vivo	  Selectivity	  of	  para-­‐substituted	  MCAT	  
analogs	  The	   study	   described	   in	   Chapter	   IV	   investigated	   abuse-­‐related	   in	   vivo	  neurochemical	   effects	   produced	   by	   MCAT	   and	   five	   para-­‐substituted	   analogues.	  There	   were	   three	   main	   findings.	   First,	   across	   a	   1.0	   log	   range	   of	   doses,	   all	   MCAT	  analogs	   increased	   extracellular	   levels	   of	   DA	   and/or	   5-­‐HT	   in	   rat	   NAc,	   albeit	   with	  different	  potencies.	  Second,	  in	  vivo	  selectivity	  to	  elevate	  DA	  vs.	  5-­‐HT	  levels	  to	  250%	  of	  baseline	  (ED250)	  varied	  across	  compounds,	  with	  MCAT	  as	   the	  most	  DA-­‐selective	  and	  4-­‐OCH3	  MCAT	  as	  the	  most	  5-­‐HT-­‐selective.	  Third,	  in	  vivo	  DA	  vs.	  5-­‐HT	  selectivity	  correlated	   with	   in	   vitro	   selectivity	   for	   DAT	   vs.	   SERT	   in	   a	   rat-­‐brain	   synaptosome	  preparation	   (R=0.95,	   P<0.01),	   and	   with	   in	   vivo	   facilitation	   of	   intracranial	   self-­‐stimulation	   in	   rats	   (R=0.89,	   P=0.02).	   Together,	   these	   results	   suggest	   that	   in	   vivo	  selectivity	   of	   para-­‐substituted	  MCAT	   analogs	   to	   elevate	   extracellular	   DA	   vs.	   5-­‐HT	  levels	  in	  NAc	  may	  be	  a	  key	  neurochemical	  determinant	  of	  abuse-­‐related	  behavioral	  effects.	  	  The	   results	   from	   Chapter	   IV	   confirm	   and	   extend	   previous	   results	   showing	  differences	   in	  neurochemical	  selectivity	  of	  various	  monoamine	  releasers,	   including	  the	  DA-­‐selective	  releasers	  amphetamine	  and	  MCAT	  and	  the	  5-­‐HT-­‐selective	  releaser	  fenfluramine.	  Similar	  to	  results	  with	  amphetamine	  in	  this	  study,	  early	  microdialysis	  studies	   in	  male	   Sprague-­‐Dawley	   rats	   reported	   amphetamine-­‐induced	   increases	   in	  accumbal	  DA	  release	  by	  a	  factor	  of	  10	  (~1000%	  increase)	  at	  a	  dose	  of	  1	  mg/kg,	  s.c.	  (Di	  Chiara	  and	   Imperato,	  1988).	  Results	  presented	  here	  are	  also	  consistent	  with	  a	  previous	   study	   investigating	   effects	   of	   MCAT	   on	   striatal	   extracellular	   DA	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concentrations	   in	  male	   Sprague-­‐Dawley	   rats,	   in	  which	   administration	   of	   1	  mg/kg,	  s.c.	   increased	  DA	  levels	  to	  419%	  of	  control	  values	  (Gygi	  et	  al.,	  1997).	  Furthermore,	  the	  present	  results	  agree	  with	  a	  prior	  study	  that	  investigated	  concurrent	  changes	  in	  DA	   and	   5-­‐HT	   levels	   in	   the	   NAc	   of	   male	   Sprague-­‐Dawley	   rats	   and	   showed	   that	  administration	  of	  1	  mg/kg,	  i.p.	  fenfluramine	  produced	  significant	  increases	  in	  5-­‐HT	  levels	   to	   ~300%	   of	   baseline	   without	   producing	   any	   significant	   changes	   in	  extracellular	  DA	  concentrations	  (Baumann	  et	  al.,	  2000).	  	  Results	   from	   the	   present	   study	   also	   agree	  with	   previous	   research	   showing	  mixed	   neurochemical	   effects	   (i.e.	   non-­‐selective	   increases	   in	   extracellular	   levels	   of	  both	  DA	  and	  5-­‐HT)	  with	  compounds	   like	  4-­‐CH3	  MCAT.	   	  One	  previous	  study,	  which	  investigated	  neurochemical	  effects	  of	  10	  mg/kg,	  s.c.	  4-­‐CH3	  MCAT	  in	  the	  NAc	  shell	  of	  male	  Wistar	  rats,	  reported	  increases	  in	  DA	  and	  5-­‐HT	  levels	  to	  approximately	  22-­‐fold	  and	   9-­‐fold	   of	   control	   levels,	   respectively	   (Wright	   et	   al.,	   2012).	   Similarly,	   another	  study	   showed	   that	   administration	   of	   1	   mg/kg,	   i.v.	   4-­‐CH3	   MCAT	   in	   male	   Sprague-­‐Dawley	   rats	   produced	   peak	   increases	   in	   accumbal	   DA	   levels	   to	   2.9-­‐fold	   above	  baseline	   and	   in	   5-­‐HT	   levels	   to	   11.1-­‐fold	   above	   baseline	   (Baumann	   et	   al.,	   2012).	  Microdialysis	   studies	   have	   also	   been	   conducted	   on	   the	   de-­‐carbonylated,	  amphetamine	  analog	  of	  4-­‐F	  MCAT	  (i.e.	  4-­‐fluoroamphetamine,	  PAL-­‐303;	  Baumann	  et	  al.,	   2011).	   Results	   from	   this	   study	   show	   that	   i.v.	   injection	   of	   3	   mg/kg	   4-­‐fluoroamphetamine	   produces	   similar	   increases	   in	   NAc	   DA	   and	   5-­‐HT	   levels,	   to	  ~1200%	   and	   1400%	   of	   baseline,	   respectively.	   These	   data	   suggest	   that	   4-­‐fluoroamphetamine	  non-­‐selectively	   increases	  DA	  and	  5-­‐HT	   concentrations	   in	  NAc,	  similar	  to	  our	  present	  results	  for	  the	  N-­‐methyl,	  beta-­‐ketone	  analog	  4-­‐F	  MCAT.	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The	  present	  study	  extends	  these	  previous	  results	  by	  including	  4-­‐OCH3	  MCAT	  and	  three	  halogenated	  MCAT	  analogs,	  4-­‐F	  MCAT,	  4-­‐Cl	  MCAT	  and	  4-­‐Br	  MCAT.	  Like	  4-­‐CH3	   MCAT,	   these	   para-­‐substituted	   MCAT	   analogs	   function	   as	   non-­‐selective	  monoamine	  releasers.	  4-­‐F	  MCAT	  and	  4-­‐Cl	  MCAT	  had	  similar	  potencies	  for	  increasing	  DA	   and	   5-­‐HT	   levels	   to	   250%	   of	   baseline,	   in	   addition	   to	   having	   similar	   DA/5-­‐HT	  selectivities.	   Consistent	   with	   these	   results,	   previous	   studies	   with	   halogenated	  amphetamine	   analogs	   showed	   that	   para-­‐fluoroamphetamine	   had	   greater	   DAT	  selectivity	   and	   more	   robust,	   amphetamine-­‐like	   behavioral	   effects	   than	   para-­‐chloroamphetamine	   (Marona-­‐Lewicka	   et	   al.,	   1995;	   Baumann	   et	   al.,	   2011).	   4-­‐Br	  MCAT,	  the	  other	  halogenated	  MCAT	  analog,	  exhibited	  similar	  potency	  to	  increase	  5-­‐HT,	  but	  was	  less	  potent	  at	  increasing	  NAc	  DA	  levels	  and	  thus	  had	  reduced	  DA/5-­‐HT	  selectivity	  when	  compared	  to	  its	  4-­‐F	  and	  4-­‐Cl	  counterparts.	  Of	  all	  tested	  compounds,	  4-­‐OCH3	  MCAT	  was	  the	  least	  potent	  analog	  to	  increase	  accumbal	  DA	  and	  5-­‐HT	  levels,	  and	  it	  had	  the	  lowest	  selectivity	  for	  DA/5-­‐HT.	  	   As	   described	   in	   Chapter	   III,	   QSAR	   analysis	   was	   used	   to	   explore	   molecular	  mechanisms	   contributing	   to	   monoamine	   releaser	   abuse	   potential	   by	   evaluating	  structural	   determinants	   of	   selectivity	   for	   in	  vitro	  monoamine	   release	   via	   DAT-­‐vs.-­‐SERT,	  and	  of	  abuse-­‐related	  ICSS	  effects	  (Bonano	  et	  al.,	  2014a;	  Sakloth	  et	  al.,	  2014).	  Results	  of	  QSAR	  analysis	  suggested	  that	  steric	  characteristics	  of	  the	  para	  substituent	  play	  a	  critical	   role	   in	  determining	   in	  vitro	   selectivity	   for	  DAT-­‐vs.-­‐SERT,	  and	   that	   in	  
vitro	   DAT-­‐vs.-­‐SERT	   selectivity	   is	   a	   key	   determinant	   of	   abuse-­‐related	   ICSS	   effects.	  Results	  presented	   in	  Chapter	   IV	  extend	  on	   these	   findings	  by	  also	  demonstrating	  a	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significant	   correlation	   between	   in	   vivo	   DA/5-­‐HT	   selectivity	   and	   ICSS	   facilitation	  (R=0.89,	  P=0.02).	  	   Although	   the	   correlation	   between	   in	   vivo	   DA/5-­‐HT	   selectivity	   and	   ICSS	  facilitation	  provides	  support	  for	  the	  conclusion	  that	  DA	  is	  a	  neurochemical	  driver	  of	  abuse	   potential	   and	   that	   5-­‐HT	   is	   an	   abuse-­‐limiting	   neurotransmitter,	   it	   does	   not	  entirely	   explain	   the	   mechanism	   by	   which	   para-­‐substituted	   MCAT	   analogs	   are	  producing	   abuse-­‐related	   effects.	   While	   our	   results,	   taken	   together,	   suggest	   that	  
selectivity	  to	  increase	  DA	  vs.	  5-­‐HT	  levels	  is	  one	  of	  the	  most	  important	  determinants	  of	   a	   compound’s	   abuse	   potential,	   rather	   than	   a	   compound’s	   capacity	   to	   increase	  concentrations	   of	   either	   neurotransmitter	   individually,	   the	   results	   do	   not	   provide	  direct	   answers	   to	   questions	   like	   “how	   much	   DA	   release	   is	   “enough”	   to	   produce	  abuse?”	  or	  “how	  much	  5-­‐HT	  release	  is	  sufficient	  to	  hinder	  DA’s	  abuse-­‐related	  effects	  and	  prevent	  a	  compound	  from	  having	  abuse	  potential?”	  	  Altogether,	  the	  results	  from	  the	  microdialysis	  studies	  presented	  in	  Chapter	  IV	  provide	  evidence	   for	  a	  key	   role	  of	   relative	  DA/5-­‐HT	  selectivity	   in	  determining	   the	  abuse	   potential	   of	   para-­‐substituted	   MCAT	   analogs.	   Compounds	   with	   higher	  selectivity	   to	   increase	   accumbal	   DA	   maintain	   higher	   rates	   of	   abuse-­‐related	   ICSS,	  while	   compounds	   with	   higher	   selectivity	   to	   increase	   5-­‐HT	   exhibit	   a	   reduction	   in	  their	  capacity	  to	  facilitate	   low	  rates	  of	  ICSS	  as	  well	  as	  a	  concomitant	  depression	  of	  high	  ICSS	  rates.	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Drawing	  Conclusions	  	   Structural	   features	   of	   drug	   molecules	   are	   critical	   to	   determining	  pharmacological	   activity.	   In	   this	   dissertation,	   we	   explored	   QSARs	   for	   para-­‐substituted	   MCAT	   analogs,	   but	   other	   aspects	   of	   the	   MCAT	   scaffold	   are	   certainly	  important	  and	  also	  play	  a	  role	  in	  the	  neurochemical	  and	  behavioral	  effects	  produced	  by	   synthetic	   cathinones.	  While	  we	   focused	   on	   differential	   pharmacological	   effects	  based	   on	   structural	   variations	   of	   the	   para	   substituent	   on	   the	   phenyl	   ring	   of	   the	  MCAT	  scaffold	  (based	  on	  the	  notable	  differences	   in	  preliminary	  behavioral	  studies	  of	  MCAT	  and	  mephedrone),	  other	  substituents	  on	   the	  MCAT	  backbone	  can	  also	  be	  manipulated	  and	  would	  almost	  certainly	  influence	  pharmacological	  profiles.	  	   An	  example	  of	  structural	  manipulations	  at	  sites	  other	  than	  the	  para	  position	  on	  the	  benzene	  ring	  (see	  Figure	  V.6	  below)	  that	  yield	  differential	  effects	  on	  synthetic	  cathinone	   pharmacology	   is	   described	   in	   a	   recently	   published	   manuscript	   by	  Baumann	   et	   al.	   (2015),	   in	   which	   two	   analogs	   of	   mephedrone	   (4-­‐methyl-­‐N-­‐methylcathinone)	   with	   extensions	   to	   the	   N-­‐alkyl	   chain	   were	   investigated.	   These	  compounds,	   4-­‐methyl-­‐N-­‐ethylcathinone	   (4-­‐MEC)	   and	   4-­‐methyl-­‐N-­‐pyrrolidino-­‐propiophenone	   (4-­‐MePPP),	   were	   studied	   to	   determine	   effects	   of	   each	   drug	   at	  monoamine	  transporters	  and	  to	  compare	  these	  effects	  with	  those	  produced	  by	  the	  parent	   compound	  mephedrone.	   In	   contrast	   to	   mephedrone,	   which	   functions	   as	   a	  monoamine	   transporter	   substrate	   (i.e.	   releaser)	   at	   both	   DAT	   and	   SERT,	   4-­‐MEC	  displayed	  unique	  activity	  by	  acting	  as	  an	  uptake	  blocker	  at	  DAT	  but	  as	  a	  substrate	  at	  SERT.	  This	  finding	  suggests	  that	  subtle	  extension	  of	  the	  N-­‐alkyl	  chain	  of	  cathinones,	  from	   methyl	   to	   ethyl,	   is	   sufficient	   to	   convert	   activity	   at	   DAT	   from	   release	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(mephedrone)	  to	  uptake	  inhibition	  (4-­‐MEC).	  However,	  this	  minor	  change	  in	  N-­‐alkyl	  chain	  length	  was	  not	  sufficient	  to	  alter	  release	  activity	  at	  SERT,	  as	  mephedrone	  and	  4-­‐MEC	   displayed	   similar	   potency	   (EC50	   ~100nM)	   to	   evoke	   release	   at	   SERT.	  Interestingly,	   4-­‐MePPP	  did	   not	   function	   as	   a	   substrate	   at	   either	  DAT	   or	   SERT	  but	  rather	  as	  a	  selective	  DAT	  blocker	  with	  little	  activity	  at	  SERT.	  Thus,	  further	  extension	  of	   the	  alkyl	  chain	   to	   form	  a	  pyrrolidine	  ring	  converted	   the	  compound	   from	  a	  non-­‐selective	   monoamine	   releaser/uptake	   inhibitor	   to	   a	   DAT-­‐selective	   blocker.	   The	  molecular	   pharmacology	   of	   4-­‐MePPP	   closely	   resembles	   that	   of	   other	  pyrrolidinophenone	   compounds	   like	   pyrovalerone	   and	   MDPV,	   which	   function	   as	  potent	   blockers	   at	   DAT	   and	   NET	   with	   little	   action	   at	   SERT	   (Meltzer	   et	   al.,	   2006;	  Baumann	  et	  al.,	  2013;	  Cameron	  et	  al.,	  2013b;	  Kolanos	  et	  al.,	  2013;	  Marusich	  et	  al.,	  2014).	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Figure	  V.6	  
	  
R1	   indicates	   the	   site	   of	   the	   para	   substituent,	   which	   was	   manipulated	   in	   these	  
dissertation	  studies.	  R2	  indicates	  the	  site	  of	  the	  alkyl	  amine	  chain.	  At	  the	  para	  position	  
on	   the	  benzene	  ring	  (R1),	   increased	  steric	  volume	  reduces	  potency	   for	  DAT-­‐mediated	  
release,	   increases	   potency	   for	   SERT-­‐mediated	   release,	   reduces	   DAT-­‐vs.-­‐SERT	  
selectivity,	  and	  reduces	  abuse-­‐related	  behavioral	  effects.	  For	  the	  alkyl	  amine	  (R2),	  the	  
addition	   of	   substituents	   can	   convert	   compounds	   from	   monoamine	   transporter	  
substrates	   to	   inhibitors,	   and	   as	   the	   length	   of	   the	   chain	   increases,	   potency	   for	   DAT	  
uptake	   inhibition	   increases,	   potency	   for	   SERT	  uptake	   inhibition	  decreases,	   and	  DAT-­‐
vs.-­‐SERT	  selectivity	  increases.	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which	  this	  series	  of	  MCAT	  analogs	  may	  influence	  abuse-­‐related	  behavior	  other	  than	  by	  exerting	  effects	  on	  DAT	  and	  SERT,	  which	  manifest	   as	   increases	   in	  extracellular	  levels	   of	   NAc	   DA	   and	   5-­‐HT,	   include:	   1)	   acting	   on	   brain	   regions	   other	   than	   the	  mesolimbic	  DA	  pathway;	  2)	  acting	  at	  monoamine	  transporters	  other	  than	  DAT	  and	  SERT;	   and	   3)	   binding	   and	   directly	   activating	   other	   pre-­‐	   and/or	   post-­‐synaptic	  receptors.	   First,	   monoaminergic	   neurotransmitter	   systems	   project	   diffusely	  throughout	   the	   brain,	   and	   involvement	   of	   brain	   regions	   other	   than	   VTA-­‐NAc	  may	  play	  an	   important	  role	   in	  producing	  abuse-­‐related	  behaviors.	  For	  example,	  studies	  have	   found	   roles	   for	   non-­‐dopaminergic	   mechanisms	   of	   the	   supramammilary,	  rostromedial	  tegmental,	  and	  midbrain	  raphe	  nuclei	  in	  reward,	  including	  GABAergic	  and	   glutamatergic	   mechanisms	   (Ikemoto,	   2010;	   Ikemoto	   2005;	   Miliaressis	   et	   al.	  1975).	   Second,	   drug	   effects	   on	   abuse-­‐related	   behavior	  may	   also	   be	   influenced	   by	  drug	   activity	   at	   other	   monoamine	   transporters	   (i.e.	   NET).	   Various	   studies	   have	  demonstrated	   that	   MCAT	   and	   its	   analogs	   function	   as	   monoamine	   releasers	   that	  promote	  release	  of	  NE	  as	  well	  as	  DA	  (Kalix	  and	  Glennon,	  1986;	  Wagner	  et	  al.	  1982;	  Nielsen	   and	   Schechter	   1985;	   Cozzi	   et	   al.	   1999,	   2013),	   suggesting	   a	   role	   for	  noradrenergic	   neurotransmission	   in	   the	   rewarding	   effects	   produced	   by	   these	  compounds.	  Lastly,	  drug	  effects	  on	  other	  receptor	  targets	  may	  influence	  behavioral	  endpoints	  by	  directly	   activating	   receptors	   located	  both	  pre-­‐	   and	  post-­‐synaptically.	  For	   example,	   one	   recent	   study	   investigating	  monoamine	   transporter	   and	   receptor	  interaction	   profiles	   of	   a	   series	   of	   amphetamine	   and	   cathinone	   derivatives	  demonstrated	   affinity	   of	   some	   compounds	   for	   the	   5-­‐HT2A	   receptor	   (Rickli	   et	   al.	  2015).	   Other	   studies	   have	   shown	   that	   5-­‐HT	   acts	   on	   5-­‐HT2A	   receptors	   located	   in	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midbrain	  to	  increase	  firing	  of	  DA	  neurons	  in	  the	  VTA	  (Pessia	  et	  al.	  1994;	  Prisco	  et	  al.	  1994);	   thus,	  direct	  activation	  of	  5-­‐HT2A	   receptors	  by	   test	  drugs	  may	  play	  a	   role	   in	  producing	  abuse-­‐related	  behaviors.	  	  
	  
Future	  Directions	  	   QSAR	   analysis	   is	   a	   useful	   tool,	   not	   only	   for	   predicting	   the	   pharmacological	  effects	   of	   novel	   compounds,	   but	   also	   for	   generating	   molecular	   models	   to	   better	  understand	  the	  mechanisms	  underlying	  drug	  effects.	  Future	  QSAR	  studies	  exploring	  other	   molecular	   aspects	   of	   the	   MCAT	   scaffold,	   such	   as	   the	   impact	   of	   terminal	  N-­‐substitutions	   or	   ortho-­‐	   and	   meta-­‐	   substitutions	   on	   the	   benzene	   ring,	   would	   be	  helpful	   in	   understanding	   precisely	   how	   the	   structure	   of	   cathinone	   analogs	  influences	   molecular	   function	   at	   monoamine	   transporters,	   thereby	   driving	   or	  limiting	   abuse	   potential.	   Additionally,	   as	   the	   library	   of	   structural	   MCAT	   analogs	  continues	  to	  grow	  and	  the	  understanding	  of	  neuropharmacological	  effects	  improves,	  more	  accurate	  models	  of	  drug	  interaction	  with	  human	  DAT	  and	  SERT	  proteins	  will	  be	  developed.	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